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Protective effects of peri-menopausal oestrogen replacement: 
A test of the critical period hypothesis 
Sophie Anastasia Rebecca Pettit  
Oestrogen decline during the menopause leads to decline in cognitive performance 
because oestrogen receptor sites are found in the prefrontal cortex and 
hippocampus of the female brain, areas associated with memory and attention 
functions. Extensive research over the past two decades has tested the effects of 
administering Hormone Replacement Therapy (HRT) to maintain oestrogen levels. 
MRI studies have shown improvements in hippocampal volume and frontal 
functions with HRT, but evidence for associated improvements in verbal memory 
performance has been mixed. Some studies have even found detrimental effects of 
HRT, leading to the suggestion of a critical period for HRT administration relative 
to menopause.  
Oestrogen receptor sites are found in frontal brain regions associated with working 
memory (WM) functions including attention. These functions have been 
researched less than verbal memory, but with similarly mixed findings. The 
research reported in this thesis tested the critical period hypothesis in relati on to 
WM. Study one tested the prediction that HRT will benefit WM if the therapy is 
initiated during the peri-menopause, and will harm it if initiated post-menopause. 
A naturalistic sample of 121 women were recruited, comprising women who varied 
in the time they had begun taking HRT, and menopausal status-matched controls 
who had never taken HRT. Participants completed three tests of WM span and the 
Sustained Attention to Response Task (SART) on two occasions 12 months apa rt. 
WM performance supported the critical period hypothesis, with women who had 
begun the therapy after the menopause displayed worsened WM capacity when 
compared to peri-menopausal initiators and post-menopausal women with no 
history of HRT use. At one year follow up, postmenopausal HRT users were still 
underperforming compared to peri-HRT initiators and those in the post-
menopausal stage with no history of HRT use. No significant differences were 
identified between groups on the SART.  
The effects of natural supplements on physical symptoms of the menopause have 
been researched, but there is little research on their effects on cognitive 
symptoms and none specifically testing the critical period hypothesis. Study two 
tested the effects of soya isoflavones on WM during peri- and post-menopausal 
stages. One hundred and twelve peri- and post-menopausal women were randomly 
allocated to receive either placebo or 100mg soya supplement in capsules daily for 
three months. Participants and researcher were blind to this  allocation. 
Participants completed two tests of WM span and two Sustained Attention (SA) 
tasks at baseline, after three months of soya/placebo, and after a further three 
months without supplement. There was no effect of isoflavones on cognition, 
regardless of time of initiation of the supplement.  
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This thesis offers a unique contribution to the literature, by establishing 
empirically that HRT may have long-lasting benefits for WM if administered in the 
peri-menopause period, and detriments if taken post-menopause. There was no 
evidence that administration of soya-based phytoestrogens for three months peri- 
or post-menopause replicated these effects of HRT on cognition.  
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Summary 
 
This thesis assesses the hormone replacement therapy (HRT) literature  
and ascertains the role of time of initiation of oestrogen therapies in the 
protection of cognitive function in menopausal women. At present the critical 
period hypothesis suggests that when HRT is taken during the peri -menopausal 
stage, frontal lobe function will be protected from the slowing down of 
neurogenesis that takes place during the menopause. The window of 
opportunity is poorly defined, therefore the present study will compare HRT 
users who have initiated the therapy specifically within 12 months of their last 
menstrual bleed (peri-menopausal stage) with those who initiated the therapy 
in excess of 12 months since their last menstrual bleed (post -menopausal 
stage). This tight window of comparison is yet to be explored, as previous 
studies have used wider age gaps as a defining feature of stage in the 
climacteric. The present study will also consider the role of HRT on cognition in 
post-menopausal women, comparing post-menopausal initiators to those in the 
post-menopausal stage with no history of HRT use. Also of importance to the 
literature, the first study will be extremely specific in the types of cognitive 
tasks chosen for exploration, where the literature as a whole struggles to pin 
point the exact type of frontal lobe function HRT may target and protect, often 
using large batteries of cognitive tasks without specific predictions about which 
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will be most sensitive to oestrogen. The thesis will then go on to explore the 
use of isoflavones (natural phytoestrogens that can mimic oestrogen in the 
body and brain) as a substitute for HRT in the protection of cognition. A 
randomised controlled trial (RCT) will explore ideas established in the HRT 
literature to see if natural phytoestrogens, which alleviate hot flushes, also 
work to benefit cognition. Wider implications include phytoestrogens as a  
potential replacement for HRT. 
 
The thesis aims to address the following questions: 
 Does early initiation of HRT protect executive function performance as 
compared to matched controls? 
 
 Does late initiation of HRT damage executive function performance as 
compared to matched controls? 
 
 Does Sustained Attention (SA), as well as WM, benefit from early 
initiation of HRT? 
 
 Are isoflavones a realistic substitute for HRT to maintain WM and SA ? 
 
 Is there a critical period of initiation for isoflavones? 
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Oestrogen action in the body and brain 
 
1.1 Oestrogen action 
 
Oestrogen is a female sex hormone produced mainly in the ovaries. Other 
sex hormones include androgens (the male sex hormones) and progesterone (the 
‘pregnancy’ hormone). Hormones are chemicals that are secreted by the body as 
a part of the endocrine system. They provide similar messaging systems as 
neurotransmitters however where neurotransmitters act on specific neurons, 
hormones can affect the body to induce long-term state changes such as global 
states of behaviour and this can take much longer. At any time there are more 
than 50 hormones in the bloodstream which have been secreted by various 
organs under the control of the hypothalamus. When hormones are secreted 
into the bloodstream they reach all parts of the body, but only certain target 
cells have receptors that allow them to respond to particular hormones. In these, 
the specific hormone can bind to the receptor cell and trigger a change in the 
cell’s chemical behaviour (Carlson, 2012; Toates, 2007; Wickens, 2009). The 
synthesis and secretion of oestrogens (and progesterone) is stimulated by 
Follicle-Stimulating Hormone (FSH) and Luteinising Hormone (LH), and controlled 
by the Hypothalamic Gonadotropin Releasing Hormone (GnRH). When levels of 
oestrogen (and progesterone) exceed a threshold, they inhib it FSH and LH 
synthesis (Stevenson, Cox, & Britt, 1981).    
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Generally the hypothalamus works to maintain homeostasis and keep a 
balance of hormones in the body. In the case of oestrogens, this balance varies 
through natural rhythms, such as the menstrual cycle and events such as 
pregnancy and menopause. These are points during a female lifespan where 
oestrogen levels will naturally change. During the menstrual cycle levels of 
oestrogen fluctuate from their highest points mid cycle (during the ovulation 
phase) to their lowest points at the end of the cycle and through the menstrual 
bleed (during the menstrual phase). In a healthy menstruating female the 
fluctuations are relatively steady throughout the female life span until she 
reaches the menopause, with the exception of pregnancy. During pregnancy 
oestrogen levels increase gradually, reaching their highest levels in the third 
trimester of pregnancy. At this point in the female’s life span she will naturally 
experience her highest levels of oestrogen. During  the menopause oestrogen 
levels decline in both the body and the brain reaching the lowest natural point in 
the female’s life span (Melton, 2000). This decline can be responsible for a range 
of reported problems or menopausal symptoms experienced during th is 
transitional stage, one of the largest reported problems overall being disturbed 
memory (Philips & Sherwin, 1992).  
Figure 1.1 shows oestrogen change as experienced during the different 
stages of the menopause.  
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Figure 1.1:  Oestrogen levels during different stages of the menopause, 
cited from: http://www.34-menopause-
symptoms.com/osteoporosis-causes.htm 
 
Oestrone (E1), oestradiol (E2) and oestriol (E3) are the major occurring 
oestrogens in women, and these diffuse across cell membranes to bind to and 
activate oestrogen receptors (Shao, Cheng & Jin, 2012). The actions of these 
major oestrogens are therefore dependent on and mediated by the o estrogen 
receptor in that cell (Okada et al., 2008). These three forms of oestrogen have 
differing potency levels that dominate depending on stage in a female’s life. For 
example, during normal reproductive function oestradiol is most active and most 
potent of the major oestrogens but it changes to oestriol during pregnancy and 
oestrone during the menopause (Jansson & Holmdahl, 1998).  
Oestrogen receptors act by entering the cell cytoplasm, bindin g to 
specific oestrogen receptor sites via the regulation of transcriptional processes, 
which leads to the up- or down-regulation of gene transcription (Simoncini et al., 
2004). This genomic ability is unique to nuclear receptors, and allows direct 
interaction with, and control of genomic DNA. Oestrogen receptors have also 
been shown to have non-genomic actions that are independent of these 
interactions with DNA (Losel & Wehling, 2004), binding to cytoplasmic oestrogen 
receptors causing changes in cell function that are independent of changes in 
Stage in menopause 
Figure has been removed 
due to Copyright restrictions 
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gene transcription (Aquila et al., 2004; Heinlein & Chang, 2002). Thus, genomic 
effects are those that involve triggering or changing transcription processes 
during protein synthesis and non-genomic effects are those acting on cell 
membranes. 
Because of the genomic and non-genomic effects of oestrogens, cells and 
organs are regulated by an interaction of these two mechanisms, including the 
cardiovascular and central nervous system (Simoncini & Genazzani, 2003) and 
oestrogen influences brain mechanisms via both genomic and non-genomic 
routes.  
1.2  Oestrogen creates differences in female brain structure, 
mechanisms and activity 
 
Exposures to sex-sensitive hormones create differences between males 
and females, and this can include differences in the macroscopic structure of the 
brain, which may account for differences in functioning of the brain (Craig & 
Murphy, 2006; Gorski, 1998). Common differences between male and female 
behaviour are often attributed to their dominat ing sex hormones and this can 
include small differences in brain structure, brain mechanisms and cognitive 
performance (Epting & Overman, 1988; Kimura & Hampson, 1994). The study of 
the action of oestrogen in the brain has advanced from known influences in  
sexual behaviour, reproductive effects and neuroendocrine function to known 
effects on motor coordination, pain mechanisms, dementia, depressive illness 
and cognitive function (Brinton, 2001; Brinton, 2009; McEwen, 1999).  
A healthy, normally functioning brain contains ten billion neurons, and 
every neuron has axon connections to thousands of other neurons allowing 
numerous biochemical receptors that respond to and trigger various actions. The 
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brain and these receptors are widely responsive to gonadal horm ones (McEwen, 
1999) where a proportion of the receptors in the female brain are responsive to 
oestrogens via oestrogen binding sites. In fact, 20 per-cent of the total number 
of neurons in the cortex, hippocampus and amygdala have oestrogen binding 
sites (Gustafsson, 2000).  
Initial cellular evidence for oestrogen actions in the brain was based 
upon the technique of steroid autoradiology. Here Pfaff and Keiner (1973) 
mapped out [3H] oestradiol uptake and retention to locate oestrogen -
concentrating neurons in the brain, which were found in the hypothalamus, 
amygdala, hippocampus and cortical and limbic areas which are involved in 
memory and learning processes (Gibbs, 2000a; Markou, Duka, & Prelevic, 2007; 
Wang, Hara, Janssem, Rapp, & Morrison, 2010).  The amygdala and hippocampus 
are both found in the temporal lobe and responsible for specific memory and 
learning (see figure 1.2). The existence of oestrogen receptor neurons in the 
hippocampus was further clarified by Loy, Gerlach and McEwen (1988) and 
Orikasa (2000). Specifically, oestrogens can indirectly stimulate nerve cell 
growth in hippocampus neurons and this is associated with improved lear ning 
and memory (Gazzaley, Weiland, & McEwen, 1996; Wooley, Weiland, McEwne & 
Schwartzkroin, 1997). 
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Figure 1.2: Areas of the brain with oestrogen receptor sites. Cited from: 
http://www.memorylossonline.com/glossary/basalforebrai
n.html 
 
Wang and colleagues (2010) have located an abundance of oestrogen 
receptor sites within the prefrontal cortex (PFC) suggesting that these specific 
receptor sites are oestrogen responsive. Miller, Conney, Rasgon, Fairbanks and 
Small (2002) used Positron Emission Tomography (PET) and identified an 
increase in glucose metabolic rates in the PFC and hippocampus for hormone 
replacement therapy (HRT) users during the completion of verbal and WM tasks. 
They suggested that the cortex and hippocampus may be the most  important 
areas of consideration for effect during menopausal oestrogen decline, perhaps 
due to being highly saturated in oestrogen binding sites.  
Tang and colleagues (2004) further clarified the location of oestrogen in 
the PFC, suggesting oestrogen to be primarily located in regions of the PFC 
involved in executive function. Monkeys who had undergone ovariectomy 
immediately received either oestradiol or a placebo. For those receiving 
oestrogen treatment, spine numbers of dendrites in the PFC significantl y 
increased compared with the placebo group, whose spine numbers did not 
Image has been removed 
due to Copyright restrictions 
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increase. The researchers specified this change to be in layer one of area 46 of 
the dorsolateral PFC, an area involved with working memory (WM) and sustained 
attention (SA). In contrast, the researchers considered oestrogen change in spine 
numbers of layer one of area six, in which there were no difference between 
oestrogen and placebo users, further reinforcing the idea that oestrogen can 
influence certain neocortical regions in the PFC.  
Neuro-imaging studies that compare HRT users to non-users further 
demonstrate the effect of oestrogen on the brain. For example, Erickson, and 
colleagues (2005) used high-resolution Magnetic Resonance Imaging (MRI) to 
examine the effects of HRT on brain volume in postmenopausal women and 
found HRT to be associated with spared grey matter in prefrontal, parietal, and 
temporal brain regions and white matter in medial temporal lobe regions. In 
addition to this, an association was made between longer durations of therapy 
use and greater sparing of grey matter tissue. The researchers concluded that 
age-related neural decline in both grey and white matter tissues can be 
decelerated by HRT use. In agreement, Ghidoni and colleagues (2006) found that 
women with a history of HRT use had greater white matter than those with no 
history of HRT use, and this was consistent in women who were current users 
and past users of HRT. They suggested oestrogen to have a ‘trophic effect’ on 
the cerebellum. 
Oestrogen’s role in the hippocampus further supports the impact of 
oestrogen change on distinct regions of the female brain. Generally it has been 
shown that exposure to oestrogen during proestrus (either naturally or with 
intervention) greatly enhances the density of dendrite spines in the 
hippocampus (Gould, Woolley, Frankfurt, & McEwen, 1990; Mukai et al., 2010; 
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Woolley & McEwen, 1993). These changes in spine density have encouraged 
synapse density and hippocampal transition of electrical signals (Montoya & 
Carrer, 1997; Warren, Humphreys, Juraska, & Greenough, 1995; Wong & Moss, 
1992).  
Erickson, Voss, Prakash, Chaddlock and Kramer (2010) used MRI in a 
cross-sectional sample of 102 women to detect hippocampal, amygdala and 
caudate nucleus volume between those who had never received HRT, those who 
had initiated the therapy close to the menopause and those  who initiated the 
therapy post-menopause. For both left and right hemispheres, those who began 
HRT at initiation of menopause had bigger hippocampal volume then either 
other groups. And in their study Lord, Buss, Lupien and Pruessner (2008) 
included postmenopausal women currently using HRT, past HRT users and never 
users to investigate the neuroprotective effects of oestrogens on the 
hippocampus and amygdala. HRT users exhibited larger hippocampal volumes 
than both past users and never users, which is consistent with the study by 
Erickson and colleagues (2010). The information demonstrates oestrogen’s role 
in brain function via increased blood flow and increase in spine densit y in 
specific brain regions (Maki & Resnick, 2000; Rasgon et al., 2004).  
1.2.1 Exposure to oestrogen creates differences in female brain 
activity and function 
 
Oestrogen receptors are located in specific parts of the female brain and 
oestrogen change alters performance of behaviours mediated by that brain area. 
For example, it has been demonstrated in ovariectomised rats treated with 
oestrogen therapy that this increase in oestrogen is correlated with superior 
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performance in memory tasks compared with a placebo control (Simpkins, Singh, 
& Bishop, 1994). 
In a human study, Cutter, Craig, Norbury, Robertson and Whitehead  
(2003) found that those taking HRT had significantly greater volumes of white 
matter associated with the cortex. During completion of a verba l memory task, 
those administered HRT demonstrated increased activation in the right superior 
frontal gyrus during item retrieval, a higher level of hippocampal and parietal 
lobe activation during item storage and greater left hemisphere activation 
during encoding, however no differences in task performance itself were found. 
As a means of comparison, participants were asked to remember non -verbal 
material. Interestingly there was decreased activity in these brain regions during 
storage of non-verbal material. The study highlights the effect of HRT on PFC 
activity during the completion of a verbal task.  
Using a similar study design, Shaywitz and colleagues (1999) looked at 
brain activation during the completion of verbal and non-verbal WM tasks using 
fMRI to determine whether oestrogen treatment modified expected brain 
activation patterns during the completion of these tasks. Peri -menopausal 
women were treated with either HRT or a placebo for two periods of 21 days. 
During the storage of material from the WM tasks, those receiving the oestrogen 
treatment had increased activation in the inferior parietal lobe and the superior 
frontal gyrus, similar to the study by Cutter and colleagues (2003). As with the 
study by Cutter and colleagues, despite frontal lobe activation improving in the 
group receiving oestrogen therapy, this improvement was not reflected in task 
performance itself. The participants had been receiving treatment over a short 
period only, which perhaps was not long enough to demonstrate effects in 
 
 
10 
 
cognitive performance transpiring in the tasks themselves. However both studies 
demonstrated metabolic and neurological differences in response to levels of 
oestrogen in the body. Shaywitz and colleagues (1999) concluded that oestrogen 
received by menopausal women can cause alterations in brain activation 
patterns during the performance of WM tasks, suggesting that oestrogen affects 
the PFC, an area of the brain that underlies WM processes. It should be noted 
that the difference between brain activation of oestrogen users and the placebo 
controls was greater during the verbal WM task.  
In a more recent study, Joffe and colleagues (2006) looked at the effect 
of oestrogen treatment on WM, learning and executive function against a 
placebo control in those entering the menopause. The fMRI study revealed 
increased frontal lobe activation during tests of verbal WM and spatial WM in 
those receiving oestrogen treatments. The studies further suggest oestrogen’s 
role in the PFC, and how completion of WM tasks can illustrate this effect. In 
fact several other recent human clinical and animal behavioural studies suggest 
that oestrogen replacement enhances performance on WM tasks that are reliant 
on the PFC (Duff and Hampson, 2001; Keenan, Ezzat, Ginsburg, & Moore, 2001; 
Rapp et al., 2003) and these will be discussed in more detail in section 1.4.  
The described studies have used fMRI to show that on completion of a 
memory task, blood flow and oxygen concentration levels are altered in brain 
areas gated by oestrogen binding sites such as the PFC, and that blood flow and 
oxygen levels are dependent on oestrogen levels in the brain (Dumas, Kutz, 
Naylor, Sites, & Newhouse, 2010; Joffe et al., 2006; Shaywitz et al., 1999). This 
may be dependent on type of oestrogen receptor.  
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Keenan and colleagues (2001) recognised poor executive function in 
women with lower levels of oestrogen, and proposed that oestrogen’s 
involvement with the hippocampus is secondary to these prefrontal -mediated 
changes. The PFC is associated with higher order cognitive processes  such as 
attention selection, resistance to interference, behavioural inhibition, task 
switching and decision-making (Dalley, Cardinal, & Robbins, 2004; Ragozzino, 
2007). The ability to conduct these processes with normal function and capacity 
relies on the healthy functioning of the receptor sites and synaptic activity 
within the PFC.  
To date there are at least two types of intracellular oestrogen receptors 
identified, ER-alpha and ER-beta (McEwen, 2002). These two forms of oestrogen 
receptors are encoded by separate genes but are similar in binding 
characteristics (Brinton, 2001). Although the distribution of ER -alpha has been 
fairly well established by steroid autoradiography and immunocytochemistry 
(McEwen, 2002; Pfaff, 1980; Stumpf & Sar, 1976) there is still some degree of 
uncertainty concerning the localization of ER-beta. It has been suggested that 
ER-alpha is the predominant receptor subtype of cholinergic neurons in the basal 
forebrain and also the PFC (Wang et al., 2010) whereas it is thought that  ER-beta 
are more abundantly distributed in the hippocampus and cerebellum (Shughrue, 
Lane, & Merchenthaler, 2008).  
ER-alpha and ER-beta are present in dendrite spines and presynaptic 
terminals to modulate both transmitter release and spine dynamics (Domi nguez, 
Lui, & Baudry, 2007; Hojo et al., 2008). The difference in brain localisation 
suggests that these two receptors mediate different functions. Oestrogen 
binding sites are found in the hippocampus and amygdala, and these brain areas 
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are associated with memory, attention and emotion. Because of the widespread 
presence of oestrogen receptor sites in various forms throughout the brain, 
oestrogen actions are also widespread and affect many neurotransmitter 
systems including the serotonic, noradrenergic, cho linergic and y-aminobutyric 
acidergic systems (Sherwin, 2003). It can therefore be concluded that major 
projecting neural systems (such as noradrenergic, serotonergic, cholinergic and 
dopaminergic) are subject to the influence of ovarian hormones. This is further 
discussed in the next section. 
As well as oestrogen being needed at oestrogen receptor sites to satisfy 
activation in these areas and maintain dendrite health, more intricate details of 
the neuroprotective role of oestrogen to their receptor sites and dendrite spines 
have been identified. Oestrogens can work with neurotrophins to indirectly 
stimulate nerve cell growth whereby oestrogens induce an increase in a 
membrane protein (N-methyl-D-aspartate receptors; NMDA) in hippocampus 
neurons which results in increased signalling to the excitatory neurotransmitter 
glutamate. This is associated with long-term potentiation, a proposed model of 
learning and memory (Gazzaley, et al., 1996; Wooley, et al., 1997). Binding a 
neurotrophin to their receptors results in a stimulation of the function related to 
the neurotransmitter production and release. In addition to this, oestrogens also 
have a neuroprotective action against several toxins that can result in hydrogen 
peroxide build up in the brain which can cause irreversible damage (Norbury et 
al., 2003), thus having a protective effect. 
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1.3 Oestrogen affects neurotransmitter production, duration and 
destruction 
 
Oestrogen receptor sites help to regulate the production, duration and 
destruction of neurotransmitters; chemicals that make it possible for neurons to 
communicate across their dendrites. The neurotransmitters modified by 
oestrogen action include dopamine, acetylcholine and serotonin (Craig & 
Murphy, 2006). Changes in concentration of these neurotransmit ters can affect 
their interlinking systems, mainly mood and cognition. For example, oestrogen 
action alters serotonin transition, which can lead to modifications in mood and 
cognition (Schloss & Williams, 1998). Sherwin (1994) found that mood varies 
during the different stages of the menstrual cycle, with improvements in mood 
during stages of the cycle when oestrogen levels reach their highest. During the 
menopause, women often report feelings of lowered mood, and mood is often 
included in menopausal rating scales. Subjective ratings of depression have been 
shown to increase as oestrogen levels decrease (Sagsoz, Oguzturk, Bayram, & 
Kamaci, 2001). The relationship between these mood-regulating 
neurotransmitters and oestrogen change can be explained when consi dering the 
location of these receptor sites and neurotransmitters in the brain.  
1.3.1 Dopaminergic terminals innervate pyramid cell spines in the PFC  
 
Dopamine production and action is oestrogen responsive and low levels 
of oestrogen result in a decrease in this neurotransmitter, which is associated 
with pre-menstrual syndrome, post-natal depression and post-menopausal 
depression (Fink, Sumner, Rosie, Grace, & Quinn, 1995). In fact Leranth and 
colleagues (2006) demonstrated a 30% reduction of dopaminergic cells in the 
brains of non-human primates after being deprived from oestrogen for 30 days.  
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Tang and colleagues (2004) demonstrated an increase in spine numbers 
of dendrites in area 46 of the PFC in ovariectomised monkeys when given 
oestradiol. Kritzer and Kohama (1998) also considered the role of oestrogen 
deprivation in area 46 of the PFC through ovariectomy of non-human primates. 
In their study, ovariectomy resulted in the dopaminergic system being 
compromised in this area, but this was restored with oestrogen treatment. This 
is because dopamine is facilitated by oestrogen, and dopaminergic terminals 
innervate pyramid cell spines in the PFC, an area saturated with oestrogen 
receptors (Lambe et al., 2000). Similar to the study by Tang; changes in 
dopaminergic action was most profound in layer one, area 46 of the PFC which is 
dense with both dopaminergic innervation and oestrogen action (Williams and 
Goldman-Rakic, 1993). 
Dopaminergic change plays an important role in mood, but also in 
information processing during WM tasks (Goldman-Rakic, 1996; Tang et al., 2004) 
and dopamine reduction in the dorsolateral PFC causes WM deficits in non -
human primates (Sawaguchi and Goldman-Rakic, 1995).  
1.3.2 Oestrogen change affects the cholinergic system and memory  
 Studies have demonstrated that oestrogen affects mechanisms that 
facilitate acetylcholine production, and greater production of this 
neurotransmitter will lead to better function of specific memory systems (Gibbs, 
2003). After the loss of ovarian function, the effect of oestradiol on the 
cholinergic system diminishes and this results in poorer cognitive function (Craig 
& Murphy, 2006; Gibbs & Gabor, 2003). 
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In a study by Voytko (2002), performance on visuospatial attention and 
reaction time was measured before ovariectomy, two months following the 
procedure and 14 months after treatment with either HRT or a placebo in non -
human primates. Oestrogen treatment resulted in modulation of attentional 
performance in a delayed response task. It was concluded that visuospat ial 
attention could be altered by oestrogen treatment, perhaps through the 
cholinergic system. 
 
1.3.3 Serotonin in the PFC is oestrogen responsive, influencing verbal 
memory and executive function 
 
Like dopamine, the neurotransmitter serotonin is also found in pyramid 
cells of the PFC and oestrogen receptors in this area facilitate the production of 
this neurotransmitter (Kugaya et al., 2003). Lower levels of oestrogen during the 
menstrual cycle are associated with lower levels of serotonin (Hindberg & Naes h, 
1992) and this has been related to lower mood during this time (O’Keane & 
Dinan, 1991).  
Kugaya and colleagues (2003) demonstrated an increase in serotonin 
activity in the right frontal cortex of oestrogen users above any other area, and 
this correlated with increased plasma levels of oestrogen in the same brain 
region. Participants receiving oestrogen treatment also performed better on 
tasks of verbal memory (paragraph recall and verbal paired associates tests from 
the revised Wechsler Memory Scale (WMS-R; Wechsler, 1987) and executive 
function (Trail Making Test, Reitan & Davison, 1974).  
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1.4 Oestrogen affects brain mechanisms which impact on memory 
systems 
 
Studies have highlighted the importance of oestrogen role in cognition, 
and in particular, memory (Duffy, Wiseman and File, 2003; Sherwin, 1988; 
Sherwin, 2012). Oestrogen level also seems to have a large effect on verbal 
episodic memory (Maki, Zonderman & Resnick 2001; deGroot, Hornstra, 
Roozendaal & Jolles, 2003; Sherwin, 1988).  
Oestrogen receptors can be found in the PFC and the hippocampus 
(Sherwin, 2003). Structures in the medial temporal lobe, and especially the 
hippocampus, are involved during and after learning, and this learnt information 
can be retrieved dependent on the PFC (Squire & Zola, 1996; Ungerlieder, 1995). 
Changes in brain structure and dendrite activity as a result of oestrogen change 
account for the relationship between oestrogen levels in the brain and memory 
performance (Sherwin, 2003). Brain imaging studies have helped to map out the 
neuronal changes (described in the previous section) onto behavioural changes, 
observed in the performance of cognitive tasks. For example, concentrations of 
oestrogen binding sites are found in the PFC (Tang et al., 2004), the am ygdala 
and the hippocampus (Loy et al., 1988; Orikasa, 2000). These brain areas are 
associated with memory and several studies have demonstrated a change in 
memory at times when oestrogen levels differ (Jenkins et al., 2004; Resnick, 
Metter, & Zonderman, 1997; Sherwin, 1988).  
Oestrogen levels change during pregnancy and the menopause, and 
during this time many women complain of memory problems (Craig & Murphy, 
2006; Mitchell & Woods, 2001). This is non-surprising when considering the 
location of oestrogen in the PFC and hippocampus, brain areas associated with 
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short and long term memory including explicit, implicit and episodic memory, as 
well as WM and SA. Information regarding oestrogens involvement with implicit, 
explicit, episodic and in particular verbal episodic memory is long withstanding, 
and less is understood regarding the role of oestrogen in WM and SA. Current 
research regarding oestrogen’s involvement with these memory systems will be 
described in the following section.  
1.4.1 Explicit, implicit and episodic memory 
Learning and memory are intricately linked, whether this is declarative or 
non-declarative. The temporal lobe, a region of the cerebral cortex located on 
the left and right hemispheres of the brain, consists of structures that are vital 
for long term, declarative (sometimes referred to as explicit) memory. The 
temporal lobe is involved in auditory processing and important for the 
processing of semantics in both speech and vision (Poeppel, 2003). The main 
subcortical temporal lobe structures include the limbic cortex, the amygdala 
(responsible for associating emotion with sensory input) and the hippocampus 
(responsible for formatting and organising long term memories; Swenson, 2006). 
Removal of the medial temporal lobes (including the hippocampus and amygdala ) 
results in anterograde amnesia. Lesions of the left temporal lobe result in 
impaired recall of verbal memory and lesions in the right temporal lobe result in 
impaired recall of non-verbal material.  
Healthy human aging is accompanied by changes in brain structure that 
varies by sex. For example, a hasty increase in ventricular volume begins in the 
fifth decade in men but not until the sixth decade in women (Kaye, DeCarli, 
Luxenberg, & Rapoport, 1992) suggesting that perhaps brain atrophy begins 
earlier in men than women. However the velocity of the atrophy process 
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increases with age more rapidly in women than men (Norbury et al., 2003). 
Generally, age-related loss of brain tissue is greater for females in the 
hippocampus and parietal lobes (Murphy et al., 1996). Eberling and colleagues 
(2003) suggest that, due to oestrogen receptor sites in the hippocampus, 
oestrogen protects against this age-related hippocampal atrophy. Memory for 
acquisition of new declarative or explicit memories is dependent upon the 
hippocampus and becomes compromised with increasing age (Small, Stern, Tang, 
& Mayeux, 1999). 
Explicit memory is conscious memory divided into semantic and episodic 
memory. It refers to memories that we are aware of and can recall. Implicit 
memory refers to unconscious memory (Andrade & May, 2004). For example, 
explicit memory refers to the conscious recollection of information, whereas 
implicit memory involves non-conscious habits and repetition priming (Sherwin, 
2002); it can be revealed as changes in behaviour, for example response bias or 
preference in the absence of conscious recall or recognition of the stimulus. 
Explicit memory is typically tested by paragraph recall (verbal memory), list 
learning (verbal memory) or recognition paradigms and is dependent on the 
hippocampus. It has been speculated that the right extrastriate cortex may play 
a role in implicit memory, rather than the hippocampus (Keenan, Yaldoo, Stress, 
Fuerst, & Ginsburg, 1998). Due to the relationship of explicit and implicit 
memory with the hippocampus, and the location of oestrogen receptors in this 
brain area, implicit and explicit memory performances during different points of 
the female lifespan have been explored.  
 Maki, Rich and Rosenbaum (2002) considered the role of oestrogen on 
implicit and explicit memory during different stages of the menstrual cycle. 
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Women aged between 18 and 28 completed tests of memory during their 
follicular (low levels of oestrogen) and midluteal (high levels of oestrogen) 
phases. Participants performed better on the category exemplar generation 
(measuring implicit memory), during their midluteal phase but no differences 
were found between stage in cycle for the explicit, category -cued recall task. In 
addition, oestradiol levels correlated positively with verbal fluency. 
Using paragraph recall (from the WMS-R) to assess explicit memory, and 
the work stem completion priming recall task to assess implicit memory; Keenan 
and colleagues (1998) assessed explicit and implicit memory change in pregnant 
women during their three trimesters of pregnancy. Pregnant women 
demonstrated worse implicit and explicit memory as their pregnancy progressed, 
but this did not reach significance between any trimester. Pregnant women did 
however perform significantly worse during the third trimester of pregnancy as 
compared to non-pregnant women matched for age, education and mood. Sharp, 
Brindle, Brown and Turner (1993) also demonstrated impairments in both 
implicit and explicit memory during the third trimester of pregnancy.  
Similar to the study by Keenan and colleagues (1998), Buckwalter and 
colleagues (1997) reported paragraph recall to be improved in women after 
giving birth as compared to performances during their third trimester of 
pregnancy. The two studies demonstrate that oestrogen change during 
pregnancy can have adverse effects on explicit memory but this can be corrected 
when oestrogen levels become normal again.  
As well as a relationship between oestrogen levels in the hippocampus 
and explicit and episodic memory performance, oestradiol helps protect against 
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the loss of acetylcholine, a neurotransmitter important for the formation of 
episodic memories (Singh, Meyer, Millard & Simpkins, 1994).  
Episodic memory is a declarative memory involving the recollection of 
discrete episodes and episodic performance is influenced by semantic memory 
and executive function such as attention and processing speed. Like explicit 
memory, episodic memory encoding is mediated by the hippocampus and medial 
temporal lobes (Henderson, 2009). Damage to this area results in a loss of 
episodic memory (Andrade & May, 2004). However, episodic memory has also 
been shown to have frontal lobe components (Rasgon et al., 2004; Tulving,  
Kapur, Craik, Moscovitch, & Houle, 1994) especially verbal episodic memory 
(Fletcher et al., 1995; Schmidt et al., 2002).  
When oestrogen levels are elevated during the follicular stage of the 
menstrual cycle, there is an increase in right anterior hippocampal volume, and 
this was associated with better performance during an episodic verbal memory 
task (Protopopescu et al., 2008).  
1.4.2  Verbal memory 
Oestrogen levels fluctuate throughout the menstrual cycle where the 
highest level of oestrogen occurs in the luteal phase. At this stage, verbal 
articulation is improved relative to when the participant is menstruating (Cutter 
et al., 2003; Wickham, 1958).  Women tend to perform better than men on 
verbal memory tasks, and women tend to have greater verbal task performance 
at mid cycle when oestrogen levels are at their highest suggesting that 
oestrogen facilitates verbal memory (Hurrel & Slade, 2001; Mordecai, Rubin, & 
Maki, 2008). 
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Oestrogen receptors are found in the frontal lobes and higher levels of 
activation are associated with higher concentrations of oestrogen in this brain 
area. Craig and colleagues (2008) found a positive correlation between serum 
oestradiol levels and left inferior gyrus activation (in the frontal lobe) in 
menstruating women during the encoding of verbal information. Dietrich and 
colleagues (2001) also demonstrated increased activation in the superior 
parietal cortex of those in the mid-luteal phase during completion of a word-
stem task. 
Although higher levels of oestrogen are associated with improved verbal 
memory, too great a level of oestrogen can also hinder verbal memory, further 
demonstrating an association between oestrogen levels and verbal memory. For 
example, deGroot, Adam and Hornstra (2003) compared the performance of 13 
memory and attention tasks of pregnant women (with high levels of oestrogen) 
to non-pregnant women (with normal levels of oestrogen). Pregnant women 
performed worse on language processing and attentional switching, suggesting 
that, as well as oestrogen deficiency, too great a level of oestrogen can have 
detrimental effects on verbal memory amongst other cognitive functions. The 
authors found correlations between test score and education and concluded 
education to be an important factor to be considered in data analysis.  
1.4.3  Executive function 
In familiar cognitive tasks we can respond using behaviours developed 
through learned schemas. However in some cases we may face a situation to 
which we need to ‘override’ an automatic process. In such cases we rely on our 
executive functioning. The PFC is linked to executive function, memor y and 
attention; executive function being an operation of the PFC (Miller & Cohen, 
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2001). Our understanding of the process of executive functioning has developed 
from observational studies of patients with frontal lobe damage. Although 
patients often demonstrate normal learning, memory and reasoning 
performance they frequently exhibit disorganised strategies and actions for 
everyday tasks, finding it hard to override prepotent responses and being easily 
distracted (Robertson, Manly, Andrade, Baddeley, & Yiend, 1997). The cortex 
facilitates executive functioning by maintaining patterns of activity allowing us 
to achieve tasks’ goals whereby the gain of neurones responsive to the task are 
increased. For example, focusing on one stimulus over another, the brain  would 
increase the gain of neurones responsive to that stimulus. Types of executive 
function that depend on this process are WM and SA.  
WM is a temporary storage system involving an interaction between 
attention and memory described as ‘the capacity for controlled, SA in the face of 
interference’ (Engle, Tuholski, Laughlin, & Conway, 1999). Rather than simply 
using rehearsal to embed information into our minds, WM is the ability to store 
information temporarily, and access this in order to perform complex cognitive 
tasks, requiring a certain amount of attentional control. Neuroimaging studies 
show that executive functions such as WM function is dependent on cells found 
in the PFC of the brain (Kane & Engle, 2003) and since oestrogen receptors are 
found in the PFC, oestrogen may modulate executive functioning and also WM 
(Sutcliffe, Marshall, & Neil, 2007). 
Attention is a basic function that is often used in a variety of cognitive 
and neurological functions. In the process of attention, we choose to 
concentrate on one aspect whilst ignoring or filtering out other things that may 
or may not be a distraction. According to Miller and Cohen's model (2001) the 
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PFC can exert attentional control over sensory and response neurons, overriding 
both memory and emotion. Interaction between the PFC and sensory, limbic and 
motor cortices exercise a level of cognitive control needed in selective attention 
and different forms of inhibition. If a focus or behavioural response needs to be 
maintained (usually during a continuous activity), the attention becomes 
sustained. SA is the ability to continue this focus over a greater period of time in 
the face of distraction. SA can become challenged if the task is boring, or has a 
workload that is too high. WM involves an interaction between attention and 
memory by storing information temporarily, and accessing this when needed, 
which requires control and practise of SA. SA becomes problematic in patients 
with frontal lobe and white matter damage and as such it has been suggested 
that the cortical basis of executive functioning and attention are situated in the 
frontal lobes and PFC (Whyte, Grieb-Neff, Gantz, & Polansky, 2006), home to 
oestrogen receptor sites. 
Duff and Hampson (2001) have suggested that some prefrontal functions 
are sexually differentiated. In their study, male and female students completed a 
novel multi-trial spatial WM task and a verbal WM task, prefrontal mediated 
tasks. During completion of the SPWM, females made fewer WM mistakes and 
reached conclusions significantly faster than the males. Females also 
outperformed males in the verbal WM task. 
In an fMRI study Berman and colleagues (1997) demonstrated that when 
young women were suppressed of oestrogen, oestrogen withdrawal resulted in 
reduced blood flow to the dorsolateral prefrontal and parietal cortex during 
completion of the Wisconsin card sorting task (Grant & Berg, 1948). The 
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Wisconsin card sorting task is a measure of executive function that can be 
impaired with frontal lobe damage. 
Animal studies have also demonstrated an effect on oestrogen change on 
executive function. Korol’s study (2004) demonstrated, using female rats, that 
differing oestrogen levels throughout the menstrual cycle alter the learning 
strategy used to solve a task even when learning rate is unaffected. The authors 
suggest that it is the quality of the information processed by the brain that 
becomes regulated, and this is dependent on hippocampal sensitive mechanisms.  
Here it was demonstrated that, in addition to how much is learnt, oestrogen 
levels can change what and how this information is learnt, exercising SA and WM.  
In their study, young female rats were tested on completion of a T -maze task at 
different stages of their menstrual cycle. The task allowed for free choice of the 
cognitive strategy used to solve the task. Rats could either solve the task using 
place strategy (go there) or response strategy (go right). Rats with highest 
circulating oestrogen were significantly more likely to select place strategies. 
Rats with lowest circulating oestrogen were more likely to select response 
strategy and those in the middle of their cycle had no bias. The strategy learning 
process is a hippocampal mediated process, and in this case oestrogen levels did 
not affect processing speed. 
In human studies, SA is impaired during pregnancy when oestrogen 
exceeds threshold levels in the brain and this may lead to impairment in other 
cognitive functions (deGroot et al., 2003). Crawley, Grant and Hinshaw (2005) 
administered thirteen cognitive tasks and compared pregnant and non -pregnant 
women. Two tasks were significantly different between groups. Firstly, pregnant 
women were significantly slower on a verification task ( for example, ‘all salmon 
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are fish?’). Secondly, the pregnant women where significantly worse at working 
out what floor a moving elevator was on when they were given instructions to its 
movement. The tasks used were not valid tasks but do demonstrate that c hanges 
in verbal memory, WM and attention are dependent on oestrogen levels in the 
body. Specifically, too much oestrogen as experienced during pregnancy can 
have detrimental effects on these executive functions.  
The combination of results from neuropsychological studies, fMRI 
information, and behavioural changes suggest that oestrogen can enhance 
performance of executive function and is dependent on the PFC in humans. The 
effect of oestrogen change on verbal, episodic and explicit memory is well tested, 
however the relationship with WM and SA is less well explored, and it is 
assumed that this relationship with executive function may explain memory 
problems reported by women during the menopause. Changes in oestrogen level 
during the menopause and the physical and mental effects of this hormonal 
depletion are explored in more detail in the next section.  
1.5 Hormone therapy is used to reduce menopausal symptoms in 
menopausal women 
 
During the lead up to the menopause, the patterns of neural coding in 
the temporal lobes are altered steering to the cessation of reproductive cycles. 
The interaction of ovarian and hypothalamic/pituitary ‘pacemakers’ becomes 
progressively dysfunctional and this results in the menopause (Sherwin & Henry, 
2008). In addition to this, the pool of ovarian follicles becomes limited until 
there is an eventual cease in production. These mechanisms combined result in a 
drastic decline in oestrogen levels which affect many body tissues and can 
produce menopausal symptoms, such as hot flushes,  changes in mood and a 
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decrease in bone density. Similar changes may be induced by surgical 
menopause or ovarian failure (Al-Azzawia & Palaciosb, 2009). Although female 
life expectancy during the past century has increased by 20 years, the average 
age of the menopause in industrialised countries has remained the same (51.8 
years).  This means that women live approximately a third of their lives after the 
loss of ovarian functioning (Sherwin, 2007) in a state of oestrogen deficiency 
that can challenge Quality of Life (QoL; McEwen, 1999). Current UK estimates for 
female life expectancy are 82.3 years (Office for National Statistics, 2012) and 
life expectancy for women in the UK is projected to rise to 87.0 years in 2033 
(Rutherford, 2012).  This increase in li fe expectancy will inevitably result in 
poorer QoL in women overall (Sherwin 2007), and may be helped by HRT.  
HRT can reduce menopausal symptoms including both cognitive and 
physical symptoms (Anderer, Semlitsch, Saletu, & Gruber, 2005). By 1999 an 
estimated 20 million post-menopausal women worldwide were using HRT (Beral, 
Banks, & Reeves, 2002) usually in the form of Conjugated Equine Estrogen (CEE) 
in 0.625 mg daily doses, or as very low doses (0.3 mg daily) of oestrogen 
combined with progesterone. In a Department of Health Survey conducted in 
1998, 38% of women in England aged 45-54 years had used HRT (Department of 
health, 1998).  Since the publishing of the Women’s Health Initiative study (WHI, 
Writing Group for the WHI investigators, 2002) which indicated an adverse effect 
of HRT use on heart health and cognition; prescribing of HRT has declined 
substantially (Prescription Statistics Publications, 2005). Other noteworthy 
studies include the Women’s Health Initiative Memory Study (WHIMS; Rapp, 
Espeland et al., 2003; Espeland et al., 2004; Shumaker et al., 2004) which 
recruited from the WHI, and the Million Women Study (MWS) which reported 
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Year 
one million women to have stopped taking HRT after a twofold risk of cancer in 
HRT users was revealed (Beral, 2003). After the results from the WHI became 
known, a decision was made to stop another large study, the Women’s 
International Study of Long Duration Oestrogen after Menopause (Anon, 2005). 
The percentage of women using HRT has declined over the past decade; as is  
shown in figure 1.3 (percentages from Sennik, 2009).  
 
Figure 1.3:  Percentages of total female population receiving HRT split 
for age (50-54 years or 55-59 years only) 
 
Prescription records have indicated that in 2001, six million women in the 
UK were receiving HRT. This decreased to three million in 2005 and two and a 
half million in 2009 (Lambert, 2009). Despite this decline due to fears of adverse 
effects, there are still a large proportion of women using HRT. Due to the 
continual large number of women initiating HRT at different points in their 
climacteric, it is important to establish HRT’s role in overall health and in 
particular, characteristics of HRT use which may result in optimal improve ment 
in QoL. 
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1.5.1 HRT can reduce osteoporosis when initiated within 3 years of 
completion of the menopause 
 
It has long been recognised that oestrogen deficiency may cause 
osteoporosis by contributing towards loss of bone mineral content and bone 
density, as well as encouraging fractures (Lindsay et al., 1976). The use of HRT 
has been shown to prevent such bone loss and as a result, decrease risk of 
fracture. For example, oestrogen use for a period of between five and ten years 
is associated with a 50% reduction in likelihood of fracture (Fogelman, 1991). 
The protection of bone density by oestrogen use appears to be long lasting. In 
their study, Lindsay, Hart, Forrest and Baird (1980) demonstrated a significant 
reduction of height in 100 women who had received a placebo nine years prior 
during a trial of oestrogen therapy for the prevention of post -oviarectomised 
osteoporosis. The oestrogen treated group had less central and peripheral bone 
loss, and a reduction in incidence of vertebral compression. Bone at rophy is 
likely to occur at one per-cent per annum, and this has been shown to be 
prevented in HRT users for the first three to five years of treatment (Lindsay et 
al., 1976). More recent studies with larger cohorts have also demonstrated the 
beneficial effects of oestrogen use on prevention of osteoporosis. The WHI was 
the first Randomised Controlled Trial (RCT) to demonstrate reduction of hip 
fracture risk with oestrogen use (Writing group for the WHI investigators, 2002). 
But the prevention of osteoporosis through oestrogen use may be limited to 
time of initiation relative to completion of the menopause. Demonstrated in an 
early study; oestrogen use in 114 middle-aged women two months post 
ovariectomy resulted in significant prevention of bone mineral los s compared 
with a placebo. Treatment delayed to three years resulted in significant 
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increases in bone mineral density, but this effect was lost when treatment was 
delayed to six years post operation (Aitkin, Hart & Lindsay, 1973).  
1.5.2 HRT can reduce cardiovascular disease in younger menopausal 
women 
Both oestrogen receptors are found in blood vessel cells and facilitate 
oestrogen inhibition of vascular injury such as atherosclerosis (Pare et al., 2002; 
Punnonen, Jokela, Dastidar, Nevala, & Laippala, 2000) and this decreases the risk 
of heart disease (Nadkami, Cooper, Brancaloeone, Bena, & Penetti, 2011; Rosano 
& Panina, 1999). Administration of oestrogen in menopausal women has been 
shown to affect blood flow and the vascular system (Volterrani, Rosano, C oats, 
Beal, & Collins, 1995) whereby oestrogen use can improve blood flow and 
protect the cardio vascular system. The increase in blood flow could, in part, 
account for the change in blood flow recognised in fMRI and PET studies and this 
is something that needs to be considered in analysis. However it should also be 
noted that this increase in blood flow is most prominent during the completion 
of specific, frontal mediated tasks. 
Although observational studies have recognised a benefit of HRT use on 
prevention of cardiovascular disease in menopausal women (Henderson, 
Paganini-Hill, & Ross, 1991; O’Keefe et al., 1997), two RCTs found no difference 
in coronary heart disease risk between HRT users and a placebo group (Hsia et 
al., 2006; Hulley et al., 1998). Both studies considered the role of oestrogen use 
in post-menopausal women, and risk was lower for younger initiators (aged 50-
59, Hsia et al., 2006). 
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1.6  HRT can protect natural cognitive declines experienced during 
the menopause  
 
Due to the effects of oestrogen on brain chemistry, it has been proposed 
that oestrogen use during the menopause may enhance cerebral and cogniti ve 
function (Rasgon, Magnuson, Johansson, Pedersen, & Gatz, 2005). Norbury and 
colleagues (2003) go on to suggest that oestrogens affect brain development in 
regions crucial to higher cognitive function by interacting with neuronal 
networks at many different levels.  
Animal studies have helped to investigate neuronal changes at a level of 
detail that is difficult to explore in human studies. As a result of animal studies it 
is now recognised that oestrogen influences aspects of brain chemistry known to 
be important for memory functions, such as influence on neurotransmitters 
(Craig & Murphy, 2006), and it is these functions that are impeded by oestrogen 
decline during the menopause (Brinton, Chen, Montoya, Hseih, & Minaya, 2000).  
During the menopause, oestrogen decline can lead to changes in the 
structure of the female brain (Cutter, Norbury, & Murphy, 2003) such as 
decreased blood flow to the hippocampus (Maki & Resnick, 2001) a reduction in 
the white brain matter (associated with decreased memory functions; Whyte et 
al., 2006) and a decrease in spine density of dendrites in the PFC and 
hippocampus (associated with different types of memory and attention decline; 
Hao et al., 2004; Robertson & Van Amelsvoort, 2001). At oestrogen receptor 
sites (found in the specific areas of the brain detailed above), oestrogen 
regulates synaptogenesis (increase in dendrite density and synapse). Oestrogen 
production during the menopause decreases and this results in decreased 
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dendrite density and decreased synaptic activity and can result in the cognitive 
functions mediated by this activity becoming compromised.  
After the reduction of oestrogen during the menopause, HRT promotes 
brain functioning in women and protects brain functioning as they age (Greene, 
Bellgrove, Gill, & Robertson, 2002). Neurobiological knowledge can be advanced 
through the comparison of cognitive task performance between those with a 
marked difference in some aspect of brain chemistry and those who are ‘normal’. 
In the case of oestrogen change most of our understanding of its effects has 
come from the comparison of those with different levels of oestrogen in their 
body and brain to understand the biological and neurological outcomes. For 
example, by comparing two groups of women with contrasting oestro gen levels 
we can now make the assumption that higher levels of oestrogen have a positive 
effect on emotions, verbal abilities, gross motor strength, behaviour and 
perceptual speed (Jarvik, 1975; Yaffe et al., 2000). On a large scale, studies have 
highlighted the importance of the role of oestrogen in memory (Duffy et al., 
2003; Jenkins et al., 2004; Resnick et al., 1998). Philips and Sherwin (1992) and 
Norbury and colleagues (2003) affirm that memory problems are one of the most 
commented upon by women at the climacteric, and that HRT is helpful to restore 
this. 
As described above, ovarian hormones can influence brain regions crucial 
to higher cognitive functions such as learning and memory at structural, cellular 
and functional levels (Pompili, Arnone, & Gasbarri, 2012). Currently, doctors are 
advised not to provide HRT for cognitive function in menopausal women but HRT 
can be prescribed for the alleviation of other menopausal symptoms, and it is 
recommended that the minimum dose needed is prescribed for the shortest 
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amount of time. Doctors are advised that for the treatment of menopausal 
symptoms the benefits of short-term HRT outweigh the risks in the majority of 
women less than 60 years of age. However HRT does not prevent cognitive 
decline. A large body of evidence challenges these recommendations, urging for 
reconsideration in GP recommendations against HRT use for protection of 
cognition. This evidence is described in detail over the next few sections.  
1.6.1 The potential for HRT to protect against dementia  
 
AD is the most common form of dementia, involving areas of the brain 
responsible for thought, memory and language (Richards & Hendrie, 1999). 
Incidence rates suggest that the risk of AD in women is double that of men at the 
age of 80 (Zandi, Carlson, Plassman, Welsh-Bohmer, & Mayer et al., 2002) 
leading to explorations on the association between oestrogen deficiency and AD.  
Ovarian steroids produce many effects on the brain, influencing 
processes such as cognitive function, motor activity, and devel opment of 
Parkinson’s disease and Alzheimer’s Disease (AD; McEwen, Alves, Bulloch, & 
Weiland, 1998). Episodic memory is the domain most severely affected in the 
early stages of AD (Welsh, Butters, Hughes, Mohs & Heyman, 1992) and deficits 
in encoding novel information is an early symptom of AD (Blacker et al., 2007). 
This can be encapsulated in a preclinical stage of AD, known as mild cognitive 
impairment, a mild neurocognitive decline that occurs in the presence of day to 
day functioning (Levy, Lah, Goldstein, Steenland, & Bliwise, 2006). Executive 
function is also severely affected (Blacker et al., 2007).  
Over the past two decades, there has been considerable research 
investigating the risks and benefits of HRT with regards to neurodegenerative 
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diseases. For example, Kawas and colleagues (1998) demonstrated that HRT is 
associated with a significantly reduced risk for AD, and Tang and colleagues 
(1996) also demonstrated a reduced risk for AD and went on to identify an 
inverse relationship between duration of  use and risk. During a long term follow 
up study; Dye, Miller, Singer and Levine (2012) found a reduced risk of AD and 
improved cognitive function in menopausal women who had initiated HRT at an 
earlier date, with a mixed impact on Parkinson’s disease.  
In another study, the researchers wanted to investigate the impact of 
two to three years of HRT use during the menopause on the risk of cognitive 
impairment five to 15 years later. A total of 343 postmenopausal women who 
had participated in a randomised clinical trial studying the effects of HRT on 
osteoporosis were invited to take part in this follow up study considering their 
current cognition (Bagger, Tanko, Alexandersen, Qin, & Christiansen, 2005). At 
15 years after the therapy was completed, participants had a mean age of 65 
years and had not since received any form of HRT. Cognitive function was 
assessed using the short Blessed test (Katzman et al., 1983), which includes tests 
of orientation, concentration and memory function where a cognitive score of 
less than six indicates cognitive impairment. There was no difference in cognitive 
mean scores at 15 year follow up between the users and placebo nonusers. 
However for those who had received HRT, the risk of cognitive impairment 
(demonstrated by a score lower than six) was decreased by 65%. The researchers 
suggested from this that early use of HRT during the menopause may prevent 
cognitive impairment in later life, but that later use may have a detrimental 
impact. A review by Dye and colleagues (2012) also suggested a reduced risk of 
AD with earlier HRT use, whereas the WHIMS found an increase in risk of AD 
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when HRT was initiated a decade or more after the menopause. Data from the 
WHIMS demonstrate a higher incidence of cognitive impairment and dementia 
among HRT users who initiated the therapy during the post -menopausal stage, 
as compared to placebo controls (Rapp et al., 2003; Shumaker et al., 2003). 
Similarly, participants were over one decade past the natural menopause at 
point of HRT initiation, and perhaps this was too late to protect cognitive decline 
at this point. Due to the large implications of AD research, possible detrimental 
effects of HRT on cognitive function have been explored.  
One study found HRT enhanced cognition for women with already 
developed AD. In their study, Asthana and colleagues (1999) evaluated the 
cognitive response to HRT for menopausal women with AD. Twelve women with 
AD of mild-moderate severity received six weeks of either oestradiol or a 
placebo. For women receiving HRT, enhancement in verbal memory was 
positively correlated with plasma levels of oestradiol. In the placebo group, no 
significant effects were found. The results of the study suggest that short HRT 
use may enhance cognition for post-menopausal women with AD. 
The memory of women who experience rapid oestrogen decline at a 
younger age, perhaps through removal of part or all of the reproductive system, 
can be investigated for any changes before and after surgery, or compared with 
women with normal reproductive function matched for age. If surgery has had a 
detrimental effect on memory at this point, it can be assumed that this is not an 
aging effect. Such memory change can then be compared to the normal 
menopausal population for similarities. By investigating surgically menopausal 
women it has been demonstrated that earlier age of surgical menopause 
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increases the risk of cognitive impairment in later life and even increase the risk 
of neurological diseases such as AD (Rocca et al., 2007; Rocca, Grossardt, & 
Maraganore, 2008). This means it is important to prescribe HRT as close to the 
surgical menopause as possible, and may have implications for the natural 
menopause too. In addition, such studies have demonstrated that HRT can 
enhance short term memory as well as long term memory and the capacity for 
learning new associations (Sherwin, 2005; Philips & Sherwin, 1992). The effect of 
HRT on such memory systems are described below. 
1.6.2 HRT enhances Verbal, episodic and explicit memory in 
menopausal women 
 
AD has higher prevalence in women, which has led to the development of 
research regarding estimated prevalence of AD in women, and the potential to 
reduce this with the use of HRT. Similarly, specific cognitive tasks are also sex 
sensitive, which has led to developments in research regarding HRT and verbal 
memory.  
The positive effect of higher levels of oestrogen on verbal memory has 
been a popular area of research in earlier decades (deGroot et al. , 2003; Maki et 
al., 2001; Sherwin, 1988) and the idea that oestrogen levels in the brain affect 
verbal memory is longstanding (Wickham, 1958). The effects of HRT have since 
been drawn into consideration, highlighting the positive effects of HRT on verbal 
memory (Sherwin 1997, 2007b, 2008). Oestradiol is assoc iated with a reduced 
amount of decline in verbal memory among menopausal women, with benefits 
seen in therapy durations ranging from three months to two years in women just 
completing the menopause (Bagger et al., 2005; Dumas, Hancur-Bucci, Naylor, 
Sites, & Newhouse, 2008; Silverman, Geist, & Kenna, 2010).  LeBlanc, Neiss, 
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Carello, Samuals and Janowsky (2007) failed to demonstrate improvements in 
verbal memory in women who had just completed the menopause; however the 
treatment duration was a shorter time of two months only. 
Rensnick and colleagues (1998) assessed regional blood flow in 
menopausal HRT users and non-users during delayed recognition of verbal and 
figural information. Increased activation was recognised in the right frontal 
regions and right parahippocampal gyrus during verbal memory processing, and 
the right parahippocampal and inferior parietal regions during figural processing. 
Further to this, Joffe and colleagues (2006) demonstrated increased activation of 
the frontal lobes during recall of verbal information from a verbal memory task 
in menopausal participants receiving HRT, compared to placebo controls. These 
studies combined confirm verbal memory to be mediated by the frontal lobes, 
and show a relationship between increased frontal lobe activation with 
oestrogen replacement during the completion of verbal memory tasks.  
Verbal memory has been shown to improve using paragraph recall (from 
the WMS-R) and also list recall from the California Verbal Learning Task (CVLT; 
Delis, Kramer, Kaplan & Ober, 1987) in menopausal women receiving HRT 
(Sherwin, 1988). In a more recent study, Maki  and colleagues (2001) looked at 
verbal memory scores of 184 menopausal and post-menopausal women aged 
between 50 and 89 years of age. Of these, 81 women had never r eceived HRT 
and 103 women were current users. Participants completed the CVLT, the digit 
span task from the Wechsler Adult Intelligence Scale Revised (Wechsler, 1939) 
and the Benton Visual Retention Test (Benton, 1968). On the CVLT, HRT users 
outperformed non-users on immediate recall in each of the five list -learning 
trials, recall after both short and long delays, word recognition and clustering of 
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words into semantic categories indicating being better engaged in active 
learning. The selected population had too large an age span and it would have 
been more appropriate to lower the upper age limit to combat ageing effects 
which have a large impact on WM and attention. 
In order to help discriminate the positive effect of HRT use on verbal 
memory from other cognitive tasks, Kampen and Sherwin (1994) investigated the 
effect of HRT use in post-menopausal women on verbal memory, spatial memory, 
language and attention. HRT users demonstrated better immediate and delayed 
paragraph recall (also from the WMS-R) than matched controls with no history of 
HRT use. No differences were found on any other tasks, suggesting verbal 
memory to be susceptible to oestrogen change.  
Similar to AD research, differences in the protection of verbal memory by 
HRT use have been found depending on the participants’ age. In their study, 
Dumas and colleagues (2008) compared a group of 50-62 year olds with a group 
70-81 year olds to see if the benefits of HRT on verbal memory could be seen in 
women who were almost 20 years beyond the menopause. Reduction of 
mistakes was only seen in the younger group. However Tiernery and colleagues 
(2009) did show a reduced amount of mistakes made during a verbal memory 
task for women aged between 61 and 87 years, but this was only demonstrated 
in women who scored above average on the verbal task initially, and not those 
with normal, or lower than average score. For the study by Tiernery and 
colleagues, most participants had an average or below average score on the 
verbal task and this is typical of the general population. 
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Several human studies have shown the beneficial role of oestrogen in the 
hippocampus, an area of the brain associated with episodic memory (which can 
be measured using verbal memory tasks such as list recall and paragraph recall). 
Using Magnetic resonance spectroscopy, Robertson and Van Amelsvoort (2001) 
compared HRT users and non-users to young women (of normal menstrual 
functioning) for energy metabolism in specific brain areas. HRT users and young 
women had increased signal activity in the hippocampus and parietal lobe 
compared to non-users. Interestingly there was no difference between signal 
activity of the HRT-user group and naturally menstruating females, suggesting 
that HRT use had restored hippocampal activity to normal menstruating fu nction.  
Maki and Resnick (2000) examined longitudinal changes in regional 
cerebral blood flow over a two year interval in women on and off HRT. Each 
participant demonstrated significant differences in cerebral blood flow 
dependent on whether they were taking HRT at that point or not. Specifically, 
differences in cerebral blood flow were found in the right hippocampus, the 
parahippocampal gyrus, and the left middle temporal gyrus whereby those with 
lower levels of oestrogen in their body demonstrated less b lood flow to these 
brain regions. The researchers went on to confirm that women who were 
experiencing less blood flow to these brain regions (as experienced naturally 
during the menopause) demonstrated less neuronal activity in these regions. 
This can result in lessened cognitive efficiency which can cause deficiency in 
types of memory capacity that operate in these brain areas.  
In addition, the cholinergic system mediates the ability of oestradiol to 
affect the hippocampus and associated behaviours (Danie l, Hulst, & Lee, 2005; 
Dohanich, Korol, & Shors, 2009). In rat studies, oestradiol has been reported to 
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enhance cholinergic muscarinic receptor density and enhance cholinergic uptake 
and activity in the hippocampus.  
When ovariectomised rats receive oestrogen therapy, spine density 
increases in the CA1 area of the hippocampus, and not area CA3. The CA1 area of 
the hippocampus plays a role in explicit memory, which could support 
improvements in explicit memory with HRT use (Tang et al., 2004). Gibbs (2000b) 
found that rats who experienced a deficiency in oestrogen also suffered from a 
deficiency of brain nerve growth in the hippocampus. When these rats were 
given short-term HRT, the brain areas restored themselves with stronger 
dendrite spines which results in increased synaptic activity and activation. As 
well as oestrogen increasing neural plasticity in the hippocampus, Frick and 
colleagues (2004) demonstrated that this increase could affect memory in 
ovariectomised middle-aged female mice using the radial arm maze.  
Episodic memory has also been suggested to have frontal lobe 
components (Janowsky, Shimamaura, & Squire, 1989; Tulving et al., 1994) and to 
be mediated in part by the posterior cortex, the posterior cortex being 
dependant on the PFC. Fletcher and colleagues (1995) and Schmidt and 
colleagues (2002) describe verbal memory as a type of episodic memory 
mediated by the left PFC during encoding, and the right PFC during retrieval.  
Rasgon and colleagues (2004) compared regional metabolic activity 
between postmenopausal oestrogen users and non-users, predicting that 
oestrogen use will result in preserved regional metabolism. Neuropsychological 
tests were administered to assess cognitive performance. Unfortunately 
participants in the oestrogen group were significantly younger than those in the 
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non-users group (more than 10 years difference between mean ages). To help 
correct for the effect of age on cognition, age was added as a covariate in 
analysis. Analysis revealed that those in the oestrogen non-users group had a 
significant decline in the posterior cingulate cortex’s regional metabolic activity 
whereas oestrogen users had no such decline. The researchers concluded that 
HRT can help protect metabolic decline in this brain area as a result of the 
menopause, and that those receiving HRT may have better function in the 
posterior cortex to help continue neurogenesis and combat neurodegenerative 
disease. 
Studies have demonstrated that HRT is beneficial to verbal memory and 
other memory functions. Those with higher levels of education may be able to 
combat these problems, but only in simple memory tasks.  It is now believed 
that oestrogen affects higher level cognitive functions, especially if these have a 
verbal component (Rosenberg & Park, 2002; Sherwin, 1997;  Sherwin, 2012). 
1.6.3 HRT can target executive function systems in the PFC 
 
Keenan and colleagues (2001) suggest that previously reported cognitive 
declines mediated by the hippocampus are secondary to executive dysfunction 
mediated by the PFC. In their study, HRT users were compared to placebo 
controls on a battery of tasks including memory and executive function tasks. 
Results suggested that oestrogen influences prefrontal -cortex mediated tasks, 
and not those mediated by the hippocampus. Specifically, oestrogen users out-
performed placebo controls on a discrimination component of the CVLT, 
inhibition control and the N-Back test of WM (Kirchner, 1958). In support of this 
view point, Wegesin and Stern (2007) demonstrated that HRT use resulted in 
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better source memory (which relies more heavily on executive processes) than 
item memory when compared to non-users.  
HRT use encourages dendrite growth in layer one, area 46 of the PFC 
(Tang et al., 2004) which may account for stronger WM and SA performance in 
HRT users in the study by Keenan and colleagues (2001). In addition to this, 
several other studies have also recognised an improvement in WM and SA 
performance for those receiving HRT treatment compared to placebo controls 
and this is described in detail below. 
Working memory 
Pompili and colleagues (2012) suggests that further clarification in the 
role of oestrogen in WM is needed in part due to conflicting research (mostly 
from animal models). The relationship between oestrogen and WM has been 
well established in rat studies whereby oestrogen replacement in young 
ovariectomised rats has been shown to improve WM involving a two -choice 
water escape WM task (Bimonte & Denenberg, 1999; O’Neil, Means, Poole, & 
Hamm, 1996) and moderated maze tasks (Fader et al., 1999;  Korol & Kolo, 2002; 
Zurkovsky, Brown, Boyd, Fell, & Korol, 2007). Spatial WM in rats is mediated by 
the hippocampus (Korol et al., 2004). In humans, WM is mediated by the PFC, 
and the beneficial effects of oestrogen on activation in this area have been 
demonstrated (Joffe et al., 2006; Smith et al., 2006; Shaywitz et al., 1999). WM 
capacity exhibited through superior performance of menopausal oestrogen users 
has also been demonstrated (Dumas et al., 2010; Keenan et al., 2001; Stephens, 
Bristow, & Pachana, 2006). 
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In the study by Shaywitz and colleagues (1999), the researchers 
considered the effect of HRT on brain activation during the completion of a 
verbal and a non-verbal WM task. Those receiving the oestrogen treatment had 
increased activation in the left hemisphere during encoding into WM and the 
right superior frontal gyrus during retrieval for the verbal task only (similar to 
the study by Cutter and colleagues, 2003). The activation patterns described are 
similar to patterns of activation seen in younger adults (Dumas et al., 2010). The 
researchers deduced that oestrogen received by menopausal women can cause 
alterations in brain activation patterns during the performance of WM tasks. 
Task performance remained similar between groups perhaps due to ceilin g 
effects.  
One study was able to demonstrate both increased neuronal activation 
during completion of a spatial WM task, as well as improvements in task score 
itself (Joffe et al., 2006). In their study, participants were randomly assigned to 
oestradiol or a placebo for 12 weeks. Both prior to and on completion of 
treatment the participants completed tests of executive function including 
verbal and spatial WM, complex verbal recall and learning as well as a measure 
of menopausal symptoms. Results showed significant activation during tasks of 
verbal and spatial WM in the superior frontal gyrus for the higher WM load 
condition only. The group receiving oestrogen therapy also selectively reduced 
errors of perseveration during verbal recall, a frontal mediated f unction. 
Measures using fMRI showed a significant increase in frontal lobe activity for the 
oestrogen users only. In addition, women with higher rated menopausal 
symptoms experienced greater cognitive benefit with oestrogen therapy perhaps 
due to an alleviation of the symptoms themselves. In this case, HRT helped to 
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improve executive functioning as demonstrated by reduced perseverative errors 
and PFC activation during verbal and spatial WM tasks.  
Smith and colleagues (2006) also considered the effects of H RT on spatial 
WM. Participants either received one month of oestrogen replacement or a 
placebo. Treatment was reversed after a wash out period. Like the study by Joffe 
and colleagues (2006), the PFC was activated during completion of the spatial 
WM task for the oestrogen users only, and this was irrespective of order of 
treatment. Both studies demonstrated an increase in activation of the frontal 
lobes during storage of spatial WM material.  
It has been suggested that oestrogen specifically affects the delay ed 
response performance characteristic of WM (Bailey et al., 2011). Differing to the 
studies by Smith and colleagues (2006) and Joffe and colleagues (2006); Dumas  
and colleagues (2010) explored the active manipulation of material typical of 
Baddeley’s WM model (1986). The researchers used fMRI to examine the effects 
of oestradiol on information manipulation during completion of components of 
the N-back task, mediated by the frontal lobes. At baseline and three months 
following treatment, each woman completed a visual verbal N-back sequential 
letter test with three difficulty levels (based on cognitive load). They found that 
women treated with oestradiol for three months had an increase in frontal 
activity during completion of the two more challenging levels  of the WM task 
compared to a placebo control, however this was not evident in task score itself. 
The study again demonstrates a beneficial effect of oestrogen in prefrontal 
mediated tasks such as WM, and similar to the study by Joffe and colleagues 
(2006), the beneficial effect of oestrogen on task score may be dependent on 
difficulty of the task.  
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Jenkins and colleagues (2004) considered the role of anti-oestrogens 
(taxomifen) on cognition in menopausal breast cancer patients, compared to 
healthy menopausal women with no history of HRT use. Participants were asked 
to complete the verbal memory paragraph recall test, visual memory faces 
recognition test, spatial span WM task, letter sequence WM task and digit span 
WM task (Wechsler, 1998), The Kendrick digit copying task for processing speed 
(Kendrick and Watts, 1999) and the GHQ-12 (Goldberg & Williams, 1988) and 
Beck depression inventory (BDI; Beck & Steer, 1984). Average scores were lower 
for the oestrogen suppressed group for each task, and this differen ce was 
significant for the verbal memory task and processing speed. Higher scores on 
the BDI were not significantly correlated with lower score on any of the 
cognitive measures and those with low GHQ-12 scores (to demonstrate normal 
mental health) and high scores (indication of a common mental health problem 
such as anxiety and depression) did not differ in cognitive performance.  
The research highlighted above identifies a beneficial effect of oestrogen 
on prefrontal mediated tasks, and in particular, WM. This effect can be 
enhanced by HRT use. 
WM involves regions of the brain that are receptive to oestrogen, yet in 
some cases, despite increased activation in brain areas during completion of WM 
tasks in oestrogen users, this was not demonstrated in task per formance itself. 
WM span tasks are one of the most widely used measurement tools in cognitive 
psychology and highlight individual differences in general intellectual ability and 
can be used across different age groups (Kane & Engle, 2004). WM span tasks 
were designed based on Baddeley and Hitch’s (1974) theory of WM which 
demonstrates the importance of an immediate memory system capable of 
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storing a limited amount of information whilst being cognitively attentive 
elsewhere. The system requires more complex storage mechanisms then other 
types of memory in order to form the crucial interface between perception and 
memory, and between attention and action. Memory span reflects the speed at 
which items can be rehearsed as well as the rate at which the ‘trace’ fa des 
(Baddeley, 2007). However, the event of rehearsal can be distracted in the face 
of alternative tasks, as represented throughout everyday responsibilities 
(Murray, 1968). Task performance is therefore dependent of difficulty of the 
task, and exercise of cognitive load. Through completion of WM tasks, brain 
areas will become active but differences in task performance may only become 
apparent when tasks are of a certain level of difficulty.  
Because WM Capacity (WMC) can diminish with age (in women this can  
occur quickly from 65 years and onwards), researchers need to be cautious 
about the upper age of the participant. By inviting post -menopausal women to 
complete their studies to measure WM differences between HRT users and non -
users, perhaps researchers are confusing brain aging effects with hormonal 
effects (Grigorova, Sherwin, & Tulandi, 2006). This may be apparent in some 
studies designed to investigate the possible effects of HRT on executive function 
and WM to which no or small effects have been found between groups (such as 
Janowsky, Carello, & Orwoll, 1999; Keenan et al., 2001 and Shaywitz et al., 1999).  
Sustained attention 
It has been suggested that SA may become problematic during the 
menopause as changes in oestrogen levels have been linked to a de crease of 
functioning oestrogen receptor sites in the PFC and white matter of the brain, 
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and deficits in frontal lobe functioning. In addition to this, oestrogen decrease 
during the menopause can result in decreased WM capacity and SA may rely on 
WM when information processing and storage become competitive (Knudson, 
2007). Cognitive measures demonstrating SA include reaction time tasks and 
oestrogen change during the menopause may have effect on reaction speed 
during reaction time tasks (Wuttke et al., 1975). 
Several animal and human studies have reported that gradual oestradiol 
reduction due to the menopause slowly diminishes activity in the cholinergic 
system. This may have an effect on cognitive functions sensitive to cholinergic 
activity in the frontal and hippocampal areas of the brain such as SA (Sarter, 
Givens, & Bruno, 2000). Voytko, Tinkler, Browne and Collins (2009) found 
oestrogen influences attention in surgically-menopausal monkeys and the 
cholinergic system is one of the mechanisms by which oestrogen modulates 
attention. SA is also impaired when women are given a hormone suppressant to 
combat breast cancer (Wieneke & Dienst, 2007), suggesting that it may become 
impaired during the menopause and potentially protected with oestrogen 
replacement. 
Changes in SA during the menopause and response to HRT are well 
explored in animal studies, but not in human studies. For example, high -dose 
oestradiol injections have been shown to improve aspects of the five -choice 
serial reaction time task in ovariectomised young rats (Barnes, Staal, Muir, & 
Good, 2006). However, rats who were ovariectomised and given oestrogen 
several days after surgery demonstrated adverse effects in delayed spatial 
alternation and inhibition control (Wang et al., 2008). Although rats r eceiving 
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oestrogen treatment performed worse in these executive function tasks, the 
study still confirmed a relationship between oestrogen change and WM and SA.  
A number of studies have indeed reported an improvement with HRT in 
executive function (Fedor-Freybergh, 1977) and the studies reviewed above 
show that attention is oestrogen responsive in animals, impaired during the 
menopause following oestrogen deficiency (naturally or surgically) and improved 
with HRT use. Less is known about the relationship between SA and oestrogen 
change during the menopause in humans, however the location of oestrogens in 
the PFC, the relationship between WM, SA and executive function, and the 
relationship between SA change in pregnant women (Crawley et al., 2005; 
deGroot et al., 2003) and during the menstrual cycle (Duff & Hampson, 2001) 
gives warrant to explore SA in HRT users and non-user matched controls. 
Overall, it has been demonstrated that HRT use can improve frontal lobe 
activation, or improve cognitive task performance mediated on the frontal lobes, 
when accessing the following memory systems: verbal memory (Jacobs et al., 
1998; Kampen & Sherwin, 1994; Maki et al., 2001; Sherwin 1988), verbal WM 
(Joffe et al., 2006; Jonides et al., 1998; Shaywitz et al, 1999), spatia l WM (Joffe 
et al., 2006; Smith et al., 2006), WM (Duff & Hampson, 2001; Jenkins et al., 2004; 
Keenan et al., 2001; Morrison, Brinton, Schmidt, & Gore, 2002; Morrison, Wang, 
Hara, Janssen, & Rapp, 2010), episodic memory (Cutter & Norberry, 2003) and 
attention (Resnick et al., 1997). Of these, WM and SA are less well investigated, 
and the interaction of oestrogen with WM and attention performance has room 
for exploration.  
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Jenkins and colleagues (2004) did not find an interaction between mood 
score and cognitive performance in a large test battery. Generally it is assumed 
that mood does play a role in cognitive performance, and the interaction 
between oestrogen, mood and cognition are described in more detail below.  
1.6.4 HRT maintains neurotransmitter activity in the PFC and 
hippocampus and this improves mood 
 
Sherwin found HRT users to have improved mood after oestrogen 
treatment (Phillips & Sherwin, 1992; Sherwin 1997) and this may be due to the 
role of oestrogen on neurotransmitter production.  
Cutter and colleagues (2003) and Moses and colleagues (2000) 
demonstrated that short-term use of HRT in menopausal women can result in 
higher levels of a naturally occurring amino acid (5-HT) which contributes to the 
workings of the serotonergic system (low levels of 5-HT and serotonergic activity 
are consistent in patients suffering from depression). At a cellular level, 
oestrogen increases the rate of destruction of Monoamine Oxidase (MAO), the 
enzyme that breaks down serotonin and also affects intra-neuronal serotonin 
transport (Wise, Dubal, Rau, Brown, & Suzuki, 2005). An increase in oestrogen 
increases the destruction which results in increased serotonin levels and better 
mood. The highlighted studies show that oestrogen affects neurotransmitters 
that influence mood states, and that HRT use in menopausal women can help 
combat hormonal related depression.  
The neurotransmitters believed to be responsible for many aspects of 
cognitive function including memory are serotonin, noradrenalin and 
acetylcholine (Pelletier & Romaine, 2001). The PFC, hippocampus and midbrain’s 
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dopamine and serotonin systems are hormone responsive from maturity, and 
oestrogen affects these neurotransmitters as well as their receptor sites in the 
brain (Fink et al., 1995; McEwen, 2001, Kugaya et al., 2003). Based on the 
location of these oestrogen binding sites and the effect of oestrogens on 
serotonergic, noradrenergic and dopaminergic systems it can concl uded that 
these major neural systems are subject to the influence of oestrogen change 
during the menopause. Leranth and colleagues (2006) demonstrated a 30% 
reduction of dopaminergic cells in the brains of non-human primates after being 
deprived from oestrogen for 30 days. Reduced oestrogen as experienced during 
the menopause can lead to the inhibition of dopaminergic, noradrenergic and 
serotonic activity; and inhibition of these neurotransmitters is associated with 
reduced mental performance and learning (Kugler, Seus, Krauskopf, Brecht, & 
Raschig, 1980; Norbury et al., 2003). 
Richardson (1991) suggests that the cognitive impairments often 
demonstrated in women entering the menopause are due to menopausal 
symptoms such as low mood experienced pre and post oestrogen change. 
Oestrogen levels effect neurotransmitters which influence a change in mood, 
and cognitive performance can be hindered or facilitated by these 
neurotransmitters. It is important to measure mood when assessing cognition to 
identify whether it is a contributing factor to performance (Duffy, et al., 2003, 
Sherwin, 2012).  
To support this, it has been reported that people who suffer from 
depression complain of problems in day to day memory (Watts, 1993). Cronholm 
and Otterson (1961) suggested that those suffering with depression also find it 
difficult to learn, a key component in many SA and WM tasks. Kahn, et al (1975) 
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demonstrated a correlation between memory complaint and level of depression, 
but that this did not predict memory score. Further  studies demonstrated that 
negative emotions such as depression can have a negative effect on WM (Ellis & 
Ashbrook, 1988; Hertel and Hardin, 1990).  
Dumas, Hancur-Bucci, Naylor, Sites and Newhouse (2008) showed a direct 
cognitive effect as a result of oestrogen’s interaction with the cholinergic system 
in peri-, but not post-menopausal women. Menopausal women were randomly 
placed on 17-beta oestradiol or a placebo for three months at which point they 
completed their first cognitive test battery whilst receiv ing an antimuscarinic 
drug to block acetylcholine receptors involved in memory. Participants then 
received a further three months of cross over treatment (from HRT to placebo, 
from placebo to HRT) after which they completed the cognitive tasks for a 
second time whilst receiving the drug. The cognitive test battery included 
attention and verbal and nonverbal learning and episodic memory tasks. Those 
receiving HRT performed better during the episodic memory task, attention 
tasks and tasks with a speed component whereby oestrodial pre-treatment 
weakened the anticholinergic drug-induced cognitive impairments. The study 
demonstrated an interaction between oestrogen and the cholinergic system and 
the effects on pre-frontal mediated cognitive performance in menopausal 
women. 
Oestrogen administration has also been shown to augment cholinergic 
transmission and enhance dendrite spine formation in the hippocampus, and this 
has been linked to improved learning and memory in rodents (Liu et al., 2008). 
Specifically, oestrogen administration has been linked to improved spatial WM in 
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rodent’s recently ovariectomised (Daniel, Hulst, & Berbling, 2006; Fader et al., 
1999).  
Hu and colleagues (2006) suggested that HRT use is most beneficial to the 
maintenance of the cholinergic neurons in the hippocampus of ovariectomised 
rats. With an increase of acetylcholine and cholinergic activity in response to 
oestrogen in the hippocampus it can be concluded that memory systems should 
improve. In humans and non-human primates, specific cognitions susceptible to 
change in these neurotransmitter activities have been highlighted and linked to 
oestrogen change. Jacobs and D’Esposito (2011) examined the effect of 
oestradiol on WM in healthy young women taking into consideration the 
baseline levels of dopamine in the PFC. They concluded that oestradiol levels do 
impact on WM capacity and that this impact depends on baseline dopamine.  
Oestrogen influences neurotransmitter functioning by increasing the 
availability of acetylcholine which is involved in memory systems (Van 
Amelsvoort et al., 2001) and is a determinant of changes in PFC functioning 
(Grigorova et al., 2006) such as SA. Posner and Peterson (2012) suggest attention 
relies heavily on the activity of noradrenaline. And finally, Sarter and colleagues 
(2000) as well as Bellgrove, Hawi, Kirley, Robertson and Gill (2005) suggest that 
an increase in acetylcholine and dopamine will improve SA.  
1.6.5 Neuroprotection against toxic insults 
 
Oestrogens protect against several toxins which cause irreve rsible 
damage via hydrogen peroxide accumulation in the brain (Norbury et al., 2003). 
Brinton and colleagues (2000) demonstrated that low levels of oestrogen just 
before onset and during time of neuronal degeneration can have optimal effects 
 
 
52 
 
for neuroprotection by the prevention of hydrogen peroxide and other toxin 
build up. It is not yet clear whether there is one unifying neuroprotective 
mechanism or multiple mechanisms selectively protective against certain toxins 
induced by oestrogen, but available data suggest it is more likely to be a broad 
class of oestrogen-induced protective mechanisms protecting against a broad 
range of toxins (Brinton, 2005). It is still unclear which (if any) of these 
mechanisms is directly responsible for conferring a reduction in the risk of 
neurodegenerative disease. Data from Brinton’s lab on the neuroprotective 
effects of oestrogen indicate three levels of oestrogen action; chemical, 
biochemical and genomic (Brinton, 2001). Again, it is not completely clear to 
what extent each level of action lead to neuroprotection however each seems to 
be significant. 
1.6.6 Detrimental, or no effects of the therapy 
 
Despite research confirming the beneficial role of HRT on cognition, 
several studies have proposed a damaging effect (D. Jacobs  et al., 1998). Resnick 
and colleagues (2009) reported that oestrogen therapy can increase the risk for 
developing dementia and may impair memory performance. Specifically, Resnick 
and her team concluded that the increased risk in developing dementia may b e 
due to a decrease in hippocampal volume of women who initiate HRT during 
their post-menopausal stage (as supported by Coker et al., 2009). Decreased 
hippocampal volume could reduce cholinergic activity resulting in challenged 
WM capacity and SA (Lord et al., 2008). In addition to this, some studies have 
found no differences between post-menopausal HRT users and non-users during 
a WM task (The WHIMS).  
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Data from the Resnick laboratory suggests that the time window for 
reversal for oestrogen-deficit induced memory loss seems to be quite limited 
(Resnick et al., 1997). In concordance with this, studies that have only 
considered peri-menopausal women have found a positive effect of HRT use on 
brain activation during the completion of a cognitive task (Shaywitz  et al., 1999). 
Other studies have only found such effects in participants who are peri -
menopausal (Bagger et al., 2005; Dumas et al., 2008; Dye et al., 2012; Erickson 
et al., 2010; Lord et al., 2008; Norbury et al., 2007). And some have suggested 
that HRT use in post-menopausal women can be detrimental to cognition (the 
WHIMS). Shumaker and colleagues (2003) reported that oestrogen use in 
postmenopausal women (aged between 65 and 79 years) could increase the risk 
of dementia. In their randomised, double bl ind, placebo controlled study; 
women received HRT or a placebo control. The study was carried out over a 
seven to nine year period and participants completed global tasks of cognitive 
function to predict onset of dementia. Those in the HRT group had higher  
instances of predicted dementia and the researchers concluded that HRT should 
not be recommended to those in the postmenopausal stage as a solution to 
cognitive decline. The study differed from previous studies by recruiting an older 
age group, and recommendations were made against women receiving HRT in 
this particular age group only. 
HRT can be received orally or transdermally, through use of tablets, nasal 
sprays, skin patches, implants or injections, and these different methods will 
impact on different genomic and non-genomic mechanisms. For example, oral 
oestrogen preparations are more likely to induce positive effects on serum 
lipoprotein lipid metabolism than transdermal oestrogens (Ansbacher, 2001). In 
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addition, when oestrogens are taken orally, less E2 is freely available to the 
brain than transdermal oestrogen therapy. Duration of treatment and 
concentration of exposure can also have marked effects on genomic and non -
genomic mechanisms. For example, continuous exposure of oestrogen to the 
brain for a prolonged period of time may result in reduced neuronal response to 
oestrogen treatment (Toran-Allerand, 2006). In a study using a constant 
administration of oestrogen therapy in ovariectomised rats, no improvement 
was seen in WM score until the method of HRT management was changed to a 
cycle of higher and lower fluctuations of oestrogen similar to the fluctuations 
experienced during a normal menstrual cycle (Gresack & Frick, 2006). In human 
studies, continuous exposure of women to oestrogens caused a down -regulation 
of ER-alpha in the brain and other tissues (Mohamed & Abdel -Rahmann, 2000; 
Thakur & Sharma, 2007). GPs are therefore advised to recommend short use of 
HRT, in order to maximise benefits and reduce associated risks of treatment.  
1.7 Summary 
 
Oestrone (E1), oestradiol (E2) and oestriol (E3) are the major occurring 
oestrogens in women, and these defuse across cell membranes to bind to and 
activate specific oestrogen receptor sites (Shao et al., 2012; Simoncini et al., 
2004). The actions of these major oestrogens are therefore dependant on and 
mediated by the oestrogen receptor in that cell (Okada et al., 2008). These three 
forms of oestrogen have differing potency levels that dominate dep ending on 
stage in a female’s life. Because of the genomic and non -genomic effects of 
oestrogens, cells and organs are regulated by an interaction of these two 
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mechanisms, including the cardiovascular and central nervous system (Simoncini 
& Genazzani, 2003).  
Oestrogen levels will naturally change throughout the female lifespan, 
reaching their highest levels in the third trimester of pregnancy the lowest 
natural point during the menopause (Melton, 2000). This decline can be 
responsible for a range of reported problems or menopausal symptoms 
experienced during this time.  
Oestrogen actions affect neurotransmitter systems including the 
serotonic, noradrenergic, cholinergic and y-aminobutyric acidergic systems and 
these systems are subject to the influence of ovarian hormones, as 
demonstrated in changed emotion during different stages of the climacteric 
(Sherwin, 2003; Sherwin & Henry, 2008). 
Oestrogens significantly affect the microstructure of brain regions crucial 
to higher cognitive function (Norbury et al.,  2003). Oestrogen receptors are 
found in the cerebral cortex, midbrain, hippocampus, brain stem, hypothalamus 
and pituitary gland with high concentrations in the hypothalamus, pituitary, 
hippocampus and amygdala; areas crucial for memory function and execu tive 
function (Norbury et al., 2003). Oestrogen has been shown to bind to cell 
membrane receptors and affect secondary messenger systems used by growth 
factors and neurotransmitters (McEwen, 1999). HRT can bind in similar ways and 
has effects on the brain at macroscopic, microscopic, functional, metabolic and 
neurotransmitter levels (Brinton, 2005). During the menopause, a reduction in 
oestrogen levels results in reduced dendrite density and synaptic activity in 
these brain areas. This affects higher cognit ive functions such as WM and 
attention. HRT has a neuroprotective role on dendrite density, brain volume of 
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the PFC, brain matter and the hippocampus and connectivity between dendrites 
and increased neurotransmission.  
Oestrogen levels in the brain can influence brain regions crucial to higher 
cognitive functions such as learning and memory at structural, cellular and 
functional levels (Pompili et al., 2012). Oestrogens play an important role in age 
related declines in cognitive processes in healthy women. After the reduction of 
oestrogen during the menopause, HRT promotes brain functioning in women and 
protects brain functioning as they age. There is strong evidence for a 
relationship between lower levels of oestrogen as a result of the menopause and 
cognitive decline that can be separated from the effect of age. For example, 
young rats which have had their ovaries removed for the purpose of the study 
show the same cognitive deficits and improvement with oestradiol supplements 
as postmenopausal rats (Daniel, Fadwe, Spencer, & Dohanich, 1997; Korol & Kolo, 
2002). In recent years there has been an increase in the number of animal 
studies evaluating the effects of oestrogen on learning and memory whereby 
most of these studies have shown that a constant delivery of the therapy results 
in improved memory performance and hippocampal neuroprotection (Cooke, 
2005; Daniel, 2006; Pompili, Tomaz, Benedetto, Tavares, & Gasbarri, 2010; 
Sandstrom & Rowen, 2007). Similar results can be seen in humans (Dumas et al., 
2008; Dye et al., 2012; Erickson et al., 2010; Sherwin & Tulandi, 1996).  
The PFC is critical for intact WM and oestrogen enhances performance on 
WM tasks (Keenan et al., 2001). Oestrogen levels influence executive functions, 
specifically WM performance and performance of cognitive tasks with an 
attentional component. Generally, RCTs have found that oestrogen specifically 
affects short term and long term verbal memory and WM (Sherwin & Henry, 
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2008) and that in the case of three RCTs which found no effect of oestrogen  on 
cognition, two did not choose a verbal WM task (Ditkoff et al., 1991 ; Janowsky, 
Charvez, & Orwoll, 2000) and one included participants who were elderly and no 
longer experiencing menopausal symptoms (Duka, Tasker, & McGowan, 2000). It 
has been suggested that oestradiol facilitates performance as WM load increases 
(Bimonte & Denenberg, 1999). As such, HRT may be most beneficial in instances 
where WM load becomes challenging (Dumas et al., 2010). The problems of WM 
and attention during the menopause are due to the changing levels of oestrogen 
in the PFC and hippocampus which results in less synaptic activity and 
cholinergic activity in these areas. Oestrogen also stimulates serotonin, 
noradrenalin and acetylcholine production. A reduction in oestrogen leve ls 
results in reduced levels of these neurotransmitters, and these reductions 
further worsen cognitive performance and memory capacity (Reilly, 2000).  
Several studies have highlighted the beneficial effect of oestrogen on 
brain activity during the completion of WM tasks, yet this effect does not 
transpire in task performance itself (Erickson et al., 2010; Shaywitz et al., 1999), 
leaving some doubt about the vulnerability of WM to oestrogen changes. And 
only some, not all, prefrontal dependent cognitive tasks seem to be effected by 
oestrogen suggesting that the role of oestrogen in executive function is very 
domain specific (Duka et al., 2000). Although the roles of oestrogen change on 
episodic memory and verbal memory have been well established, less is 
understood regarding oestrogens’ role in WM function, and there is a lack of 
evidence exploring the relationship with SA. Both WM, and especially SA, would 
benefit from further exploration. 
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Studies that have demonstrated an effect of HRT on cognition have 
typically used younger populations. Several studies have indicated no effects of 
oestrogen therapy on cognition, and even detrimental effects of HRT on 
cognition in postmenopausal women. Detrimental effects of oestrogen on 
cognitive performance seem to be time specific, and are encapsulated in the 
critical period hypothesis. 
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Critical period 
 
2.1 HRT can protect cognition in peri-menopausal women 
 
During the past few decades, extensive research has tested whether the 
administration of oestrogen in the form of HRT can help maintain cognitive 
functions in menopausal women. Results have been mixed and seem largely 
dependent on the time of initiation of the treatment. The inconsistencies of 
oestrogen’s role in cognition during the post -menopause are compounded with 
the release of the findings from The WHIMS (Espeland et al., 2004). Further 
analysis of the WHIMS suggested that the risk of cognitive impairment and 
probable dementia did not differ between HRT users and the placebo control; 
where HRT users had non-significantly higher risk averages. The results have 
caused much controversy within the literature, and leaders of the field have 
considered to how this information contributes to the research as a whole. On 
consolidation with RCTs that also failed to produce results, studies were deemed 
similar for dose of HRT and frontal lobe and hippocampal cognitive task content. 
The way these studies differed from successful studies was in the age of the 
participant.  
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The average age of the participants in the WHIMS was 72 years. The 
study fails to support the idea that oestrogen can protect against cognitive 
decline in women over the age of 65 years. On closer look of study results; some 
participants did maintain cognitive capacity as a result of HRT use and generally 
these women had initiated the therapy during their peri -menopausal stage, 
typically in their forties and early fifties. Preliminary reanalysis of the WHIMS 
data found that the women who took HRT prior to their enrolment in the WHIMS 
(and before the age of 65) were 50% less likely to develop AD and dementia 
compared to the non-users (Henderson, Espeland, Hogan, Rapp, & Stefanick, 
2007). Using this information in the attempt to resolve discrepancies between 
conflicting research through the careful consideration of the literature, the 
critical period hypothesis (Maki, 2006; Sherwin & Henry, 2008) attempts to 
reconcile the literature. 
The critical period hypothesis suggests that HRT use should be initiated 
during the onset of the menopause to maintain neurobiological function (Gibbs 
& Gabor, 2003; Resnick & Henderson, 2002; Sherwin, 2012). Current research 
has identified the potential period or ‘a window of opportunity’ for HRT to be 
taken relative to onset of the menopause in order to produce optimal r elief from 
menopausal symptoms. These symptoms include cognitive strain, and in 
particular, a challenge in WM functions. The theory helps to explain the 
unexpected findings of the WHIMS.  
Rodent studies have helped to develop theories regarding oestrogen’s 
role in the brain and cognition, and although animal models and human models 
differ, the studies have often been a useful starting place for human studies. 
Generally research from rat studies has demonstrated an improvement in 
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performance on tasks which are hippocampally dependent (such as spatial WM 
tasks) when oestrogen is allotted to young ovariectomised rats. This has been 
demonstrated with the use of a variety of methodologies (Bimont e & Deneberg, 
1999; Bimonte-Nelson  et al., 2003; Gibbs, 2000b). Although the female rat 
model is often used to study mechanisms by which oestrogen may affect 
learning and memory it must be considered that the rodent reproductive cycle 
differs significantly from primates’ and humans’, as does their cognitive function 
(Sherwin & Henry, 2008). Turning our attention to human studies, the 
researchers considered studies that have been developed to test the critical 
period theory and those without that intention but to which do support. 
Since the development of the critical period hypothesis several studies 
have attempted to confirm or disconfirm the theory dependant on the 
participant’s age at initiation, and explore how the concept applies to the 
underlying neurobiology. Such studies will be addressed for the duration of the 
chapter.  
2.2 Evidence for the critical period hypothesis from RCTs and 
Observational studies 
 
The critical period hypothesis suggests that improved cognition through 
HRT use is better obtained when treatment is initiated during the onset of the 
menopause, at the average age of 51.8 years (Sherwin, 2003). Once the 
menopause is exceeded to a certain point, initiation of HRT will no longer be as 
effective in its protection of brain function and following this, cognition. The 
point to which this may succeed is yet to be defined.  
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According to the theory, successful cognitive maintenance would be 
expected in peri-menopausal women given HRT compared to a placebo control, 
whereas in post-menopausal HRT users we would expect no difference. Some 
studies have even demonstrated detrimental effects of HRT use on cognition in 
post-menopausal women (Schmidt et al., 1996; Steffens et al, 1999). RCTs have 
demonstrated results which favour the critical period hypothesis. For example, 
in peri-menopausal and early postmenopausal women whose mean age was 51 
years, those who randomly received HRT experienced significant improvements 
on a frontally mediated task of executive function, manifested in a reduction of 
errors compared to placebo controls (Joffe et al., 2006).  
Similar results have been found in a large observational study. 
MacLennan and colleagues (2006) studied the interaction between effects of 
time of initiation and duration of HRT on several cognitive functions. A total of 
428 women aged 60 years and above were recruited from a computer -generated 
random selection of Adelaide households. Demographic and lifestyle information 
was recorded, as well as details of HRT use. Participants were screened for 
depression and their current mood was assessed. Cognitive tasks included a task 
measuring global cognition (Mini-Mental State Examination), attention (Trail 
Making Test Parts A and B), verbal learning and memory (Consortium to 
Establish a Registry for AD word list), and verbal expression (letter fluency, 
category fluency and the Boston Naming Test). Analysis was adjusted for age, 
education, mood, body mass index, smoking, alcohol intake and history of 
cerebrovascular disease. The researchers compared HRT users to matched 
controls with no history of HRT use. Participants in the HRT group were only 
included if they had been using HRT for a minimum of  one year. Those who had 
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begun the therapy prior to the age of 56 years were classified as early HRT users. 
Those who had begun the therapy after this time were classified as late users of 
the therapy. The researchers identified several significant differe nces in 
cognitive performance between the two groups. Firstly, early initiators of the 
therapy performed better than late initiators on the mini -mental state 
examination and were faster than non-users on the Trail Making Test. Early 
initiators who were long-term users performed better on tests of letter fluency 
(verbal memory) then never users. Generally HRT users performed better on the 
trail-making test regardless of time of initiation and duration of therapy. There 
was a small trend only in late initiators and worsened performance than never 
users on the mini-mental state examination and letter fluency task.  
Although results broadly support the critical period hypothesis, the 
researchers chose to divide early users from late users at 56 years old. This i s 
almost four years older than the national average age of the menopause, and 
perhaps the cut-off could have been reduced. Even more accurate would be to 
ask the participants if they had initiated the therapy before or after their last 
menstrual bleed, to take account of individual variation in timing of menopause.  
As well as studies demonstrating improved cognition in peri -menopausal 
HRT users, studies which demonstrate detrimental or no effect of HRT on 
cognition in postmenopausal women also support the critical period hypothesis. 
A handful of RCTs have failed to find any beneficial effects of oestrogen on 
cognition in postmenopausal women.  Ditkoff and colleagues (1991) looked at 
the effect of oestrogen use on QoL and psychological function in a randomis ed, 
double-blind study comparing oestrogen users to a placebo control. Thirty -six 
women aged between 45 and 60 years (with a mean age of 53 years) were 
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recruited and assessed on the Profile of Adaption to Life scale, the Beck 
Depression Inventory and the d igit span and digit symbol from Wechsler’s Adult 
Intelligence Scales. Both tasks from the Wechsler’s Adult Intelligence Scale were 
chosen as a test of immediate recall, recent memory and require attention in 
addition to memory, suggesting a level of execut ive function. The oestrogen 
users reported improved QoL and improved mood as compared to the placebo 
control however no difference in cognitive function was apparent. Although the 
researchers included women who were aged between 45 and 60, the women had 
previously undergone hysterectomy and it is not clear which point of the 
climacteric scale the women were experiencing. The study did not indicate the 
average age of hysterectomy of the participants, but did indicate that data was 
collected several years post-surgery and that the researchers were targeting 
women in the post-menopausal stage. The women kept a diary of menopausal 
symptoms and reported no hot flushes and less than three symptoms 
experienced in total per week suggesting they had not reached asymp tomatic 
status. This could suggest that the participants were on nearing the end of the 
menopause, with diminished symptoms at the post-menopausal stage and 
missing the window of opportunity for beneficial effects of oestrogen. Oestrogen 
did seem to have an effect on mood and QoL indicating that the participants 
were still benefitting from the treatment on one level. Perhaps the 
neuroprotective effects of oestrogen were not yet apparent in the chosen 
memory tasks. The tasks had no verbal component and the researchers state 
themselves that memory testing can be difficult and that the Wechsler Adult 
Intelligence Scales only measures one aspect of memory. They concluded that 
the lack of differences between groups on these tasks cannot rule out the fact 
that oestrogen may influence memory systems.  
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Studies with older women have also found no effect of HRT on cognition. 
Janowsky and colleagues (2000) administered oestrogen therapy or a placebo to 
post-menopausal women (with an average age of 70 years) over a four week 
period. No difference was found in WM performance between groups after the 
treatment phase. Binder, Schechtman, Birge, Williams, and Kort (2001) 
administered HRT or placebo to postmenopausal women with an average age of 
81 years over a period of nine months. The lengthy administrating of the therapy 
addresses the shorter period of HRT administration in Janowsky’s study. By 
selecting participants with an average age of 81 years the researchers risk the 
interaction of age effects in the study and participants would have been beyond 
the end of the climacteric scale. After nine months of HRT no differences were 
found between groups in tests of verbal memory or fluency, visual memory, 
attention, or psychomotor speed thus satisfying the critical period hypoth esis. 
And finally, LeBlanc and colleagues (2007) examined how menopausal 
symptoms can impact on cognition, and whether symptom relief from HRT use 
can result in improved cognitive capacity. Thirty-two healthy post-menopausal 
women (on average three years since their last menstrual bleed) were 
administered HRT or placebo over an eight week period. HRT use did not impact 
on symptoms impact or cognitive performance.  
The discussed RCTs have helped to pinpoint the critical period by 
supporting the idea that giving HRT early in menopause may be beneficial and 
that late HRT administered to post-menopausal women may have no effect on 
cognitive performance. However, peri- and post-menopausal groups have been 
poorly defined in these cases. 
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Jones and Gallo (2001) suggest that a decline in brain metabolism 
correlates with subjective memory complaints initially and the decline in 
memory performance demonstrated in differing task performance follows on 
later. This information may explain why differences between metabolic changes 
in the brain can be present during the completion of a task, but not evident in 
task performance score itself (Norbury et al., 2003; Rasgon et al., 2005; Shaywitz 
et al., 1999). If this is the case, then randomised studies may be of more value to 
the critical period hypothesis if measuring brain changes (which seem to be 
more sensitive) rather than cognitive changes (which may only transpire in 
certain tasks or if task difficulty is increased; Keenan & colleagues (2001) as a 
result of oestrogen use during the peri-menopause. Observational studies may 
be of more value when investigating the longer term, cognitive effects of HRT 
initiation, with differing durations of oestrogen use, and strong measures of 
these cognitions need to be defined. For example, a solid measure of WM that 
will be sensitive enough to pick up on these differences.  
2.3  HRT alleviates disrupted cognition as experienced with induced 
menopause; indications of more than just an aging effect  
 
Findings of oestrogen-cognition studies in which the women are aged 60 
years or over at the time of their recruitment are confounded by the 
consequences of brain aging. How can we be sure that the differences we see 
between peri-menopausal cognitive capacity and post-menopausal cognitive 
capacity are in fact due to the fluctuations of oestrogen and HRT rather than a 
simple age related decline? Exploration of younger populations who have 
undergone surgical menopause has helped to refine this.  
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In some cases of ill health parts of the female reproduct ive system may 
have to be removed as treatment, for example, to eradicate various forms of 
cancer. Patients may experience loss of the uterus alone (hysterectomy), 
removal of one or both ovaries (unilateral or bilateral ovariectomy) or a 
combination. Removal of any of these parts of the reproductive system results in 
the cessation of menstrual bleeds, which ultimately deems the individual as 
menopausal by definition. However, it is important to consider that only the 
removal of both ovaries will result in the cessation of oestrogen production, and 
as such, only those whose two ovaries have been removed will experience 
menopausal symptoms from surgery onwards (Benedetti et al., 2001). Those who 
have undergone hysterectomy or unilateral ovariectomy and still h ave at least 
one of their ovaries will continue to produce oestrogen and not experience 
menopausal symptoms until they reach the natural age of the menopause. These 
women may be given HRT that contains oestrogen alone.  
For those who have undergone bilateral ovariectomy and no longer have 
any functioning ovaries, while the natural menopausal transition typically occurs 
over a period of years with a steady decline of oestrogen throughout this period, 
surgical menopause is extremely abrupt whereby oestrogen le vels plummet. In 
these women, typical menopausal symptoms manifest quickly after surgery 
irrelevant of the age of the participant. For these women, they may experience 
loss of two thirds of their oestrogen, experiencing continuous problems with 
mood and cognition (Hendrix, 2005). 
 Studies have shown that women who enter the menopause prematurely 
due to removal of both ovaries (typically before the age of 45) and do not 
receive HRT have a fivefold risk for mortality directly related to neurological 
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disorders such as depression, parkinsonism and dementia (Parker, Jacoby, Shoup, 
& Rocca, 2009; Rivera, Grossardt, Rhodes, & Rocca, 2009; Rocca, Shuster, 
Grossardt, Maraganore, & Gostout et al., 2009). In studies of younger peri -
menopausal women who underwent surgical removal of both ovaries, those who 
were treated with oestrogen maintained their pre-operation scores on tests of 
verbal memory where as those who received a placebo experience a significant 
decrease in verbal memory score post-surgery (Philips & Sherwin, 1992; Sherwin, 
1988). Such studies demonstrate the protective role of oestrogen on cognition, 
and the younger age of the participant eradicates aging effects.  
Complete removal of both ovaries results in the cessation of oestrogen 
production, but in some medical cases removal is not necessary but temporary 
paralysis of ovary function may prevent, for example, the growth of cists. An 
intervention of gonadotropin releasing hormones such as leuprolide acetate 
depot (LAD) results in the suppression of ovarian function and oestrogen 
production. Oestrogen suppression in younger women results in similar cognitive 
impairments as those experienced during the menopause. Sherwin and Tulandi 
(1996) administered LAD to women with an average age of 32 years and noted a 
decrease in verbal memory after 12 weeks of ovarian suppression. After ovarian 
suppression, participants either received HRT or a placebo. The deficits were 
reversed in women who had received oestrogen after the suppression, but not in 
those who had received the placebo.  
In concordance with this, Varney and colleagues (1993) also found 
decreased scores in two verbal memory tasks as well as digit sequencing and a 
two-point discrimination task in younger women treated with LAD and Palomba 
and colleagues (2004) reported a significant decrease in Wechsler memory 
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scores and scores of the Mini-Mental State Examination in peri-menopausal 
women receiving LAD over a six month period. However, Owens, Matthews and 
Everson (2002) failed to find any effect of ovarian suppression on the CVLT, digit 
span task or verbal fluency task in 16 women administered with a high dose of 
LAD as compared to baseline scores. Participants underwent a stress -inducing 
protocol prior to cognitive testing at baseline only and not follow up wh ich may 
have lowered scores of cognitive performance in the first instance.  
Similar effects of LAD can also be seen in neurological studies. Berman 
and colleagues (1997) distributed LAD to three groups of healthy young peri -
menopausal women over a 16 week period. PET scans taken at point of problem-
solving and memory task performance indicated a weakening of typical brain 
activation patterns normally indicated in brain scans during these tasks. 
Additional to this the LAD treatment resulted in the mitigatio n of increased 
regional cerebral blood flow normally ascertained during the completion of 
these tasks. Again, after the addition of oestrogen therapy the diminishments in 
brain activation levelled to return to normal. Grigorova, Sherwin and Tulandi 
(2006) completed a study with similar methodology which considered the effect 
of suppressed ovarian function on a wide range of prefrontal cortex mediated 
cognitive tasks including WM. Twenty-five peri-menopausal women (with a mean 
age of 36.1 years) receiving LAD over a four week period were compared to 25 
placebo controls (with a mean age of 36.7 years) matched for age, years of 
education and socioeconomic status. After four weeks of LAD intervention, 
oestrogen levels within the group had dropped to those in the  postmenopausal 
range. Participants completed the CVLT, the Visual Search Cancellation Task to 
measure attention and visual scanning, and six tests of prefrontal cortex and 
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executive function to which there were no measured differences between 
groups. This does not support the previously mentioned studies, which found 
differences between base line and after intervention on verbal memory scores. 
Participants were also asked to complete a verbal WM task, a non-verbal WM 
task (modified versions of the N-Back test) and a sequential WM task (the Letter-
Number Sequencing Subtest; WAIS-III). For the verbal and non-verbal N-Back 
tests, those who had been treated with LAD had fewer correct responses post 
intervention whereas the placebo control did not differ in response score. This 
suggests that HRT can help protect cognition, but this is specific to cognitive 
domain, such as verbal and WM. For the Letter-Number Sequencing Subtest, 
those induced into a post-menopausal state scored significantly worse when 
compared to their post intervention scores whereas scores of the control group 
had actually increased. The researchers noted that the participants failed to 
learn from repeated exposure of the task and then carried on to perform worse 
on the task. It is possible that the effect of LAD on cognition only transpired 
when cognitive assessments exceeded a particular level of difficulty. This is 
consistent with the study by Keenan and colleagues (2001) where the effects of 
oestrogen suppression on WM were only seen when the task became challenging 
and WM capacity over loaded.  
From the studies discussed in this section it can be concluded that 
cognitive decline is consistent in women experiencing the natural menopause, 
and those who have had surgical menopause, suggesting a link to oestrogen loss 
rather than simple aging effects.  This cognitive decline may be combated by HRT 
use, which has been demonstrated in participants who have initiated therapy 
close to surgical menopause, or during their peri -menopausal stage. This implies 
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that the protective effect of HRT is dependent on time of initiation of the 
therapy, as discussed in the next section.  
2.4  The neuroprotective role of oestrogen replacement is limited to 
the critical period 
 
Scott, Zhang, Wang, Vadlamudi and Brann (2012) suggest that the 
neuroprotective role of oestrogen is limited to the critical period. Adams, Shah, 
Janssen and Morrison (2002) showed that HRT administration to young 
ovariectomised rats can result in increased dendrite spine density and synapse 
density, opposite to the effect of aging, demonstrating a positive effect of HRT 
on young rats. However HRT was without effect on aged ovariectomised rats, 
consistent with the critical period hypothesis. In similar studies, HRT was 
effective in increasing hippocampal spine density in young rats four days post 
ovariectomy, but not as effective after 12 days following ovariectomy (Gibbs, 
2000c; Silva et al., 2003) confirming that the delay between ovariectomy and 
initiation of HRT impaired the ability of the hormone to modulate synaptic 
density (Sherwin & Henry 2008).  
Gibbs (2000c) concluded from his study that the ability of HRT to enhance 
cholinergic function also declines with age. Considering the effects of HRT on 
cognition as a result of neuronal change, Daniel and colleagues (2006) 
administered HRT to young rats immediately following ovariectomy. A significant 
improvement was seen in the HRT group performance of acquisition and delay 
trials of WM compared to a placebo control. However, when treatment was 
delayed for a five month period, no enhancements in memory performance were 
evident. Chen and colleagues (2006) suggests that if neurons are healthy at the 
time of oestrogen exposure, the response to oestrogen is beneficial for 
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neurological function and survival but if neurological health is compromised 
(perhaps with aging or as a result of the menopause), oestrogen exposure 
exacerbates neurological demise. In their study the researchers wished to assess 
the neuroprotective effect of different doses of HRT for continuous, intense or 
intermittent therapy on dissected hippocampi from the brains of 18 embryonic 
rat foetuses and grew these on a well plate whilst treating the hippocampal 
neuron’s with different concentrations of oestrogen. The researchers simulated 
a range of oestrogen levels on the hippocampal neurons to induce a state similar 
to the peri-menopause. The level of oestrogen exposure was then reduced to a 
consistent low or high dose either continuously, sporadically or as a one off.  The 
researchers found that in each case the low dose of oestrogen increased the 
survival rate of the neurons by preventing both neuron death and 
neurodegeneration. In contrast, exposure to the higher concentration at an y 
point resulted in neuronal death. Implications from this part of the study can be 
made to postmenopausal women who experience a sudden influx of oestrogen 
therapy after brain levels have diminished, suggesting to why HRT should be 
initiated during the peri-menopausal stage.  
In human studies, Dumas and colleagues (2008) examined the influence 
of age on the ability of oestradiol to affect cholinergic system functioning and 
cholinergic system functioning on verbal memory and attention in two groups of 
peri (50-62 years) and post (70-81 years) menopausal women. The younger HRT 
group demonstrated improved episodic verbal memory compared to the control. 
However the oestradiol treatment impaired performance in those in the older 
age group. Similarly, the ability of oestrogen to enhance cholinergic function 
also declines with delay (Gibbs, 2000c; Savonenko & Markowska, 2003). In 
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summary, early use of HRT can maintain cholinergic activity as compared to 
placebos, and this can help to maintain attention.  
Brain changes in response to HRT can be present in larger levels such as a 
change in brain volume which can be responsible for certain degenerative 
diseases. During aging and following the menopause, brain volume can decrease 
with an increase in ventricle volume (L. Raz et al., 2013). This can lead to stroke. 
Also consistent with the critical period hypothesis, Suzuki, Brown, Cruz, Yang and 
Bridwell (2006) demonstrated a beneficial effect of HRT on stroke prevention 
and recovery if the therapy was initiated during onset of the menopause.  
Some researchers believe that cognitive deficits experienced by 
postmenopausal women are due to executive dysfunction and that the 
prefrontal cortex is the site of oestrogens effect on cognition (Bailey et al., 2011; 
Keenan et al., 2001). Scott and colleagues (2012) have suggested that oestrogen 
is an important neuroprotective factor in a variety of neurodegenerative 
disorders and sexually dimorphic diseases. Specifically, oestrogen receptor alpha 
is a key mediator of neuroprotection in cerebral ischemia. Oestrogen receptor 
(alpha) is located both pre and post synaptically in the prefrontal cortex (Wang 
et al., 2010).  
Daniel and colleagues (2006) investigated the validity of the critical 
period hypothesis as applied to prefrontal cortex mediated behaviours. In their 
study, young ovariectomised rats receiving oestrogen treatment outperformed 
placebo controls on the radial arm maze. The researchers concluded that the 
critical period hypothesis retains validity across prefrontal cortex cog nitive 
domains, and can affect WM in middle-aged rats.  
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Bohacek, Bearl and Daniel (2008) propose a mechanism by which the 
responsiveness of the nervous system could be altered with oestrogen 
deprivation to affect cognition. They suggest that with oestrogen  deficiency, the 
brain can become less responsive to HRT, affecting the responses of many 
targets of oestrogen action including dendrites in the prefrontal cortex.  
An almost universally obtained result (Shaywitz et al., 1999) is greater 
left-frontal hemisphere activation during encoding, and greater right -frontal 
hemisphere activation during retrieval; the Hemispheric Encoding/Retrieval 
Asymmetry (HERA) effect (Tulving et al., 1994). Evidence suggests that HRT given 
to women entering the menopause can result in a ‘sharpening’ of the HERA 
pattern (Norbury et al., 2003), whereby oestrogen users completing retrieval 
tasks have more activation in the right-frontal hemisphere as compared to 
placebo control, similar to that seen in young, menstruating women. Shayw itz 
and colleagues (1997) demonstrated this increased activation in women who 
were five months from their last menstrual bleed during the encoding and 
retrieval of verbal material in a verbal working memory task.  
When young rats are ovariectomised and oestrogen treatment is initiated 
within four days, synaptic density in the hippocampus is significantly greater 
than rats whose therapy is withheld until 12 days and beyond suggesting that a 
delay of the therapy may impair its ability to modulate synaptic den sity (Silva et 
al., 2003). The same patterns have been seen in young monkeys (Hao et al., 2004; 
Hao et al., 2006). In humans, the hippocampus atrophies at an annual rate of 
one to two percentage per decade in late life for non-demented individuals (Raz 
et al., 2005)  and this deterioration is related to memory impairment (Kramer et 
al., 2007). For this reason, any beneficial effects of HRT on hippocampal effects 
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are of much importance. HRT use in post-menopausal women can result in 
reduced hippocampal volumes (mean age of 77.5 years, Coker et al., 2009; 
Resnick et al., 2009). This further highlights the possible detrimental effects of 
HRT when initiated during the post-menopausal stage (Erickson et al., 2010).  
Neurobiological research suggests that early HRT use may protect 
prefrontal cortex and hippocampal function, dendrite density in these brain 
areas, brain volume and cholinergic systems. Late initiation may have no effect, 
or even a detrimental effect. The evidence confirms a critical period for HRT 
initiation, and this may have substantial effects on associated cognitions.  
2.5 Early initiation of HRT can protect different aspects of cognition  
 
Verbal memory in particular may benefit from early HRT use (Maki, 2006) 
but this may be dependent on task difficulty. RCTs involving women younger 
than 65 years have demonstrated an enhancing effect of HRT on verbal memory 
compared to placebo controls (Krug, Molle, Dodt, Fehm, & Born, 2003; 
Linzmayer et al., 2001; Philips & Sherwin, 1992; Shaywitz et al., 2003). St udies 
looking at the effect of HRT on verbal memory in women over 65 years of age 
have found no effect (Binder et al., 2001) or harmful effects (Grady et al., 2002). 
To help contribute to the critical period theory Maki (2005) found that by 
prescribing HRT to those during the onset of their menopause, hippocampally 
mediated functions (especially that of verbal memory) were protected and 
maintained by the additional oestrogen supplements. From neuroimaging 
studies it can be concluded that oestrogen has a neuro-protective effect in the 
brain at cellular, neurochemical and metabolic levels (Brinton, 2005) and this 
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can carry through to cognitive task performance. However not all studies 
demonstrate this effect.  
2.5.1 Executive function, attention and working memory 
 
It has been suggested that when HRT is initiated more than a couple of years 
after the completion of the menopause there will be no change in executive 
function and even an increased risk in neurodegenerative disease (Henderson, 
Benke, Green, Cupples, & Farrer, 2005; MacLennan et al., 2006). Herlitz , Thilers 
and Habib (2007), as well as Greendale and colleagues (2009) have suggested 
that it is our ability to learn which becomes under scrutiny from the menopause 
onwards. To combat problems in executive function and a risk of degenerative 
disease during this time, several RCTs and laboratory studies have suggested 
that HRT initiated at this stage can maintain executive function (Keenan et al., 
2001) and reduce risk of neurodegenerative disease (Rocca et al., 2011).  
Rat studies are a good indication of the possible outcome of HRT at 
cellular and cognitive levels in humans, but due to the differences in the rat and 
human brain and the reproductive and climacteric systems the implications of 
rat studies to human studies is put under scrutiny. More transferable 
information can be attributed from primate studies. The rhesus monkey is often 
chosen in primate studies due to their similarities to human 28 -day 
menstruation periods, their experience of the menopause, their ability to 
perform cognitive tasks similar to those administered to humans and their age 
related declines in executive function and memory (Gore, Windsor -Engnell, & 
Treesawa, 2004). In addition to this, the rhesus monkey does not develop certain 
degenerative diseases such as AD which helps to reduce confounding variables 
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of digenesis (Rapp, Morrison & Roberts, 2003). A difference to be considered is 
that monkeys have seasonal cessation of reproductive function and a short 
menopausal life relative to women due to the late onset of the menopause 
(Lacreuse, 2006). Nonetheless monkeys are a suitable means for comparison and 
Gasbarri, Pompili, & d’Onofrio (2008) suggested that oestrogen can facilitate 
learning and memory to improve WM scores in monkeys. Studies using the 
rhesus monkey have helped to place the critical period hypothesis in animal 
studies.  
In a RCT Lacreuse and Herndon (2003) showed improved WM span in 
ovariectomised monkeys treated instantly with oestrogen compared to a placebo 
control, demonstrating a positive effect of HRT on executive function and WM in 
early HRT users and confirming the critical period hypothesis. In a later study 
Lacreuse, Chhabra, Hall and Herndon (2004) failed to show an improvement in 
executive function of ovariectomised rhesus monkeys using HRT. The monkeys 
completed a modified version of the Wisconsin Card Sort Test adapted to the 
non-human primate. In the test, monkeys had to select three -dimensional 
objects based on colour or shape. The monkeys were treated with eithe r HRT or 
a placebo and asked to complete the task following one specific rule. Twenty -
four hours later, the monkeys were given the opposite treatment (e.g. placebo 
day one, HRT day two; HRT day one, placebo day two) and asked to complete the 
task once more, following a new rule. The researchers felt a wash out period 
between the treatment change was not necessary, however this may have been 
ill conceived. Of large importance, selected primates were administered the 
therapy several months after ovariectomy, perhaps missing the window of 
opportunity for maximum effects of the therapy on executive memory.  
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The critical period has also been demonstrated using human studies 
considering the effect of HRT on WM in peri- and post-menopausal women. Khoo 
and colleagues (2010) measured detrimental risks of HRT on WM when initiated 
three years post completion of the menopause. In their observational study, 410 
HRT users between the ages of 40 and 80 years were recruited. They were tested 
for cognitive change over a five year period using the global measure the Mini-
Mental State Examination, National Adult Reading Test (NART) and the Wechsler 
memory scale. The researchers included age, lifestyle factors and natural 
cognitive decline as covariates, assuming that cognitive score would naturally 
decline by ten percent over the five year period. Results were mixed where HRT 
was associated with worsened general memory but improved cognition overall. 
The researchers concluded that the effect of HRT on cognition may be domain 
specific. With such a wide age range of 40 to 80 years, despite age being a 
covariate it still becomes problematic in study analysis with the average age 
between groups differing to a large degree. Kurt, Bekci and Karakas (2006) 
considered the role of late initiation of HRT on several cognitive domains. Late 
HRT use did not have a significant effect on a broad spectrum of 
neuropsychological scores that measured immediate and delayed visual and 
verbal memory, visuospatial perception and orientation, SA, visual s earch and 
scan, impulsivity and response speed and executive functions.  
In a similar study, Binder and colleagues (2001) also failed to find 
significant differences during completion of a Verbal Fluency Test, Wechsler 
Paired Associate Learning and 20 minute Delayed Recall, Trail making A and B 
Tests, Cancellation Random Letter and Random Form. Participants were aged 75 
years and older at time of HRT initiation, missing the critical period for initiation.  
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In the Cache County longitudinal study of elderly women and men, 
women who had initiated HRT in previous years at close proximity to the onset 
of the menopause had a significantly reduced risk of developing AD. Current 
users in the post-menopausal stage where not protected (Zandi et al., 2002). The 
study was designed to assess the critical period hypothesis, and the researchers 
concluded that there is a window of opportunity to take HRT during the peri -
menopausal stage in order to maximise protective effects of HRT on associated 
neurones helping to maintain WM. In another observational study, Grigorova 
and Sherwin (2006) considered post-menopausal HRT users and the effect of the 
treatment on WM, verbal memory and executive function performance. 
Postmenopausal women (mean age 65 years) who used either oestrogen  only or 
oestrogen plus progesterone were compared to controls matched for age and 
education who had never used HRT. The results revealed no differences between 
verbal and WM performance between HRT users and non-users, and the 
researchers concluded no effect of HRT use on executive function overall. It can 
be established from this study that HRT initiated during the postmenopausal 
stage had no effect on the selected tasks, which conforms to the critical period 
hypothesis.  In disagreement with some studies yet confirmative with others; 
there were no detrimental effects of the late initiated therapy on cognition. This 
could be a result of different cognitive measures of assessment. Although the 
study revealed no differences between HRT users and non-users, WM scores of 
the N-Back test (Kirchner, 1958) indicated that those receiving the treatment 
were more likely to make mistakes than those on the placebo control hinting at 
some detrimental affects of late HRT use.  
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Despite the critical period hypothesis satisfying some of the disputes 
arisen from the literature as a whole, not all research falls in concordance with 
the hypothesis. Two studies found verbal memory significantly improved in over 
65 year olds after the administration of oestrogen for duration of t wo to three 
weeks only (Duka et al., 2000; Yaffe et al., 2000). Krug, Born and Rasch (2006) 
showed an improvement in two tests of WM and one of hippocampal function in 
postmenopausal women after being administered HRT for three days only. The 
researchers concluded that a short burst of HRT to create an ‘oestrogen peak’ 
can improve prefrontal cortex and hippocampal function, and short term use of 
HRT may be beneficial for cognitive performance in post -menopausal women. It 
may also be that certain types of cognition are responsive to small oestrogen 
changes at postmenopausal point only, and not prolonged use initiated during 
this time. Another study which demonstrates this administered HRT to a cohort 
of women with AD who had a start age of 72 years. HRT resulted in a slight 
benefit to combating degenerative disease in the short term of two months use 
but an adverse progression of disease in the long term of at least 12 months use 
(Zandi et al., 2002). In a study considering the effect of HRT on AD, Mulnard and  
colleagues (2000) administered HRT or a placebo control for 12 months to 120 
women with mild to moderate AD. Women were asked to complete tasks of 
visual memory, attention and executive function. Similar to the results from the 
study by Zandiand and colleagues, HRT use did not improve cognitive 
performance for any task, and in fact cognitive performance in this group 
worsened overall. The studies demonstrate that, although a short period of HRT 
use in post-menopausal women may show some cognitive response,  HRT use 
beyond two months (and thus more typical of real life use) results in poorer 
cognitive performance, and this supports the critical period hypothesis.  
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The critical period hypothesis suggests that HRT will only maintain 
cognition if the therapy is initiated during the early stages of the menopause 
before the natural decrease of oestrogen occurs (Brinton, 200 9, Sherwin, 2012). 
The duration of this window of opportunity is not well defined. Others have also 
suggested that late HRT use can heighten the risk for developing dementia and 
may impair memory performance (Resnick & Henderson, 2002). The effects of 
initiating the therapy during the post-menopausal stage are less well understood. 
Gleason, Cholerton, Carlsson, Johnson and Asthana (2005) suggest th at if 
treatment is prolonged to five years beyond the window of opportunity there is 
an increased risk in developing dementia. Assuming oestrogen receptor sites are 
less active post-menopause; a sudden abundance of oestrogen therapy may 
become overwhelming for the receptor sites thus becoming detrimental to 
frontal lobe functioning. Briton suggested that the exposure of unhealthy 
neurons to oestrogen is without benefit and detrimental to the degeneration 
process. 
Confidence in observational findings of HRT use on cognition is limited by 
concerns involving the ‘healthy user bias’. This is  the tendency for women 
choosing to receive HRT to be better educated, healthier perhaps due to being 
more health conscious (Matthews, Kuller, Wing, Meilahn, & Plantinga, 19 96) and 
younger (Maki, 2006). For this reason, it is important that studies have groups 
balanced for age, education and health (for example, normal mood and normal 
cognitive function). Zandi and colleagues (2002) suggested that the positive 
effect of HRT on AD reduction is not likely to be associated with the healthy user 
bias, and several studies have attempted to reduce the possibilities of 
confounding variables. Sherwin (2008) strongly highlights the fact that normal 
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brain aging can lead to problems in cognition, especially after the age of 50 
where there is a quicker decline in memory, processing speed and executive 
function. As a result, studies should recruit participants who are balanced for 
and of similar age between groups.  
2.6 Summary 
 
Sherwin and Henry (2008) suggested that time of initiation of HRT will 
have effects on the protective role of the therapy and prevention of cognitive 
decline. During the menopause, oestrogen reduction in the brain can cause 
structural changes which can affect related cognitive functions. If HRT is 
initiated before or during these structural changes at the peri -menopausal stage, 
the therapy protects the brain from such changes, thus avoiding associated 
cognitive decline (Chen et al., 2006; Lee & McEwen, 2001; Maki, 2006 ). If the 
therapy is initiated too late after the menopause, there may be no effects in 
brain structure at this point (Adams et al., 2002) or an exacerbation of 
neurological demise due to the neurons already being compromised (Chen et al, 
2006). In support of this, studies have demonstrated that women taking HRT 
soon after the onset of the menopause suffer less from cognitive decline than 
those who take the therapy post-menopause (MacLennan et al., 2006; Matthews, 
Cauley, Yaffe, & Zmuda, 1999). What is less clear is the precise on set and 
duration of this window of opportunity, to which there should be a general 
consensus to aid in study design, and this can be largely influenced by the 
methods adopted by researchers to define peri - and post-menopausal groups. 
In previous research, executive or WM functions were assumed to be 
necessary for task completion, but not directly tested. Late users sometimes, but 
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not always, suffer from a detrimental effect of the treatment on some, but not 
all of these selected tasks. The relationship between postmenopausal initiation 
of HRT and cognitive domain has been established, but needs more clarification, 
and the identification of specific cognitive tasks that are sensitive to oestrogen 
change. For example, it is now assumed that early HRT use protect WM but only 
when the task is at a certain level of difficulty. Less is known about the 
relationship between HRT use and SA.  
Despite significant progress in the understanding of oestrogen in relation 
to cognitive function and neuron protection there are still conflicting views on 
the shielding effects exerted by HRT (LeBlanc et al., 2007; Pompili et al., 2012). 
Generally rat studies have proved more conclusive that human studies. Several 
studies of the effect of bilateral ovariectomy on cognitive function in peri-
menopausal women have found that surgical menopause produces marked 
differences across executive function which could be prevented by HRT if 
initiated at the correct time (Bailey et al., 2011). However many RCTs and 
laboratory studies have failed to reproduce this effect and it is difficult to 
determine whether this is due to a failure of smaller sample sizes to accurately 
represent a larger population or a failure in less sensitive cognitive assessments 
being chosen to detect subtle changes in cognitive function (Vearncombe & 
Pachana, 2009). Follow up studies and studies using the same methodology may 
help to establish the role of oestrogen in frontal lobe functions.  
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2.7 The interaction of time of initiation of HRT will affect executive 
function performance; rational for the present study design  
 
There is mixed evidence for benefits of HRT on cognition and some 
evidence that discrepancies are due to differences in timing of HRT initiation 
relative to stage in the climacteric, known as the critical period hypothesis (Craig 
et al., 2008; Maki, 2006).  
Sherwin and Henry (2008) suggested that time of initiation of HRT will 
have effects on the protective role of the therapy and prevention of cognitive 
decline. During the menopause, oestrogen reduction in the brain can cause 
structural changes which can affect related cognitive functions. If HRT is 
initiated before or during these structural changes at the peri -menopausal stage, 
the therapy protects the brain from such changes, thus avoiding associated 
cognitive decline (Chen et al., 2006; Lee & McEwen, 2001; Maki, 2006). If the 
therapy is initiated too late after the menopause, there may be no effects in 
brain structure at this point (Adams et al., 2002) or an exacerbation of 
neurological demise due to the neurons already being compromised (Chen et al, 
2006).  
Of less clarity is the effect of HRT use on cognition when initiated during 
the post-menopausal stage. Some studies have demonstrated no effects of HRT 
use when initiated in post-menopausal women on a variety of cognitive tasks 
demonstrating episodic memory and executive functions such as WM and 
attention (Binder, 2001; Janowsky et al., 2000; LeBlanc et al., 2007). Other 
studies have suggested that HRT initiation during the post -menopausal stage can 
result in cognitive impairment (Espeland et al., 2004; Grigorova & Sherwin, 2006; 
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Mulnard et al., 2000). The present study considered the interaction of time of 
initiation of HRT on cognitive performance.  
The beginning and duration of the critical period is yet to be defined and should 
not be determined by age 
Studies have demonstrated that women taking HRT soon after the onset 
of the menopause suffer less from cognitive decline than those who take the 
therapy post-menopause (MacLennan et al., 2006; Matthews, Cauley, Yaffe, & 
Zmuda, 1999). What is less clear is the precise on set and duration of this 
window of opportunity, to which there should be a general consensus to aid in 
study design, and this can be largely influenced by the methods adopted by 
researchers to define peri- and post-menopausal groups. 
Women with a history of HRT use were compared to women with no 
history of HRT use. The critical period was investigated, and women were 
organised in relation to her stage in the climacteric. Previous studies have 
tended to define time of HRT initiation in relation to women’s age rather than in 
relation to her stage in the climacteric (MacLennan et al., 2006). Because of 
variability in onset of the menopause (Sherwin, 2007), age alone does not 
capture whether someone is peri- or post-menopausal. The present study 
considers time elapsed since last menstrual bleed in order to aid clarification of 
the critical period. 
In order to pinpoint stage in the climacterics participants in the present 
study were asked when their last menstrual bleed was. According to national 
guidelines (NHS, 2012), a woman completes the menopause when her last 
menstrual bleed is in excess of 12 months ago (Brambilla et al. , 1994; McKinlay, 
1996); menopausal symptoms can be experienced several years prior or post this 
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time (Sherwin, 2007). Participants who had never initiated HRT, and who 
reported their last menstrual bleed within 12 months were classified as peri -
menopausal. Those who had reported their last menstrual bleed beyond 12 
months were classified as post-menopausal. Similarly, those who initiated HRT 
within 12 months of their last menstrual bleed were classified as peri -
menopausal HRT initiators, those who initiated their therapy beyond this point 
are classified as post-menopausal HRT initiators. In the UK the average age of 
the onset of the menopause is 51.7 years, plus or minus 7 years (Sherwin, 2007) 
and a woman can start to experience menopausal symptoms between the ages  
of 45 and 55 years. For this reason, participants will be included from the age of 
45 years and above, until 65 years, when menopausal symptoms have ceased.  
The reliability of asking participants to estimate their last menstrual 
bleed may be questionable, unless participants were in excess of this time frame 
(either several years since last menstrual bleed or having a recent menstrual 
bleed). Previous research has demonstrated that participants will estimate last 
menstrual bleed to be one year both at baseline, and at follow up one year later 
(Colditz et al., 1986). For this reason, participants were asked to describe their 
last menstrual bleed, and relate this to an event to help pinpoint the exact date.  
Even though there is consensus that it is better to  start HRT during the 
peri-menopause, previous studies have defined peri - and post-menopause in 
terms of age, so women who are below the mean age of menopause are 
assumed to be peri-menopause, while those who are older are assumed to be 
post-menopause. Defining menopausal stage in terms of chronological age 
ignores the variation in age at menopause. Once the menopause is exceeded to a 
certain point, initiation of HRT will no longer be as effective in its protection of 
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brain function and following this, cognition. This makes accuracy in defining and 
pinpointing the critical period extremely important.  
The present study addressed these issues by testing women who had 
initiated HRT during the critical period, and after the critical period, and 
compared these two groups to non-HRT users matched for stage in the 
climacteric. 
Incorporating an observational design allows exploration of the potential longer 
lasting effects of the critical period 
 
The present study incorporated an observational design, enabling the 
long term effects of HRT initiation on cognition to be explored, something that 
previous studies have not considered. Oestrogen fluctuation during the 
menopause and HRT use can result in changes in brain mechanisms, with 
changes in cognitive performance to follow. By using an observational study 
design, the researchers were able to recruit HRT users with a history of HRT use 
initiated several months prior to testing, to allow better chance of recognising 
these cognitive changes, something that previous RCT’s have not been able to 
explore. 
Measuring mood and menopausal symptoms 
Richardson (1991) suggests that the cognitive impairments often 
demonstrated in women entering the menopause are due to menopausal 
symptoms such as low mood experienced pre and post oestrogen change. 
Mood is oestrogen responsive, and can have an effect on task 
performance. Specifically, low levels of oestrogen results in a decrease of 
 
 
88 
 
dopamine which is associated with menopausal depression (Fink  et al., 1995) 
and dopaminergic cells have been shown to reduce by 30% in non-human 
primates after being 30 days of oestrogen deprivation (Leranth et al., 200 0). 
Dopaminergic reduction in layer one, area 46 of the PFC as a result of oestrogen 
deprivation can be restored with oestrogen treatment (Kritzer & Kohama, 1998) 
and dopaminergic change plays an important role information processing duri ng 
WM tasks (Goldman-Rakic, 1995; Tang et al., 2004).  
It has been reported that people who suffer from depression complain of 
problems in day to day memory (Watts, 1993). Further studies have indeed 
demonstrated that negative mood can have detrimental effects on WM capacity 
and attention (Ellis & Ashbrook, 1988; Hertel & Hardin, 1990). Cronholm and 
Otterson (1961) found that those suffering with depression als o found it difficult 
to learn.  
Jacobs and D’Esposito (2011) examined the effect of oestradiol on WM in 
healthy young women taking into consideration the baseline levels of dopamine 
in the prefrontal cortex. They concluded that oestradiol levels do impact on WM 
capacity and that this impact depends on baseline dopamine.  
Sherwin found HRT users to have improved mood after oestrogen 
treatment (Phillips & Sherwin, 1992; Sherwin 1997) and it is possible that 
baseline mood scores between HRT users and non-users will differ. For this 
reason, it is important to measure mood with the potential to use mood score as 
a covariate in analysis. 
In the oestrogen literature, mood has been measured as a potential 
covariate, and to check variance across groups (Grigorova et al., 2006). The 
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shortened General Health Questionnaire (GHQ-12) has been selected to measure 
mood as is a quick tool that is easy to administer and sensitive to mood 
differences. Roy-Byrne, Russo, Michelson, Zatzick, Pitman and Berliner (2004) 
reported internal consistency for the GHQ-12 assessed via Cronbach’s alpha 
ranging from 0.82 to 0.93. Depending on the type of patient, scor es six months 
apart correlated between 0.51 and 0.90. Content validity was demonstrated by 
showing that each test item highly discriminated between participants with 
lower rated score (with depression) and participants with normal rated score. 
For these reasons the GHQ-12 was selected to be included in the task battery.  
Previous studies have measured menopausal symptoms as a potential 
covariate (Grigorova et al., 2006).  As such it was deemed as useful to include a 
menopausal QoL scale score to determine symptoms experienced by the 
participant. The Menopausal Quality of Life scale (MQoL; P. Jacobs, Hyland, & 
Ley, 2000) was developed using 1188 questionnaires from two samples recruited 
from two Family Health Service Association (FHSA) lists and one sample 
recruited through an advertisement in a women’s magazine. The MQoL is a 48 
item menopause-specific QOL questionnaire where each item represents a 
symptom from a different domain. Responses range from a six item likert scale 
of ‘I am never like this’ to ‘I am always like this’. The scale was constructed after 
analysing single interviews of 32 women and four focus groups involving 29 
women using an adaptation of content summary. P. Jacobs and colleagues (2000) 
suggest that the majority of previous QoL menopausal  studies fail to include 
women over the age of 55 years which results in limited information on those in 
the end of their climacteric change whereas this scale was developed including 
postmenopausal women. Participants were asked to rate the relationship 
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between the menopause and cognition, and specifically to describe the 
relationship between the menopause and memory, the menopause and 
cognition and the menopause and attention. This allowed the researchers to 
consider the effect of expectation. The MQoL scale is highly related to the Global 
Quality of Life Scale (GQoL). Cronbach’s alpha range from .92 for the total MQoL 
scale and inter-correlations between menopausal domains scores range from .25 
to .68. It is divided into seven domains, allowing easy explo ration of 
participant’s subjective estimation of the impact of cognition on QoL.  
Measuring mental and physical health 
As people get older, chronic health conditions, co -morbidity and levels of 
medication usage rise (Lewis, Rook & Schwarzer, 1994). The effi ciency of organ 
function decreases, including lung and heart capacity (Physical development: age 
45-65, n.d.). The most common health problems experienced in those aged 
between 45 and 65 are arthritis, asthma, coronary heart disease, diabetes, high 
blood pressure, common mental health problems and stroke (Health: age 45 -65, 
n. d.). Participants of this age experienced a range of chronic conditions, 
resulting in a range of medications being taken. In accordance, P. Jacobs and 
colleagues (2000) asked participants in their study to list medication usage 
during the last few months up to participation in order to evaluate co -morbidity. 
The present study also requested medication being taken, and chronic 
conditions experienced in the three months leading to study participation.  
In the WHIMs study involving 3,200 women over a five year period 
(Espeland et al., 2004); the study only excluded women with signs of probable 
dementia, and included those with mild chronic conditions such as poor bone 
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health and high blood pressure. Kampen and Sherwin (1994) only excluded 
participants who had a history of head injury, stroke, heart attack, alcoholism, 
drug abuse, depression or any other major health problem. Schmidt and 
colleagues (1996) also excluded participants with dementia, drug abuse and 
neuropsychiatric problems. Henderson and colleagues (1996) excluded those 
with probable dementia, stroke and in addition, surgical menopause and 
Verghese and colleagues (2000) also excluded those with surgical menopause, as 
well as dementia and depression. And finally, Steffens and colleagues (1999) 
excluded women with a history of either stroke or dementia.  
In accordance, the current study excluded those with probable dementia, 
a history of stroke, a history of heart disease, a history  of alcohol or drug abuse, 
mental health problems and those who had undergone surgical menopause. In 
addition, participants were excluded if they had learning difficulties or were not 
fluent in English. 
Lord and colleagues (2008) also requested from their participants the 
total number of doctor visits over the past year. The present study felt it was 
appropriate to ask participants how often in the past three months leading up to 
the study they had visited a GP. This could be compared to national averaged f or 
that age group. 
With details of medication use, chronic conditions experienced, and GP 
visits leading up to, and including day of the study, an idea of typical health 
across each group could be accumulated.  
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Detail of HRT use 
For HRT users, details of type of HRT taken, duration of the therapy 
intervention (in months), and months passed since last treatment were recorded. 
Participants were only included if they had been receiving HRT continuously at 
any point for at least three months. This is because studies showing HRT use for 
less than this duration have had mixed results (for example, LeBlanc et al., 2007).  
Education 
A participant’s intelligence and/or level of education may have an effect 
on WM performance. It is therefore important to recognise the participants IQ 
and/or highest level of education, to make sure groups are balanced for IQ 
and/or educational level. The chosen WM tasks are cognitively demanding. 
Rather than ask participants to complete an IQ test, participants were simply 
asked their highest level of education to check groups were balanced for 
education (and to be used as a potential covariate). Previous studies which  have 
asked the participant for their highest level of education, rather than administer 
an IQ measure include studies by Grigorova et al., 2006; MacLennan et al., 2006 
and Lord et al., 2008. This is especially important as studies have demonstrated 
that HRT users completing WM tasks benefit from oestrogen use when the task 
becomes difficult (Grigorova et al., 2006; Keenan et al., 2001). This  point will 
differ between participants.  
In a short report it was noted that women in their third trimester of 
pregnancy who were less educated struggled more with the difficult components 
of Engle’s three WM tasks then those with a higher level (Jacobs & Pettit, 2008). 
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Because of the relationship with Engle’s three WM tasks in this case, it is 
especially important to request participant ’s highest level of education. 
Because aging is related to cognitive decline in older adults (Singh -
Manoux et al., 2012), participants were asked for their age and this was used as 
a covariate in study analysis. This coincides with the study by Rasgon and 
colleagues (2004). 
Early HRT use protects against decline in cognitive functions mediated by the 
prefrontal cortex, a rational for the selection of WM and SA tasks 
Keenan and colleagues (2001) suggest executive dysfunction mediated by 
the PFC to be the primary problem of oestrogen decline during the menopause. 
The relationship between the PFC and oestrogen change (as discusse d in chapter 
one) suggest that early HRT use will protect cognitive functions mediated by the 
PFC, and in particular, WM as associated with layer one, area 46 of the PFC (Tang 
et al., 2004).  
Episodic memory is mediated by the hippocampus and PFC. Several 
studies have demonstrated an improvement in episodic memory using paragraph 
recall, and list recall tasks with HRT use (Dumas et al., 2008; Joffe et al., 2006; 
Kampin & Sherwin, 1994; Maki et al., 2001). For example, Kugaya and colleagues 
(2003) demonstrated an increase in serotonin activity and oestrogen plasma 
levels in the right frontal cortex of oestrogen users. These participants 
performed better on episodic memory tasks including paragraph recall and 
verbal paired associates tests from the WMS-R. Because of the location of 
oestrogen receptors in the PFC, more studies are beginning to investigate the 
relationship between oestrogen change and executive function. In the same 
study participants performed better on executive function using the Trail Making 
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Test. The trail making test is a test of visual attention and task switching, 
incorporating both WM and SA. It can be used as a predictor for AD.  
Some larger scale studies neglected to include tasks of executive function. 
In the WHIMS by Espeland and colleagues involving over 3,200 women over five 
years, no differences were found in cognitive performance between HRT users 
and non-users measured by the modified Mini-Mental State Examination (MMSE). 
The MMSE is a global cognitive measure used to screen for de mentia. The task is 
usually administered on several occasions to map out rate of progression of 
cognitive impairment. Questions such as “name this picture” (e.g. a pencil or a 
pen), and “what day is it today” are  simple questions in normal populations. The 
study only included women free from probable dementia, suggesting the task to 
be too simple for this population. Sherwin (2007) suggests that future studies 
need to administer valid and reliable measures of specific cognitive domains 
rather than tests that measure globally cognitive functions, such as the modified 
Mini Mental State Examination which is unable to evaluate performance in 
specific cognitive domains. 
The executive function that has generated most interest and exploration 
over the past decade is WM (Joffe et al., 2006; Pompili et al., 2012; Smith et al., 
2006), although this is still relatively unexplored. WM capacity can be influenced 
by oestrogen change and protected by HRT use (Dumas et al., 2010; Keenan et 
al., 2001).  
Sherwin (2007) noted the protective effect of oestrogen on both verbal 
memory and WM. However, her studies have not always led to the same 
conclusion (Sherwin, 1997), highlighting the importance of choosing a sensitive 
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measure of WM.  Several studies have demonstrated a change in PFC function 
with HRT use during the completion of WM tasks, but this has not been 
demonstrated in task performance itself (for example, Shaywitz et al, 1999). This 
further clarifies the need for well selected WM tasks.  
In the study by Grigorova, Sherwin and Tulandi (2006), participants 
completed a verbal WM task, a non-verbal WM task (modified versions of the N-
Back test) and a sequential WM task (the Letter-Number Sequencing Subtest; 
WAIS-III). All three tasks were susceptible to oestrogen change. The Letter-
Number Sequencing Subtest represents components of WM (short term memory 
and attention), but does not exercise some of the more difficult components of 
the WM model. The fact that differences were found in the verbal and non -
verbal forms of the N-Back task suggests that oestrogen change can affect 
performance on different types of WM, which is of interest. In this particular 
study it was possible that the effect of oestrogen deficiency on cognition only 
transpired when cognitive assessments exceeded a particular level of difficulty. 
This is consistent with the study by Keenan and colleagues (2001), where the 
effects of oestrogen suppression on WM were only seen when the task became 
challenging. Because task difficulty is important, the chosen WM task should also 
have different levels of difficulty. Participants recruited varied in level of 
education, and tasks needed to be suitable for such a population.  
Engle’s WM tasks are established in the field, have high validity, and have 
a variety of components such as reading or counting which gives them some 
degree of variability. Engle’s WM tasks incorporate three different types of WM; 
verbal WM, spatial WM and mathematical WM. Oestrogen change has been 
shown to affect different types of WM such as verbal WM and spatial WM. By 
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selecting Engle’s WM tasks, the tasks represent three different types of WM, 
each of which can be measured using tasks that are similar in presentation, 
difficulty and are highly correlated with each other (Conway, Kane & Engel, 
2004). This means that each type of WM can be equally represented and 
assessed. Because the tasks correlate with each other, together they are a 
strong measure of WM Capacity (WMC).  
By using measures of three different types of WM, the effect of HRT on 
WM can really be tested, picking up sensitivities that other studies have 
overlooked. Engle’s WM tasks are the Reading span (Rspan; Daneman & 
Carpenter, 1980), Operation span (OSpan; Turner & Engle, 1986) and Counting 
Span (CSpan; Engle et al. 1999). The RSpan task  is a strong predictor of verbal 
performance (Friedman & Miyake, 2000). The Ospan was developed as an 
extension of the Rspan task (being a proxy for reading comprehension) and both 
tasks account for common variance in higher order tasks. The Cspan was 
developed to include attention control in counting specific objects, and helps to 
overcome the potential verbal constraints of the RSpan and OSpan. Engle’s WM 
tasks load on the same factor as WM span tasks testing spatial processing and 
storage (Kane & Engle, 2004).  Participants need to store words, letters, or digits 
whilst processing material, and need to allocate attention or resources to the 
storage and processing components appropriately. They involve confirmation of 
a maths sum (Ospan) or sentence (Rspan) and memory for a following word or 
letter.  
To be a good measure of WM, Engle suggests that two tasks of the three 
need to be completed in order to predict a reliable WM score. In this case, and 
based on the arguments presented above, it is suitable to use all three tasks. 
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Similarities in the literature suggest that differences in WM are only 
present between HRT groups when the task is relatively difficult. Neuroimaging 
studies have shown a change in PFC activation with oestrogen use during 
completion of a WM task, but this has not impacted on task performance 
(Shaywitz et al., 1999). It is possible that these differences only transpire when a 
task is of a particular difficulty level. Griorova and colleagues (2006) concluded 
that the effect of oestrogen levels on WM task performance may only be 
apparent if the task itself is of a certain level of difficulty. And sometimes the 
effects of oestrogen change on WM only transpire when task difficulty is 
increased (Keenan et al., 2001), suggesting that task difficulty should be 
considered during task selection. 
Engle’s WM tasks are relatively complex, where the participant needs to 
use both manipulation of the stimulus whilst solving a task before retrieval can 
take place. Engle’s WM tasks have 12-16 trials which differ in difficulty level, 
where participants are asked to remember between two and six items per trial 
whilst in the face of distraction. These items are counterbalanced. Because of 
the differing levels of difficulty between trials, Engle’s WM tasks will become 
challenging at different points depending on the participant’s capacity, making 
the tasks suitable for different age groups socio-economic status. 
The WM span tasks have been developed over the years in order to 
strengthen their reliability, for example, using words and letters that are easy to 
distinguish between (Baddeley, 1966; Conrad & Hull, 1964) and using neutral 
items to avoid mood congruency effects (Teasdale, Taylor, & Fogarty, 1980).  
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 Oestrogen decrease during the menopause can result in decreased WM 
capacity and SA may rely on WM when information processing and storage 
become competitive (Knudson, 2007). The role of oestrogen change on attention 
has recently received small consideration, but this has not been explored in 
great depth.  
Changes in SA during the menopause and response to HRT is well 
explored in animal studies (Barnes et al., 2006; Wang et al., 2008), but not in 
human studies. SA has been shown to be impaired during pregnancy (deGroot, 
Adam, & Hornstra, 2003). Crawley and colleagues (2005) demonstrated 
compromised SA in pregnant women when working out what floor a moving 
elevator was on when they were given instructions to its movement. The task 
was designed by the investigators. SA becomes impaired when women are given 
a hormone suppressant to combat breast cancer (Wieneke & Dienst, 2007). Less 
is known about the impact of oestrogen change on SA in menopausal women, 
making it of great interest. 
Many cognitive tasks do require attention, such as speed tasks or choice 
tasks, but results may be mixed due to tasks being indirect measures of 
attention. A task that may be suitable as a direct measure of SA is the Sustained 
Attention to Response Task (SART, Robertsonet al., 1997). Performance of the 
SART has been shown to be sensitive to subtle impairments in attention 
following traumatic brain injury and performance correlates with both SA, and 
the Cognitive Failures Questionnaire (CFQ). This means the task should be 
sensitive to menopausal symptomatology. 
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The SART was developed specifically to measure subtle attention deficits 
in patients with Traumatic Brain Injury (TBI). TBI particularly affects the frontal 
lobes, resulting in poor performance in frontal lobe mediated tasks. HRT 
initiation during the peri-menopausal stage has been shown to increase frontal 
lobe activation (Joffe et al., 2006; Knudson, 2007; Shaywitz et al., 1999), and the 
SART may be a suitable task to pick up effects of this increased activation on 
cognitive function for those with early HRT use. The task has little demand on 
other cognitions such as memory, practising continuous attention to response, 
and predicts both self-reported and informant-reported failures of attention in 
normal participants (Robertson et al., 1997). The SART correlates with other 
measures of SA (Manly, Robertson, Galloway & Hawkins, 1999; Robertson et al., 
1997) but has advantages to other tasks by being easy and quick to administrate 
and complete, and simple in design. For example, the change in stimuli font size 
of the SART and the relatively random organisation of the stimuli eradicate 
expectation whilst maintaining attention effort. Generally, individual’s response 
time correlates with errors made. Differences occur dependently on whether the 
individual puts more emphasis on response speed or correct target response 
(Robertson et al., 1997). Typically, participants incorrectly respond 6.36 times 
out of 25 during the completion of the SART and those who responded quicker 
make more errors overall.  
Together, completion of the three different types of WM task, and the 
SART as a measure of sustained attention, will give good indication of the effect 
of HRT use on executive function when administrated during the peri - and post-
menopausal stages. 
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The critical period hypothesis suggests that HRT initiation is most 
beneficial to cognition when taken during the peri -menopausal stage (Maki, 
2006; Resnick, 2002; Sherwin, 2006). Because of this (and to coincide with 
previous research testing HRT use in peri-menopausal women on executive 
function and WM), it is expected that HRT will benefit WM only when initiated 
during the peri-menopausal stage (Joffe et al., 2006; Lacreuse & Herndon, 2003). 
Participants in the present study will have a history of HRT use, meaning that 
some may have initiated the therapy (and in fact, stopped receiving treatment) 
years prior to testing. These women will be compared to women who are 
currently peri-menopausal. Because of this, study outcome is uncertain. The 
effect of post-menopausal HRT initiation on WM is less certain, and the effect of 
HRT initiation, whether peri- or post-menopause, and the relationship with SA is 
thoroughly under developed. Because of these factors combined, no predictions 
were made regarding cognitive performance of any group.  
2.8  Method for study one  
 
Study One, Stage One 
Participants  A total of 121 healthy women between 45 and 65 years of 
age were recruited within the Plymouth and London areas through use of 
internet advertisement, word of mouth and advertisement throughout Plymouth 
University. The researchers classified HRT users as either HRT initiators peri -
menopause (if the therapy was initiated within 12 months of the participant’s 
last menstrual bleed during their peri-menopausal stage) or HRT initiators post-
menopause (if the therapy was initiated beyond 12 months of the participant’s 
last menopausal bleed when participants were post-menopausal) by asking the 
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participant when their last menstrual bleed was in relation to initiation of the 
therapy. Non HRT users were divided into peri -menopausal and post-menopausal 
groups, again by asking the participant when their last menstrual bleed was. 
Those whose last bleed was experienced within 12 months at time of testing 
were classed as peri-menopausal; those whose last bleed was experienced 
longer than 12 months ago were classed as post-menopausal. Participants fitted 
one of the four levels of HRT-status accordingly: HRT initiators peri-menopause 
(n = 33), HRT initiators post-menopause (n = 26), peri-menopausal non-users (n = 
33) and post-menopausal non-users (n = 29).  
Exclusion and Inclusion criteria were clearly specified on advertising 
material, and during initial communication prior to the study. Participants were 
asked to be of normal health, with no learning difficulties. Specifically, those 
with severe mental health problems (such as chronic/severe anxiety or 
depression) were excluded from the study. Those who were normally 
menstruating up to the menopause were included in the study, those with 
hysterectomy were excluded from the study) . Participants were also excluded if 
dyslexic or dyspraxic, and it was essential that participants were fluent at English.   
 
Measures  RSpan, OSpan and CSpan measured WM. Participants 
scored one point for every correctly recalled item in its correct place  within the 
sequence. For the RSpan and Ospan this was out of 42; for CSpan this was out of 
60. A higher WM score represented more correct answers indicating a larger WM 
capacity. 
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RSpan  Participants were presented with a sentence and a letter as 
follows: 
My wish had a huge garage sale ? K 
 
Participants were asked to read the sentence out loud, decide whether the 
sentence made sense by confirming “yes” or “no” out loud, and then to read the 
proceeding letter out loud. They were asked to remember this letter and press 
the space bar, at which point a second sentence and letter would appear. The 
participant was asked to repeat this process for each sentence they were 
presented with. This continued until a question mark appeared on the screen at 
which point, participants were asked to recall the sequence of letters they had 
remembered in order of presentation. Then, a new trial with new sentences and 
letters to remember would begin. There were 12 trials in total, each with 
between two and five sentence-letter pairs presented before the recall phase. 
The two, three, four and five sentence-letter pair trials appeared in random 
order. The random order used was the same random order for each participant. 
The sentences to be solved and proceeding letters were those selected by Engle. 
Letters chosen were individual in sound so not to cause potential confusion and 
increase in mistakes made (for example, the task did not include both the letters 
B and D as it can be easy to replace one with the other, due to their phonetically 
similar nature). Chosen letters included ‘J, M, F, X, L, R, B, Q’ and ‘H’.  
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OSpan  Participants were asked to perform a sequence of simple arithmetic 
calculations each followed by an unrelated word to be recalled later. Items were 
presented as follows: 
IS (10 x 2) – 4 = 18 ? CLOUD 
 
Participants were asked to work out the maths sum, being told that the maths 
sum may or may not reach the correct conclusion. They were asked to say out 
loud “yes” or “no” as to whether the solution to the maths sum was correct, and 
read out loud the proceeding word. Participants were instructed to remember 
the word and press the space bar to continue to the next sum -word pair and 
repeat the process. This continued until a question mark appeared on the screen, 
at which point they were asked to recall the sequence of words from that set in 
order. The participant would then continue by pressing the space bar to progress 
to the next set. There were 12 trials in total with between two and five sum -
word pairs presented before the recall phase. The two, three, four a nd five sum-
word pair trials appeared in random order. The random order used was the same 
random order for each participant. The equations to be solved and proceeding 
words were those selected by Engle. The chosen words were all objects which 
were unrelated to each other (for example, the word flame was the only element; 
the word chair was the only furniture). Words were individual in sound as to not 
cause potential confusion and increase in mistakes made (for example, the task 
did not include any words that rhymed with each other). The words were all 
single syllable words with common frequency in English.  
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CSpan Participants were presented with a picture of a random number of dark 
blue circles, light blue circles and dark blue squares. See figure 2 .1 below. 
 
 
 
 
 
Figure 2.1:  One example of sixty items displayed across the fifteen trials taken 
  from Cspan of a single item presented to the participant 
 
Participants were asked to count out loud only the number of dark blue circles 
and repeat the final total. In the above case the participant should respond 
‘1…2…3…4…5…6…7…8…8’. Participants were asked to remember the final 
number. Once counted, participants pressed the space bar to continue to the 
next item and repeat the process. This continued until a question mark appeared 
on the screen, at which point, the participant was asked to recall the sequence 
of totals from the trial in the correct order. The participant would press the 
space bar to begin a new set. There were 15 trials in total, with between two 
and six numbers in each to remember. The two, three, four, five and six counting 
pair trials appeared in random order. The random order used was the same 
random order for each participant. The numbers of  dark blue circles to be 
totalled were selected by Engle. 
 
Figure has been removed 
due to Copyright restrictions 
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SART  To measure SA, participants were asked to complete the SART 
(Robertson et al., 1997). To follow the standard procedure of the SART, 
participants were presented with 225 single digits (digits one to nine) across a 
4.3 minute period. Each digit was presented once for 250 msec, followed by a 
900 msec mask. The mask was a circle with a diagonal line through the centre. 
The digits were arranged in 25 blocks of nine, with each digit of one to nine only 
repeating itself once per block. Within each block, the nine digits were arranged 
randomly; the only constraint being that the number three could not be the first 
or the last digit in each block. Participants were asked to push the space bar on 
the keyboard as soon as possible for every digit except the number three . When 
the number three occurred, they were told to withhold their response. Reaction 
times per digit as well as errors (incorrect responses towards the number three) 
were recorded by the computer programme. From this, the average reaction 
time per correct response and total number of incorrect responses towards the 
number three were calculated. As each score point represented an incorrect 
response to the number three, a lower SART score represented fewer incorrect 
responses to the number three indicating better SA. Participants were made 
aware that response speed and accuracy were of equal importance. The digits 
were presented in one of five font sizes (48 point, 72 point, 94 point, 100 point 
and 120 point). This reduced the possibility of participants to b e looking for a 
response template, and rather, enforced them to search for the numerical value. 
Examples of screen shots from the three WM tasks and the SART can be found in 
appendix A; pages 276 - 280. 
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GHQ-12    The GHQ-12 is a self-administered instrument designed to assess 
adults’ mental health. Each of the 12 items asks respondents to rate the severity 
of a common mental health problem over the past few weeks using a four -point 
scale, taking approximately five minutes to administer. Ratings for items ar e 
summed to generate a total score ranging from zero to 36, with higher scores 
indicating worse conditions (Petrak & Campbell, 1999). The GHQ -12 items 
measure psychological health such as ‘have you recently been feeling unhappy 
or depressed?’ Participants completed the GHQ-12 by responding to each of 
these 12 items using the four point-scale. For the example above, participants 
would be asked to respond by choosing either ‘Less than normal’, ‘Same as 
usual’, ‘More than normal’, or ‘Much more than usual’. Scores were balanced 
depending on whether the statement was positive or negative and added to a 
total. Scores were then categorised as normal (12 – 20), borderline (21 – 26) or 
high (27 – 48) based on cut off points calculated relative to the distribution of  
scores within the sample (zero-33rd, 33rd – 67th, 67th – 100th percentiles). 
Higher scores represented a lowered mood and potentially depressed state. 
These percentiles were initially worked out based on the study’s own samples, 
and then confirmed to be the same as a normative distribution (using the GHQ-
12 scoring handbook; Goldberg & Williams, 1991). A full copy of the GHQ-12 can 
be found in appendix A; page 281. 
MQoL     The MQoL scale is comprised of seven domains that typically become 
problematic during the menopausal change. These include Energy, Feelings, 
Symptoms Impact, Interactions, Cognition, Sleep and Appetite and equate to 48 
items. For this study, only the 14 items assessing cognition and feelings were 
used, to keep the question battery manageable for participants and because 
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cognitive symptoms were expected to be the most closely related to 
performance on the cognitive tasks. A copy of the selected items can be found in 
appendix A; page 283. Participants were asked to rate on a six point scale how 
strongly they had felt each symptom over the past few months. For example; 
participants would be asked ‘I can concentrate easily’ to which they would 
response from ‘I am never like this’ to ‘I am alw ays like this’ on a six point scale. 
Items were scored and added to a total. After collaboration with the designer of 
the scale, it was decided that the scores of this specific sample should be 
categorised as normal, borderline or high based on cut off poi nts calculated 
relative to the distribution of scores within the sample (zero -33rd, 33rd – 67th, 
67th – 100th percentiles).  
 
Additional Information  Individuals were asked for their age and level of 
education. Details of the menopause were requested to determine whether the 
participant was peri or post-menopausal such as the approximate date of the 
last bleed. Participants were then asked whether or not they had ever received 
any form of HRT. Users of HRT were asked how much time had lapsed between 
last menstrual bleed and HRT initiation. They were also asked details of their 
therapy, including the type, how it is administered into the body and duration of 
treatment. Details regarding general physical health including medication taken, 
visits to the local GP within three months and any chronic conditions were 
recorded. To conclude, participants were asked about their general thoughts on 
cognition and the menopause, and whether one can affect the other. These 
where categorised and scored. The additional information took the form of a 
biographical questionnaire, which is available in appendix A; page 286. 
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Procedure  Ethical approval was granted by the University of Plymouth 
Faculty of Science and Technology ethics committee. Participants completed the 
study on University campus or in their own homes. In some cases, participants 
met in twos or threes in one of the participant’s homes to complete the study 
one at a time after each other. Participants were strictly asked not to talk about 
the tasks to each other if this was the case. In many cases, new participants 
were recruited through recommendation of another participant. Again, if this 
were the case participants were strictly asked not to talk about the tasks to each 
other until everybody involved had completed the study.  
Participants were asked to complete the SART on a lap top (Presario A900 
compac) using the space bar to respond. This task was followed by each of the 
WM tasks. WM task order was counter-balanced across participants using 
randomisation. Participants were then presented with the GHQ-12, items from 
the MQoL scale and biographical questionnaire on the lap top, and asked to 
respond to each item using the mouse to select the appropriate response.  
At the end of the study, participants were told that they had the 
opportunity to take part in the study one year following. They were asked to 
explicitly state if they did not want to be contacted in one year. They provided 
preferred contact details, and were thanked for their time.  
 
Study One, Stage Two 
Participants  A total of 90 women (74%) from the original 121 
participants returned to complete the study. Of these, 46 (of 59; 78%) had used 
HRT at some point during the completion of their menopause, with 44 (of 62; 
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71%) having never used the therapy. Twenty five of the HRT users (of the 
original 33 peri-menopausal HRT users; 76%) had initiated the therapy in their 
peri-menopausal stage and 21 (of 26; 79%) of the HRT users had initiated the 
therapy in the post-menopause. These were compared to 23 (of 33; 70%) peri-
menopausal non users and 21 (of 29; 72%) post-menopausal non-users 
respectively. Participants were contacted via email and phone using contact 
details left during the completion of stage one of the study. Participants were 
contacted on average at 11 months to give adequate time to agree to take part 
in the study.  
Measures Participants were asked to complete the same test battery 12 
months later. To measure WM, they were asked to complete three of Engle’s 
WM span tasks including RSpan, OSpan and CSpan once more. To measure 
sustained attention, they were asked to complete the  SART task. To measure 
mood and menopausal symptoms, participants were asked to complete the GHQ -
12 and the items from the MQoL scale. This was followed by a short 
questionnaire that focused on any changes since the last meeting. Specifically, 
participants were asked about any changes to the menopause such as whether 
they were still experiencing regular menstrual bleeds or not and whether their 
history of HRT use had changed such as if they had ceased therapy use or not. 
Details regarding visits to a local GP within the three months leading to 
participation and any chronic conditions were recorded. To conclude, 
participants were asked about their general thoughts on cognition and the 
menopause, and whether one can affect the other.  
Procedure Participants completed the study on University campus or in their 
own homes as previous. They were asked to complete the SART on a lap top 
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using the space bar to respond. This was then followed by each of the WM tasks. 
Participants were then presented with the GHQ-12, items from the MQoL scale 
and biographical questionnaire on the lap top, and asked to respond to each 
item using the mouse to select the appropriate response. In some cases 
participants were offered paper questionnaires to fill out instead of the 
computer versions, as many reported during the first stage of the study that 
they disliked the constant use of the laptop throughout the test battery.  
 
2.9  Results and Analysis 
  
Data regarding WMC were analysed using MANCOVA with stage of the 
climacteric (peri or post) and HRT use (history of HRT use or no history of HRT 
use) as factors and age (in years) and MQoL score as covariates. It was important 
to recognise the effect of time of HRT initiation on WM overall before 
considering domain specific WM. Data regarding the number of correct answers 
for each WM Span task (RSpan, OSpan and CSpan) were analysed using ANCOVA 
with stage in the climacteric (peri or post) and HRT use (histo ry of HRT use or no 
history of HRT use) as factors and age (in years) and MQoL score as covariates. 
This enabled exploration of time of HRT initiation on verbal, mathematical and 
spatial WM individually. The order of the tasks were counterbalanced to contr ol 
for order effects. 
Data regarding the number of incorrect responses to the number three in 
the SART were analysed using a ANCOVA with stage of the climacteric (peri or 
post) and HRT use (history of HRT use or no history of HRT use) as factors and 
age (in years), MQoL score and reaction time per correct response as covariates.  
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A total of 121 women aged between 45 and 65 years of age completed 
stage one of the study. Of these, 59 had used HRT at some point during the 
completion of their menopause, with 62 having never used the therapy. Thirty-
three HRT users who had initiated the therapy in their peri -menopausal stage 
and 26 HRT users who had initiated the therapy in the post-menopause were 
compared to 33 peri-menopausal non users and 29 post-menopausal non users 
respectively. MQoL, GHQ-12, number of visits to a GP and physical health were 
similar across groups (table 1.1). 
Table 1.1:   Mean score (± standard deviation) or count of HRT detail and health 
across menopausal group 
 Peri-
menopausal 
participants (n 
= 33) 
Post-
menopausal 
participants (n 
= 29) 
HRT initiator 
(peri) 
participants (n = 
33) 
HRT initiator 
(post) 
participants (n 
= 26) 
Total 
(n = 121) 
Mean Age 50.24 (3.60) 56.48 (4.34) 54.91 (6.01) 58.46 (3.99) 54.78 (5.49) 
GHQ-12 mean 
score 
24.36 (4.87) 24.69 (7.04) 23.10 (3.56) 24.40 (6.20) 24.17 (5.50) 
MQoL mean 
score 
14.39 (3.67) 15.55 (3.95) 15.73 (4.21) 14.81 (3.97) 15.12 (3.94) 
Mean visits to 
the GP 
0.91 (1.15) 0.66 (0.77) 0.76 (1.06) 0.73 (1.04) 0.77 (1.01) 
No. women 
taking 
medication 
12 11 13 12 48 
No. women 
with chronic 
conditions 
12 15 14 16 57 
Mean years 
taking HRT 
  5.01 (4.05) 3.77 (2.90) 4.46 (3.61) 
Mean years 
since last HRT 
  3.42 (4.85) 4.81 (3.70) 4.03 (4.40) 
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Menopausal Symptoms  
The participants were asked to estimate the approximate date of their 
most recent menstrual bleed, specifically whether this had fallen within the past 
twelve months. Of the total population, 12.4% (n = 15) reported not having 
experienced any menopausal symptoms to date, 37.2% (n = 45) estimated the 
onset of their symptoms to be less than five years ago and 27.3% ( n = 33) of the 
population estimated the start of their menopausal symptoms to be between 
five and ten years ago. Of the population, 15.7% (n = 19) estimated their last 
menstrual bleed to be between 10 and 15 years ago and 8.3% (n = 10) estimated 
the onset of their menopausal symptoms to be over 15 years ago. Table 1.2 
shows the estimated last menstrual bleed for each participant across each group.  
 
Table 1.2:  Count of last estimated menstrual bleed of each participant across 
menopausal group 
 Regular 
bleeds 
Less than 5 
yrs ago 
5 – 10 yrs 10 – 15 yrs Over 15 yrs 
Peri-
menopausal 
15 18    
Post-
menopausal 
 11 13 4 1 
HRT initiator 
(peri) 
 17 7 7 2 
HRT initiator 
(post) 
 2 11 7 6 
 
A total of 15 women in the peri-menopausal stage were experiencing 
regular menstrual bleeds, but this was not well matched by women who initiated 
HRT in their peri-menopausal stage. 
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Details of HRT 
A total of 59 women (48.8%) had reported once taking HRT for  at least 
three months. Table 1.3 shows the division of these therapy types for each peri - 
and post-menopausal HRT groups. Of those taking HRT, 50 women were 
receiving a combination of oestrogen and progesterone and nine were receiving 
oestrogen only.  
 
Table 1.3:  Count and overall percentage of participants’ therapy types across HRT 
initiators (peri- and post) 
 
 Patches Pills Implants Other 
HRT initiator 
(peri) 
8 16 6 1 
HRT initiator 
(post) 
10 14 2 1 
Total 18 (29.9%) 30 (49.7%) 8 (14.9%) 2 (3.5%) 
 
On average, those who initiated the therapy during their peri -
menopausal stage took the therapy for 5.01 years (SD = 4.85), terminating the 
treatment 3.42 years ago. Those who initiated the therapy in the post -
menopausal stage took the therapy for 3.77 years (SD = 2.90), terminating the 
treatment 4.81 years ago (SD = 3.70). In total 67.2% of the HRT using population 
had ceased the therapy within the past five years. Those still taking the therapy 
included five women who had initiated the therapy during their p ost-menopause, 
and 17 women who had initiated their therapy during their peri -menopause. 
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GHQ-12 
The GHQ-12 was scored conventionally and a lower score represented 
better mood, a higher score represented negative (or depressed) mood. Of the 
total population, 24% of the women were of ‘normal’ mood (12 -20 points), 54.5% 
were of ‘borderline’ (21-26 points) and 21.5% of participants were of ‘high’ (or 
depressed) mood (27+ points). The distribution can be seen in figure 2.2. 
 
 
Figure 2.2:  Distribution of GHQ-12 score across the study population 
 
Mean GHQ-12 scores per group as well as the total average score for the 
study population can be seen in table 1.1. The sample’s mood scores were 
normally distributed across groups, and groups did not differ between average 
mood score dependant on phase (F(1, 117) = 0.927, p = .34, d = .008) HRT use 
(F(1, 117) = 0.40, p = .53, d = .003) or the interaction between the two (F(1, 117) 
= 0.41, p = .34, d = .008). 
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MQoL 
In contrast to the GHQ-12, higher scores of the MQoL scale represent 
better QoL. Of the total population, 14.0% (n = 17) reported having poor QoL 
based on symptoms impact, 65.3% (n = 79) reported having borderline QoL and 
20.7% (n = 25) reported having good QoL. Mean MQoL scores per group as well 
as the total average score for the study population can be seen in table 1.1. The 
sample’s mood scores were normally distributed across groups, and groups did 
not differ between average mood score dependant on phase ( F(1, 117) = 0.03, p 
= .87, d = .000) HRT use (F(1, 117) = 0.17, p = .68, d = .001) or the interaction 
between the two (F(1, 117) = 2.07, p = .15, d = .017). 
 
Number of GP visits, type and frequency of chronic conditions and medication use 
do not differ across groups 
 
Participants were asked how many times they had visited a GP in the past 
three months. In the past three months 51.2% had not visited a GP, 29.8% had 
visited a GP once, 10.7% had visited a GP twice, 5.8% had visited a GP three 
times, 1.6% had visited a GP four times and 0.8% had visited a GP five times. The 
mean number of GP visits the four groups can be seen in table 1.1. The sample’s 
mood scores were normally distributed across groups, and groups did not differ 
between average mood score dependant on phase (F(1, 117) = 0.55, p = .46, d 
= .005) HRT use (F(1, 117) = 0.4, p = .85, d = .000) or the interaction between the 
two (F(1, 117) = 0.36, p = .55, d = .003). 
Of the total population, 40.5% (n = 49) stated that they were taking 
medication at time of completion of the study. Total count of those taking 
medication across the four groups can be seen in table 1.1. Medication use did 
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not differ between peri- and post- users; X2(1, n = 121) = .14, p = .71, or those 
with and without a history of HRT use; X2(1, n = 121) = .27, p = .60. 
 Participants were also asked if they suffered from a chronic 
condition, to which 45.5% of the population (n = 55) indicated that they suffered 
from a chronic condition. Total count of those suffering chronic conditions 
across the four groups can be seen in table 1.1. Chronic conditions did not differ 
between peri- and post- users; X2(1, n = 121) = 3.95, p = .48, or those with and 
without a history of HRT use;  X2(1, n = 121) = 1.48, p = .48. 
Most frequent conditions included underactive thyroid, asthma and high 
blood pressure, for which most participants were receiving treatment. In 
addition to this, a proportion of participants were taking pain killers for general 
aches and pains, as well as for migraine. The total count of reported con ditions 
can be seen in table 1.4. 
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Table 1.4: Count of reported chronic conditions across the total group  
Condition Count 
Acid reflux 1 
Allergies 1 
Anemia 1 
Asthma 8 
Osteoporosis/Arthritis/ 
Back/bone pain 
11 
Cancer (past) 2 
Diverticulitis 2 
HBP 14 
Diabetic 1 
High cholesterol 2 
Hep C 1 
Migraine 3 
Eczema 2 
MS 2 
Underactive thyroid 8 
 
Belief 
Participants were asked whether they felt the menopause could affect 
cognition, memory or attention. The majority of participants (56.2%) felt that 
the menopause may have a mild detrimental effect on cognition, memory and 
attention and 13.2% of the population felt that this detrimental effect could be 
extreme. A large proportion of the population (29.8%) believed the menopause 
to have no effect on cognition, memory and attention. And one person believed 
that the menopause could improve cognition, memory and attention. Belief did 
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not differ between peri- and post- users; X2(3, n = 121) = 1.48, p = .69, or those 
with and without a history of HRT use;  X2(3, n = 121) = 1.90, p = .60. 
 
Education 
The majority of the study’s population (41.3%) had completed educati on 
up to G.C.S.Es (O levels) and/or A levels. A large proportion of the population 
(34.7%) had completed an undergraduate degree, and some had completed 
education at post graduate (13.2%) and skills level (8.3%) qualification. A small 
percentage (2.5%) had completed their educational path at key stage three. A 
breakdown of individual educational levels across group can be seen in table 1.5. 
 
Table 1.5:  Count of current level of education across menopausal group 
 KS3 GCSE/A-level 
equivalent 
Undergraduate 
equivalent 
Post 
graduate 
equivalent 
Skills level 
equivalent 
Peri-
menopausal 
1 15 14 2 1 
Post-
menopausal 
2 9 7 4 4 
HRT initiator 
(peri) 
 15 10 6 2 
HRT initiator 
(post) 
2 9 7 4 4 
Total 3 50 42 16 10 
 
Level of education did not differ between peri - and post- users; X2(4, n = 
121) = 3.82, p = .43, or those with and without a history of HRT use;  X2(3, n = 121) 
= 3.27, p = .52. 
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The groups were similar in terms of mental and physical health, 
education, and beliefs about effects of menopause on cognition. The peri -HRT 
and peri-control groups matched each other for age. The post -HRT and post-
control groups also matched each other for age and were older than the peri -
groups. Groups were also similar for MQoL and GHQ-12 score. Correlations and 
regression models were fitted to the data.  
Correlational analyses were carried out to determine the details of the 
main analyses for this study, and to confirm that scores on the SART correlated 
with those on the WM tasks. Regression models were also fitted to the data.  
Each WM span task has been designed to measure WM, and as such 
scores of each WM task would be expected to strongly correlate with each other. 
In the present study, RSpan had a strong positive correlation wit h both OSpan (r 
= .657, p < .001) and CSpan (r = .642, p < .001). OSpan had a strong positive 
correlation with CSpan (r = .726, p < .001). This means that as WM capacity for 
one WM task increases, so does WM capacity for the other two WM tasks and 
confirms that three of these tasks will be a strong measure of WM overall. As 
the three tasks are strongly but not perfectly correlated all three measures can 
be included in a Manova (Tabachnik & Fidell, 2012). There was no correlation 
between time it took to complete the task and WM score. WM Span 
performance in each task was not affected by order of completion of the task 
when counterbalanced. 
Participants who reported better quality of life as measured by MQoL 
total score performed better on RSpan (r = .215, p =  .018) and OSpan (r = .183, p 
= .044) suggesting that mood and menopausal symptoms may affect WM 
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performance. MQoL total score was therefore included as a covariate in the 
analyses of effects of HRT and timing of HRT on cognitive performance. GHQ -12 
total score correlated negatively but weakly with OSpan (r = -.180, p = .048) but 
not RSpan (r = -.140, p = .13) or CSpan (r = -.109, p = .23). GHQ-12 was not used 
as a covariate in data analysis. Although a decrease in cognitive performance did 
not correlate with an increase in age in this sample, age was still included as a 
covariate because of well-established effects of age on WM in the literature and 
because of the unavoidable age differences between the peri - and post-
menopausal groups in our sample. As expected, the GHQ-12 total score had a 
strong negative correlation with MQoL total score (r = -.333, p < .001) showing 
that as the participants’ rating of QoL increased, GHQ -12 score decreased 
(increased quality of life coincides with lower ratings of depress ed mood). 
Participants who had a quicker reaction time on the SART were more 
likely to make mistakes by incorrectly responding to the number three (r = -.391, 
p < .001). The number of incorrect responses correlated positively with the other 
type of error, withholding a response to a non-3 digit (r = .217, p = .017). There 
is a non-significant trend between SART score and WMC, where those who 
perform better in the WM tasks make fewer mistakes during completion of the 
SART. RSpan had a negative correlation with the average reaction time to each 
correct response in the SART task (r = -.223, p = .014) as did CSpan (r = -.215, p 
= .018) suggesting that the greater the participant’s WM capacity, the quicker 
they responded correctly to the items in the SART task.  
 
 
 
 
 
121 
 
RSpan 
RSpan score was modelled using HRT use and phase as predictors. Overall 
the regression model was significant, F(3,117) = 10.48, p < .001,  with the 
combination of HRT and phase accounting for 19.2% (adjusted R-square) of the 
variation in RSpan score. In order to model the usefulness of the MQoL with 
RSpan score a hierarchical regression was carried out to compare the model 
using HRT use and phase with one also including MQoL score.  The model 
showed significant improvement in R-Square (unadjusted) from .21 to .24, 
F(4,116)=9.40, p =.026. 
A hierarchical regression was carried out to compare the original model 
using HRT use and phase with one also including GHQ-12 score.  The model 
showed no improvement in R-Square (unadjusted) from .21 to .22,  F(4,116)=8.25, 
p=.23. 
A hierarchical regression was carried out to compare the original model 
using HRT use and phase with one also including education.  The model showed 
no improvement in RSquare (unadjusted) from .21 to .24, F(7,113)=5.10, p=.35. 
And finally, a hierarchical regression was carried out to compare the 
model using HRT use and phase with one also including belief about cognition 
and the menopause.  The model showed no improvement in R -Square 
(unadjusted) from .21 to .22, F(6,114)=5.41, p=.68. 
Overall, MQoL score was the only variable which improved the regression 
model for RSpan score. 
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OSpan 
OSpan score was modelled using HRT use and phase as predictors. Overall 
the regression model was significant, F(3,117) = 5.35, p = .008,  with the 
combination of HRT and phase accounting for 9.8% (adjusted R-square) of the 
variation in OSpan score. In order to model the usefulness of the MQoL with 
OSpan score a hierarchical regression was carried out to compare the model 
using HRT use and phase with one also including MQoL score.  The model 
showed no improvement in R-Square (unadjusted) from .12 to .15, F(4,116)=4.93, 
p =.07, but this was close to significant.  
A hierarchical regression was carried out to compare the original model 
using HRT use and phase with one also including GHQ-12 score.  The model 
showed no improvement in R-Square (unadjusted) from .12 to .14, F(4,116)=4.77, 
p=.10. 
A hierarchical regression was carried out to compare the original model 
using HRT use and phase with one also including education.  The model showed 
no improvement in RSquare from .12 to .16, F(7,113)=3.09, p=.23. 
And finally, a hierarchical regression was carried out to compare the 
model using HRT use and phase with one also including belief about cognition 
and the menopause.  The model showed no improvement in R -Square 
(unadjusted) from .12 to .14, F(6,114)=3.19, p=.35. 
Overall, MQoL score, GHQ-12 score, education and belief did not impact 
on OSpan score, however MQoL was close to significance.  
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CSpan 
CSpan score was modelled using HRT use and phase as predictors. Overall 
the regression model was not significant, F(3,117) = 3.05, p = .12,  with the 
combination of HRT and phase accounting for 4.9% (adjusted R-square) of the 
variation in CSpan score. In order to model the usefulness of the MQoL with 
CSpan score a hierarchical regression was carried out to compare the model 
using HRT use and phase with one also including MQoL score.  The model 
showed no improvement in R-Square (unadjusted) from .07 to .05, F(4,116)=2.73, 
p =.20. 
A hierarchical regression was carried out to compare the model using 
HRT use and phase with one also including GHQ-12 score.  The model showed no 
improvement in R-Square (unadjusted) from .07 to .08, F(4,116)=2.48, p=.38. 
A hierarchical regression was carried out to compare the model using 
HRT use and phase with one also including education.  The model showed no 
improvement in R-Square from .07 to .09, F(7,113)=1.59, p=.70. 
A hierarchical regression was carried out to compare the model using 
HRT use and phase with one also including belief about cognition and the 
menopause.  The model showed no improvement in R-Square (unadjusted) 
from .07 to .09, F(6,114)=1.63, p=.83. 
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SART 
SART score was modelled using HRT use and phase as predictors. Overall 
the regression model was significant, F(4,116) = 0.42, p = .77,  with the 
combination of HRT and phase accounting for 1.5% (adjusted R-square) of the 
variation in SART score. In order to model the usefulness of the MQoL with SART 
score a hierarchical regression was carried out to compare the model using HRT 
use and phase with one also including MQoL score.  The model showed no 
improvement in R-Square (unadjusted) from .01 to .01, F(4,116)=0.31, p =.93. 
A hierarchical regression was carried out to compare the model using 
HRT use and phase with one also including GHQ-12 score.  The model showed no 
improvement in R-Square (unadjusted) from .01 to .01, F(4,116)=0.33, p=.81. 
A hierarchical regression was carried out to compare the model us ing 
HRT use and phase with one also including education.  The model showed no 
improvement in R-Square from .01 to .02, F(3,120)=.99, p=.18. 
A hierarchical regression was carried out to compare the model using 
HRT use and phase with one also including belief about cognition and the 
menopause.  The model showed no improvement in R-Square (unadjusted) 
from .01 to .00, F(3,120)= .48, p=.70. 
Overall, MQoL score, GHQ-12 score, education and belief did not impact 
on CSpan or SART score. MQoL did impact on RSpan score, and this was close to 
significance for OSpan score. 
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Testing the critical period hypothesis  
For each WM task participants were asked to recall a list of items in the 
correct order. A mark was given for the correct item recalled in the correct place,  
as suggested by Engle. For the WM tasks, a higher score represents greater WM 
capacity. For RSpan and OSpan the participant can score a maximum score of 42. 
For CSpan the participant can score a maximum score of 60. SART score was 
calculated by adding the total number of incorrect responses (hitting the space 
bar on the appearance of the number three) per participant. Higher scores 
represented poorer sustained attention. Mean WM and SART scores in each 
group can be seen in table 1.12. For the RSpan and OSpan, it was possible for 
participants to have a total of 42 correct responses. For the CSpan, it was 
possible for participants to have a total of 60 correct responses. The mean per -
cent proportion was calculated in order to better show the similarities and 
differences between CSpan score and the other two WM tasks.  The scores as a 
per-cent proportion have been presented as a percentage in table 1.6. 
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Table 1.6:  Mean number (+ standard deviation) of correct responses during the WM 
Span tasks and incorrect responses during the SART across menopausal 
group 
Stage in menopause HRT history Mean score SD Total % 
  RSpan   
Peri-menopausal No use 30.45 7.12 72.50% 
 HRT use 33.76 6.60 80.38% 
Post-menopausal No use 30.62 5.98 72.90% 
 HRT use 24.54 5.15 58.43% 
Total  30.12 7.03 71.7% 
  OSpan   
Peri-menopausal No use 30.52 6.50 72.67% 
 HRT use 33.85 7.40 80.60% 
Post-menopausal No use 30.14 7.31 71.76% 
 HRT use 26.50 6.81 63.10% 
Total  30.47 7.40 72.5% 
  CSpan   
Peri-menopausal No use 40.73 10.05 67.88% 
 HRT use 44.12 9.77 73.53% 
Post-menopausal No use 38.86 10.30 64.77% 
 HRT use 36.54 9.90 60.90% 
Total  40.31 10.26 67.2% 
  SART   
Peri-menopausal No use 6.97 3.71 ---------- 
 HRT use 7.45 5.52 ---------- 
Post-menopausal No use 8.14 4.88 ---------- 
 HRT use 8.12 5.28 ---------- 
Total  7.63 4.77 ---------- 
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Engle’s’ WM tasks may be investigated combined, looking at the total score 
between three tasks, in order to assess over all WM. It is then possible to investigate 
these separately, in order to investigate different WM domains (in this case; verbal, 
mathematical and spatial WM). Because oestrogen change has been shown to have effect 
on different types of WM tasks (Keenan et al., 2001), the overall WM score between 
HRT users- and non-users at different stages of the climacteric were compared, 
as well as the tasks separately. 
Multivariate analysis of covariance (Mancova) tested the effects of HRT 
use and time of use relative to menopause on cognitive performance. Age and 
MQoL were used as covariates to control for known effects of age on WM and 
observed associations between WM and MQoL. There was no main effect of HRT 
use on WM score (Wilks’ λ = .963, F(1,115) = 1.44, p = .23, d = .037). There was a 
main effect of phase on WM score (Wilks’ λ = .872, F(1,115) = 5.52, p = .001, d 
= .128), where those in the peri-menopausal stage performed better than those 
in the post-menopausal stage, regardless of HRT use and despite including age as 
a covariate. The effect of HRT on WM score was moderated by time of HRT 
initiation relative to menopausal symptoms (Wilks’ λ = .882, F(1,115) = 5.03, p 
= .003, d = .118).   As predicted by the critical period hypothesis, mean WM 
scores were highest in women taking HRT peri the menopause and lowest in 
those taking it post-menopause. 
WM data were analysed for each of the three tasks separately to test 
whether effects of HRT and phase differed depending on the nature of the 
processing component of the task (verbal for RSpan, mathematical with a verbal 
component for OSpan, and spatial for CSpan).  
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Rspan 
Mean RSpan score across each group can be seen in table 1.6 and figure 2.3. 
 
Figure 2.3: Mean RSpan score (and standard error) in HRT users and non 
users in the peri- and post-menopausal stages 
 
Consistent with the critical period hypothesis, women who had initiated 
HRT during the peri-menopausal stage scored the highest (mean = 33.76) 
representing greatest RSpan performance. Those who had initiated the therapy 
at the post-menopausal stage scored lowest (mean = 24.54) representing 
poorest RSpan performance.  Those with no history of HRT use scored slightly 
lower if peri-menopausal (mean = 30.45) than those in the post-menopausal 
stage (mean = 30.62) which was not anticipated.  
Analysis for the potential effect of HRT, phase of the climacteric and the 
interaction of the two on RSpan capacity was explored. The analysis revealed a 
non-significant effect for HRT use on RSpan score (F(1,115) = 2.47, p = .12, d 
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= .021). There was however a significant effect of phase on RSpan capacity 
(F(1,115) = 16.12, p < .001, d = .123). The effect of HRT on RSpan capacity was 
moderated by time of HRT initiation as demonstrated in a significant interaction 
effect between HRT use and phase (F(1,115) = 13.01, p < .001, d = .102). The 
interaction can be seen in figure 4.1.  
Simple effects showed HRT users who initiated HRT during the post -
menopausal stage (mean = 24.54, S.D = 5.15) to have worse RSpan capacity than 
HRT users who initiated the therapy during the peri -menopausal stage (mean = 
33.76, SD = 6.60, p < .001). HRT users who initiated the therapy during the post -
menopausal stage also performed worse than those in the post -menopausal 
stage with no history of HRT use (mean = 30.62, SD = 5.98, p = .001). Both 
differences support the critical period hypothesis. No other significant 
differences were found, however it was important to note that HRT users 
initiated in the peri-menopausal phase were close to demonstrating larger RSpan 
capacity than those in the peri-menopausal phase with no history of HRT use 
(mean = 30.45, SD = 7.12, p = .055). 
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OSpan 
Mean OSpan score across each group can be seen in table 1.6 and figure 2.4. 
 
Figure 2.4: Mean OSpan score (and standard error) in HRT users and non 
users in the peri- and post-menopausal stages.  
 
Consistent with the critical period hypothesis, women who had initiated 
HRT during the peri-menopausal stage scored the highest (mean = 33.85) 
representing greatest OSpan performance. Those who had initiated the therapy 
at the post-menopausal stage scored lowest (mean = 26.50) representing 
poorest OSpan performance.  Those with no history of HRT use scored higher if 
peri-menopausal (mean = 30.52) than those in the post -menopausal stage (mean 
= 30.14). This pattern across group is consistent with the critical period 
hypothesis.  
Analysis for the potential effect of HRT, phase of the climacteric and the 
interaction of the two on OSpan capacity was explored. The analysis revealed a 
non-significant effect for HRT use on OSpan score (F(1,115) = .118, p = .732, d 
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= .001). There was a significant effect of phase on OSpan capacity ( F(1,115) = 
8.55, p = .004, d = .069) suggesting that differences in OSpan score can be seen 
depending on stage of the climacteric.  The effect of HRT on OSpan capacity was 
moderated by time of HRT initiation as demonstrated in a significant interaction 
effect between HRT use and phase (F(1,115) = 5.63, p = .019, d = .047). The 
interaction can be seen in figure 4.2.  
Simple effects showed HRT users who initiated HRT during the post-
menopausal stage (mean = 26.50, SD = 6.81) to have worse OSpan capacity than 
HRT users who initiated the therapy during the peri -menopausal stage (mean = 
33.85, SD = 7.40, p < .001). This supports the critical period hypothesis. No other 
significant differences were found however it is important to note that HRT 
users initiated in the peri-menopausal phase were close demonstrating better 
OSpan capacity than those in the peri-menopausal phase with no history of HRT 
use (mean = 30.52, SD = 6.50, p = .056).  
 
 
 
 
 
 
 
 
 
 
132 
 
Cspan 
Mean CSpan score across each group can be seen in table 1.6 and figure 2.5. 
 
Figure 2.5: Mean CSpan score (and standard error) in HRT users- and non- 
users in the peri- and post-menopausal stages 
 
Consistent with the critical period hypothesis, women who had initiated 
HRT during the peri-menopausal stage scored highest (mean = 44.12) 
representing greatest CSpan performance. Those who had initiated the therapy 
at the post-menopausal stage scored lowest (mean = 36.54) representing 
poorest CSpan performance.  Those with no history of HRT use scored higher if 
peri-menopausal (mean = 40.73) rather than post-menopausal (mean = 38.86). 
The pattern across groups is consistent with the critical period hypothesis.  
Analysis for the potential effect of HRT, phase of the climacteric and the 
interaction of the two on CSpan performance was explored. The analysis showed 
no effect of HRT use on CSpan score (F(1,115) = 0.020, p = .89, d = .000) but a 
significant effect of phase (F(1,115) = 5.83, p = .017, d = .048). Figure 4.3 shows 
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a similar pattern of results to those obtained with RSpan and OSpan, but the 
interaction between HRT use and menopausal phase was not signifi cant (F(1,115) 
= 1.75, p = .19, d = .015). 
Despite the interaction between HRT use and time of initiation not being 
significant, the effect of phase on CSpan capacity combined with the interesting 
results from the post hoc analysis for the Ospan and Rspan warranted further 
analysis. Because the overall interaction was not significant for the CSpan, the 
conclusion should be treated with caution.  
Simple effects showed that those who had initiated HRT during the post -
menopausal stage (mean = 36.54, SD = 9.90)  had worse CSpan capacity than 
those who had initiated HRT in the peri-menopausal stage (mean = 44.12, SD = 
9.77, p = .005). No other significant differences were found. The CSpan results 
therefore support the suggestion, from the critical period hypothesi s, that it is 
better for cognitive performance to start taking HRT in the peri -menopause 
phase than post-menopause, but differences from non-users were weaker. 
The SART 
In the case of the SART, the average reaction time to each correct 
response was used as a covariate. Age was also used as a covariate to control for 
the effects of aging. 
The mean number of mistakes made on the SART across each group can 
be seen in table 1.6 and figure 2.6. 
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Figure 2.6: Mean SART score (and standard error) in HRT users and non users 
in the peri- and post-menopausal stages 
 
Those in the peri-menopausal stage with no history of HRT use scored the 
least amount of incorrect responses (mean = 6.97). Those who had i nitiated HRT 
during the peri-menopausal stage scored a similar amount of incorrect responses 
(mean = 7.45). Post-menopausal women scored the largest amount of incorrect 
responses and this was similar between HRT late initiators and non -users. The 
averages suggest that phase of menopause (peri or post) may have an effect on 
SA as oppose to HRT use. To see if HRT use and/or stage of menopause can have 
effect on task performance, or perhaps an interaction of the two; an ANCOVA 
was calculated.  
Analysis for the potential effect of HRT, phase of the climacteric and the 
interaction of the two on SART performance was explored. The analysis showed 
no effect of HRT use on SART score (F(1, 87) = 0.425, p = .52, d = .003) but a 
significant effect of phase (F(1, 87) = 5.56, p = .02, d = .033). The interaction 
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between HRT use and stage in the menopause was not significant ( F(1, 87) = 
0.443, p = .89, d = .003), depicted in figure4.4.  
2.10  One year follow up 
 
The study included a one year follow up to test whether effects of timing 
of HRT were lasting. From the original sample, there were no responses from 17 
participants. A further three participants did not have time to re -complete the 
tasks. Three participants were no longer interested in the study. Four 
participants had moved away and four participants had passed away with cancer. 
Distributions of reasons for no follow up were fairly evenly spread acro ss groups, 
as shown in Table 1.7.  
Table 1.7:   Breakdown of responses from participants invited to take part in the one 
year follow up study 
 
 Peri-menopausal Post-menopausal HRT initiator (peri) HRT initiator (post) 
No responses 6 3 4 4 
Lack of time 1 1 1  
Not interested 1  1 1 
Moved away 2 1 1  
Deceased 1 2 1  
 
From the original peri-menopausal set, 25 HRT users who had initiated 
the therapy in their peri-menopausal stage (75.8%) and 21 HRT users who had 
initiated the therapy in the post-menopause (80.8%) were compared to 23 peri-
menopausal non users (69.7%) and 21 post-menopausal non users respectively 
(72.4%). No women of the original set had initiated HRT within the year gap 
period. 
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GHQ-12 and MQoL score 
The GHQ-12 scores are very similar across groups, and depict normal 
mood. The population in this study represent the same average scores as the 
general population for the GHQ-12. The sample’s mood scores were normally 
distributed across groups (see table 1.8), and groups did not differ between 
average mood score dependant on phase (F(1, 90) = 0.30, p = .59, d = .003) HRT 
use (F(1, 90) = 0.69, p = .41, d = .008) or the interaction between the two (F(1, 
90) = 0.79, p = .67, d = .002). The sample’s MQoL scores were also normally 
distributed across groups (see table 1.15), and groups did not differ between 
average mood score dependant on phase (F(1, 90) = 0 .00, p = .96, d = .000) HRT 
use (F(1, 90) = 0.00, p = .97, d = .000) or the interaction between the two (F(1, 
90) = 0.12, p = .73, d = .001). For both GHQ-12 and MQoL; the scores across 
groups are very similar, with those who initiated HRT during their per i-
menopausal stage having best mood (represented by lowest GHQ-12 score 
average) and greatest rated QoL (represented by the highest MQoL score 
average).  
Table 1.8:  Mean (± standard deviation) GHQ-12 scores across menopausal group 
one year following 
 
 Peri-
menopausal 
Post-
menopausal 
HRT initiator 
(peri) 
HRT initiator 
(post) 
Total mean 
GHQ-12 
score 
23.35  (2.27)  23.43  (3.72) 22.44  (3.14)  23.14  (4.30)  23.07  (3.37) 
MQOL score 14.30  (3.40) 14.52  (3.83) 14.84  (3.25) 14.76  (3.62) 14.61  (3.45) 
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WM Span and SART score 
Table 1.9 shows the mean WM score (for RSpan, OSpan and CSpan), and 
per-cent of correct responses as a proportion of the total.  
Table 1.9:  Mean number (+ standard deviation) of correct responses during the WM 
tasks and incorrect responses during the SART across menopausal group 
Stage in menopause HRT history Mean score SD 
  RSpan  
Peri-menopausal Non-HRT user 30.26 7.00 
 HRT user 32.88 5.53 
Post-menopausal Non-HRT user 31.24 5.60 
 HRT user 25.33 5.38 
Total  30.07 6.45 
  OSpan  
Peri-menopausal Non-HRT user 29.83 4.62 
 HRT user 31.36 6.34 
Post-menopausal Non-HRT user 28.76 6.06 
 HRT user 27.52 5.13 
Total  29.47 5.69 
  CSpan  
Peri-menopausal Non-HRT user 40.00 8.89 
 HRT user 43.12 8.57 
Post-menopausal Non-HRT user 38.48 8.96 
 HRT user 37.95 9.39 
Total  40.03 9.03 
  SART  
Peri-menopausal Non-HRT user 6.17 3.42 
 HRT user 6.28 4.65 
Post-menopausal Non-HRT user 7.90 4.96 
 HRT user 7.81 4.74 
Total  6.99 4.40 
 
 
138 
 
In accordance with stage one of study one; stage two analysis for the WM 
tasks included the covariates of age and the MQoL score.  
 
Testing the critical period hypothesis  
Multivariate analysis of covariance (Mancova) tested the effects of HRT 
use and time of use relative to menopause on cognitive performance. Age and 
MQoL were used as covariates to control for known effects of age on WM and 
observed associations between WM and MQoL. There was no main effect of HRT 
use on WM score (Wilks’ λ = .960, F(1,84) = 1.14, p = .35, d = .039). Unlike stage 
one of the study, there was no effect of phase on WM score (Wilks’ λ = .950, 
F(1,84) = 1.43, p = .23, d = .051).  The effect of HRT on WM score was moderated 
by time of HRT initiation relative to menopausal symptoms (Wilks’ λ = .852, 
F(1,84) = 4.73, p = .005, d = .146).  
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RSpan one year following 
Mean RSpan score across each group for the one year follow up can be 
seen in table 1.9 and figure 2.7.  
 
Figure 2.7: Mean RSpan score (and standard error) in HRT users and non 
users in the peri- and post-menopausal stages one year following 
 
Mean scores followed the same pattern as stage one of data collection. 
Consistent with the critical period hypothesis, women who ha d initiated HRT 
during the peri-menopausal stage scored the highest (mean = 32.8) representing 
greatest RSpan performance. Those who had initiated the therapy during the 
post-menopausal stage scored lowest (mean = 25.33) representing poorest 
RSpan performance.  Those with no history of HRT use scored lower if in the 
peri-menopausal stage (mean = 30.26) than those in the post -menopausal stage 
(mean = 31.24).  
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Analysis for the potential effect of HRT, phase of the climacteric and the 
interaction of the two on RSpan performance was explored. Like stage one of the 
study, analysis showed a non-significant effect for HRT use on RSpan score (F(1, 
84) = 1.05, p = .31, d = .012). Unlike stage one of the study, no effect of phase on 
RSpan score was found (however this was marginal; F(1,84) = 3.87, p = .053, d 
= .044). The effect of HRT on RSpan performance was moderated by time of HRT 
initiation as demonstrated in a significant interaction effect between HRT use 
and phase (F(1,84) = 12.02, p = .001, d = .123), similar to stage one of the study. 
The interaction can be seen in figure 4.5.  
Simple effects showed HRT users who initiated HRT during the post -
menopausal stage (mean = 25.33, SD = 5.38) to have worse RSpan performance 
than HRT users who initiated the therapy during the peri-menopausal stage 
(mean = 32.88, SD = 5.53; p < .001) and those in the post-menopausal stage with 
no history of HRT use (mean = 31.24, SD = 5.60, p = .005). This pattern is the 
same as stage one of the study and no other significant differences were found. 
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OSpan one year following 
Mean OSpan score across each group for the one year follow up can be 
seen in table 1.9 and figure 2.8.  
 
Figure 2.8: Mean OSpan score (and standard error) in HRT users and non 
users in the peri- and post-menopausal stages one year following 
 
Means followed the same patterns as stage one of data collection. 
Consistent with the critical period hypothesis, women who had initiated HRT 
during the peri-menopausal stage scored the highest (mean = 31.36) 
representing greatest OSpan performance. Those who had initiated HRT in the 
post-menopausal stage scored the lowest (mean = 27.52) representing poorest 
OSpan performance. This pattern is consistent with the critical period hypothesis . 
Analysis for the potential effect of HRT, phase of the climacteric and the 
interaction of the two on OSpan performance was explored. Like stage one of 
the study, the analysis showed a non-significant effect for HRT use on OSpan 
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score (F(1,84) = 0.05, p = .821, d = .001). Analysis considering the effect of phase 
on OSpan score was conducted. Unlike stage one of the study, no effect of 
menopausal phase on OSpan score was found (F(1, 84) = 2.55, p = .11, d = .029).  
Like stage one of the study, the effect of  HRT on OSpan performance was 
moderated by time of HRT initiation as demonstrated in a significant interaction 
effect between HRT use and phase (F(1, 84) = 1.42, p = .024, d = .017), depicted 
in figure 4.6. 
Simple effects showed HRT users who initiated HRT during the peri-
menopausal stage (mean = 31.36, SD = 6.34) to have better OSpan performance 
than HRT users who initiated the therapy during the post -menopausal stage 
(mean = 27.52, SD = 5.13; p = .049). This was similar to stage one of the study. 
Unlike stage one of the study, there was no effect of late HRT initiation when 
comparing post HRT initiators to those in the post-menopausal stage with no 
history of HRT use  
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CSpan one year following 
Mean CSpan score across each group for the one year fol low up can be 
seen in table 1.9 and figure 2.9. 
 
 
Figure 2.9: Mean CSpan score (and standard error) in HRT users and non 
users in the peri- and post-menopausal stages 
 
Means followed the same patterns as stage one of data collection. 
Consistent with the critical period hypothesis, women who had initiated HRT 
during the peri-menopausal stage scored highest (mean = 43.12) representing 
greatest CSpan performance. Those who had initiated the therapy at the post-
menopausal stage scored lowest (mean = 37.95) representing poorest CSpan 
performance.  
Analysis for the potential effect of HRT, phase of the climacteric and the 
interaction of the two on CSpan performance was explored. The analysis showed 
no effect of HRT use on CSpan score (F(1, 84) = 0.26, p = .613, d = .003). Unlike 
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stage one of the study, no effect of menopausal phase on CSpan score was found 
(F(1, 84) = 2.84, p = .096, d = .033) and there was no interaction effect  between 
HRT use and stage in the menopause (F(1, 84) = 0.76, p = .39, d = .009), depicted 
in figure 4.6. 
The role of phase in CSpan score gave warrant to further analysis 
considering simple effects however unlike stage one of the study (which found 
those who had initiated HRT in the post-menopausal stage had scored 
significantly worse than those who had initiated HRT in the peri -menopausal 
stage), no further effects were found. 
 
The SART results for the one year follow-up 
The mean number of incorrect responses to the number three during 
completion of the SART across groups after one year can be seen in table 1.9 and 
figure 2.10. 
 
Figure 2.10: Mean SART score (and standard error) in HRT users and non users 
in the peri- and post-menopausal stages 
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Those in the peri-menopausal stage with no history of HRT use scored the 
least amount of incorrect responses (mean = 6.17). Those who had initiated HRT 
during the peri-menopausal stage scored a similar amount of incorrect responses 
(mean = 6.28). Post-menopausal women scored the largest amount of incorrect 
responses and this was similar between HRT late initiators and non -users. To see 
if HRT use and/or stage of menopause can have effect on task performance, or 
perhaps an interaction of the two; an ANCOVA was calculated.  
Analysis for the potential effect of HRT, phase of the climacteric and the 
interaction of the two on SART performance was explored. Like stage on of the 
study, analysis showed no effect of HRT use on SART score (F(1, 84) = 0.065, p 
= .79, d = .001) but an effect of phase  (F(1, 84) = 4.46, p = .04, d = .050). Again, 
the interaction between HRT use and menopausal phase was not significant ( F(1, 
84) = 0.00, p = .99). This can be seen in figure 4.8. Due to the lack of interacti ons, 
no further analysis was required. 
Type of HRT content (oestrogen only verses oestrogen and progesterone)  
It has been suggested that the addition of progesterone to HRT can have 
detrimental effects on cognitive performance and for this reason; the effe ct of 
HRT content on WM was explored. It has also been suggested that the addition 
of progesterone to HRT can have detrimental effects in post -menopausal women 
and for this reason; the interaction of time and HRT content on WM was also 
explored. 
Data regarding WMC were analysed using MANCOVA with stage of the 
climacteric (peri or post) and HRT content (oestrogen, n = 9; or oestrogen plus 
progesterone, n = 50) as factors and age (in years) and MQoL score as covariates. 
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Data regarding the number of correct answers for each WM Span task (RSpan, 
OSpan and CSpan) were analysed using ANCOVA with stage in the climacteric 
(peri or post) and HRT content (oestrogen or oestrogen plus progesterone) as 
factors and age (in years) and MQoL score as covariates. The interact ion effect 
of time in the climacteric and HRT use were analysed.  
There was no main effect of HRT content on WM score (Wilks’ λ = .957, 
F(1,41) = 0.59, p = .624). The was no main effect of HRT content, moderated by 
time of HRT initiation, on WM score (Wilks’ λ = .938 , F(1,41) = 0.86, p = .468).   
There was no main effect of HRT content on RSpan score (F(1,41) = 0.425, 
p = .518). The was no main effect of HRT content, moderated by time of HRT 
initiation, on WM score (F(1,41) = 0.09, p = .769).   
There was no main effect of HRT content on OSpan score (F(1,41) = 0.015, 
p = .903). The was no main effect of HRT content, moderated by time of HRT 
initiation, on WM score (F(1,41) = 0.01, p = .913).   
There was no main effect of HRT content on CSpan score (F(1,41) = 0.08, 
p = .773). The was no main effect of HRT content, moderated by time of HRT 
initiation, on WM score (F(1,41) = 0.75, p = .393).   
There was no main effect of HRT content on SART score (F(1,53) = 0.016, 
p = .899). The was no main effect of HRT content, moderated by time of HRT 
initiation, on WM score (F(1,41) = 0.05, p = .824. 
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2.11  Discussion 
 
Early HRT use can maintain different types of WM, whereas late use can become 
detrimental 
In stage one of the study those in the peri-menopausal stage performed 
better on the WM tasks than those in the postmenopausal stage regardless of 
HRT use as anticipated (Chen et al., 2006; Maki, 2006; Markou  et al., 2007; 
Sherwin, 2012; Sherwin and Henry, 2008). HRT use alone did not impact on 
performance in any task, but there was an effect of HRT on WM when 
moderated by time of HRT initiation relative to menopausal symptoms, reflected 
in the RSpan and OSpan, as well as WM overall. Specifically, those with a history 
of HRT use initiated during their peri-menopausal phase scored significantly 
higher than those who initiated their therapy during the post -menopausal phase. 
Those who initiated the therapy during the post-menopausal stage scored 
significantly lower than those in the post-menopausal stage with no history of 
HRT use in the RSpan task (close to significance for the OSpan task). Also close to 
significance was the difference between RSpan scores of peri -menopausal 
women with no history of HRT use as compared to peri -menopausal HRT 
initiators. The results for the RSpan and the OSpan, and WM overall, support the 
critical period hypothesis (Bimonte-Nelson et al., 2003; Gibbs, 2000b;  Joffe, et 
al., 2006; MacLennan et al., 2006), and clarify the effect of late use of HRT, 
which was associated with impaired cognition rather than no effect. This is less 
clear for the CSpan. 
In order to see if these effects were sustained, women were re -tested at 
12 months to observe long term changes. Unlike stage one of the study, no 
effects of phase on WMC were found. HRT use did not affect WM performance, 
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but an interaction effect for the moderation of HRT by time of initiation was 
found in the RSpan, OSpan and WM overall. Specifica lly, users who initiated HRT 
during the peri-menopausal stage had better RSpan and OSpan capacity than 
those who initiated HRT in the post-menopausal stage. In the RSpan, it was again 
demonstrated that those who initiated HRT during their post -menopausal stage 
performed worse than post-menopausal women who have never received HRT. 
Results re-confirm the critical period hypothesis and show that the effects of 
timing of HRT on cognition may be long-lasting. No differences were found for 
the follow up of the CSpan. 
The present study included participants covering a wide age group (to 
include women at both ends of the climacteric). Due to large individual variation 
in stage in the climacteric, age and cognitive performance; results would have 
been varied across the group as a whole. Despite this fact, there were still 
differences in cognitive performance between HRT early initiators and late 
initiators. 
HRT alone did not impact on score without the interaction of time of 
initiation. This suggests that the effects  of HRT use are more to do with phase of 
menopause than chronological age. This effect was partially maintained one year 
following, but some effects did not transpire. This is understandable, as during 
the 12 month period several peri-menopausal HRT non-users were closer to 
post-menopausal and several peri-menopausal HRT users had ceased their 
regular intake of the therapy. At point of follow up there were mixed clusters in 
the peri- and post-menopausal groups where some women were still receiving 
HRT (and many had ceased treatment). In a further study, it may be useful to 
separate these clusters and look at the cognitive performance of participants 
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who have ceased treatment and those who have carried on. For the present 
study, groups were too small for this to be viable. 
Integration of the present study into current literature  
Human studies have demonstrated increase activation in the frontal 
lobes during completion of WM tasks for peri -menopausal women (Cutter et al., 
2003; Erickson et al., 2010; Joffe et al., 2006; Miller et al., 2002; Shaywitz et al., 
1999). These studies demonstrate an effect of oestrogen on areas of the brain 
that underlie WM processes and that oestrogen treatment influences prefrontal 
cortex activation during completion of WM tasks. The present study 
demonstrated better WM performance in women with a history of early HRT 
initiation, which is likely to be a result of early HRT use on pre -frontal activity. 
The present study is consistent with studies that demonstrate increased PFC 
activation after peri-HRT initiation, and support arguments that HRT affects 
functions such as WM that are dependent on the PFC when administered during 
the peri-menopause. The brain imaging studies listed above have confirmed a 
difference in frontal lobe activation between early and late HRT initiators and 
the impact of this is clearly demonstrated in maintained WM capacity of early 
initiators during the completion of WM tasks. 
The present study confirms the critical period. Other studies that have 
considered early and late HRT initiation have similar results as the present study. 
For example, the study by MacLennan and colleagues (2006) demonstrated an 
improvement in verbal memory and the trial making test and there was a trend 
in post-HRT initiators to underperform. 
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Pompili and colleagues (2012) suggests that the relationship between 
oestrogen change and WM needs further exploration. The present study 
demonstrates a beneficial effect of early HRT initiation on different types of WM, 
and coincides with the study by Keenen and colleagues (2001). 
Grigorova, Sherwin and Tulandi (2006) demonstrated that oestrogen 
deficiency results in deficits in verbal and non-verbal WM using modified 
versions on the N-Back test. This is because oestrogen receptors are found in the 
prefrontal cortex (Tang et al., 2004) alongside dopamine terminals (Leranth et al., 
2006), an area which mediates WM function. This is supported by a study by 
Berman and colleagues (1999) where young women also supressed of oestrogen 
had increased activation in the PFC during completion of a WM task when 
provided with oestrogen replacement. The present study tested the effect of 
increased oestrogen on different types of WM, showing that increased oestrogen 
initiated during the critical period can help maintain  WM. The studies support 
the idea that oestrogen change, be it suppression or expression, impacts on 
different types of WM. 
Sherwin (2007) suggests that oestrogen may help to delay degenerative 
disease such as AD and that oestrogen therapy when taken in co mpliance with 
the critical period can help to prevent this. She further stresses that it should 
not be assumed that oestrogen has any direct effect on the cause of cognitive 
decline and degenerative disease. If this is the case, the late initiation of HRT 
should not correlate with incidence of degenerative disease. Several researchers 
have demonstrated a detrimental effect of late oestrogen use on cognition, 
including the present study where late HRT initiators performed worse on verbal 
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and mathematical WM. This coincides with the WHIMS, were late HRT use 
resulted in increased risk of cognitive impairment and probable dementia.  
Resnick and colleagues (2006) reported that oestrogen therapy can 
increase the risk for developing dementia. The present study findi ngs explicitly 
demonstrate a detrimental effect of late HRT initiation on WM and this is 
something that should not be taken lightly. Sherwin does highlight the fact that 
HRT has the potential to be harmful when administered to women over the age 
of 65. In the case of this study, late HRT use from completion of the menopause 
still resulted in worsened WM capacity suggesting that from as young as one 
year post completion of the menopause (on average, 52.8 years), HRT may be 
detrimental to cognition if initiated beyond this point. Again, this is important as 
it suggests that detrimental effects can be experienced far earlier than first 
anticipated. This means that researchers will need to reconsider defining their 
groups by age. 
It is possible that the effect of oestrogen change on WM only transpire 
when WM tasks are of a particular difficulty level. This is consistent with the 
study by Grigorova and colleagues who used difficult WM tasks, as well as 
Keenan and colleagues (2001) where the effects of oestrogen suppression on 
WM were only seen when the task became challenging and WM capacity over 
loaded. 
The same effect has been demonstrated in brain imaging studies. Dumas 
and colleagues (2010) found that women treated with HRT had an increase in 
frontal activity during completion of their two more difficult WM tasks only. The 
difficulty of the task is a key component in successful studies demonstrating a 
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critical period for HRT and the impact of oestrogen on memory tasks is only 
apparent when the task exerts certain cognitive strain (Krug et al., 2003; 
Linzmayer et al., 2001; Philips & Sherwin, 1992; Shaywitz et al., 2003). This 
includes verbal WM performance (Keenan et al., 2001).  
And finally, Jenkins and colleagues demonstrated that oestrogen 
suppression in young women could also result in deficits in WM performance 
during completion of a spatial WM task, letter sequence WM task and digit span 
WM task. 
The current study included WM tasks that could be manipulated for 
difficulty. The point of the task is to recognise the point where participants 
begin to struggle, and this is an indication of the participants WM capacity. 
Because the tasks are designed to find WM capacity, the trials increase in 
difficulty level, and this helps to reduce ceiling effects.  
HRT use does not affect SA 
The relationship between SA and oestrogen change in human studies is 
under developed. In animal studies, oestradiol reduction during the menopause 
slowly diminishes activity in the cholinergic system and this may have an effect 
on cognitive functions sensitive to cholinergic activity in the frontal and 
hippocampal areas of the brain such as SA (Sarter et al., 2000). In human studies, 
oestrogen reduction also causes detrimental effects in pre -frontal cortex 
mediated tasks, to which SA measures deficits in pre-frontal function. It was 
therefore expected that HRT might help with SA whereby the outcome of 
mistakes made on the SART would be in part driven by the critical period 
because WM and SA depend on systems that overlap. Literature regarding the 
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effect of oestrogen fluctuation on SA is minimal. Although the SART was 
designed to measure frontal lobe deficits, and HRT use can increase frontal lobe 
activation and related cognitions, in the present study there was no effect of 
HRT use (early or late) on SART performance.  
Some studies have demonstrated the effect of oestrogen change on 
attention. Grigorova and colleagues (2006) demonstrated that oestrogen 
deficiency may cause problems in an attention task (letter -number sequencing). 
In addition, participants failed to learn despite repeated exposure of the task. 
The SART has one simple rule to learn, but the rule practices inhibition control. 
It is possible that the SART was not difficult enough, as consistent with WM 
literature. It should also be considered that Grigorova and colleagues 
administered LAD to suppress oestrogen production, whereas the participants in 
the current study had naturally decreased levels of oestrogen, and each 
participant would have had differing levels. In addition, partici pants in 
Grigorova’s study were younger.  
To coincide with this, younger women have also demonstrated SA 
problems during pregnancy (Crawley et al., 2005; deGroot et al., 2003). The tasks 
chosen were designed for the study and not known tasks, as such their validity 
can be questioned. 
Animal studies have also demonstrated an effect of oestrogen use on WM, 
but not SA. Ovariectomised rhesus monkeys exposed to HRT improved in a 
delayed recognition span task however no treatment effects were seen on a 
delayed response task associated with the prefrontal cortex. The researchers 
suggested that for primates, oestrogen may enhance cognitive abilities that are 
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hippocampal-dependent (to which WM relies on the hippocampus in animal 
studies) but may not enhance those that are only dependent on the frontal lobes 
(Lacreuse at al., 2004). Although animal and human memory and attention 
models do differ, the effect of HRT on WM and SA in the study by Lacreuse and 
colleagues does coincide with the present study’s findings.  
Knight and Eden (1996) also suggest that actions of compounds with 
oestrogenic activity are species specific, one example being tamoxifen which is 
agonistic in humans and oestrogenic in mice. This may also explain differences 
between animal and human models. 
 The subtle differences between tasks and the diverse differences in 
outcome between studies that have included HRT and non-HRT users (animals 
and humans) suggests that more understanding is needed to recognise the 
reasons for these differences.  
Although WM and SA are unique, their characteristics overlap and SA 
contributes to the completion of WM tasks (Schweizer & Moosbrugger, 2004). 
However the attentional process is secondary to the more complex WM system 
of control. In support of this theory, the present study coincides with work by 
Lazzaretti and colleagues, which demonstrated the impairment of verbal WM in 
patients with pre-frontal cortex damage whilst SA has remained intact 
(Lazzaretti et al., 2012).  
Duff and Hampson (2001) describe WM as intrinsically involving verbal or 
visual information and its active manipulation, it may be that the SART is not 
sensitive to oestrogen change because it is not challenging enough, and lacks a 
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verbal component. The relationship between SA and the dopamine system  is also 
less established. 
The present study does contribute to, and confirm literature that 
demonstrates an effect of oestrogen use on WM. The relationship between SA 
and HRT use is underdeveloped, and the current study suggests that HRT use 
and/or initiation does not affect attention. More clarification is needed in the 
relationship between oestrogen change in the frontal lobe and impact on 
associated cognitions. 
Impact of the present study on the current literature; pinpointing the critical 
period by last menstrual bleed and not age  
Generally, animal studies have induced early menopause surgically, and 
provided HRT close to the removal of the ovaries. For example, oestrogen 
administration has been shown to augment cholinergic transmission and 
enhance dendrite spine formation in the hippocampus, and this has been linked 
to improved spatial WM in younger rodents (Fader et al., 1999) and not for 
those who have experienced long periods of oestrogen deficiency prior to 
treatment initiation (Daniel et al., 2006).  
Human studies involving naturally menopausal populations are less clear, 
and have used age as guidance for deeming a participant as peri -menopausal or 
post-menopausal. In studies exploring the critical period, researchers have 
defined their groups based on the participant’s age by assuming the average age 
of the menopause. The average age of the menopause has large variation. To 
design a study considering this window of opportunity and to define this period 
by age seems largely redundant.  
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The present study was more precise, taking into account each individual 
participant’s last menstrual bleed, pinpointing the critical period to be within 
twelve months of the last menstrual bleed, something that previous studies have 
not considered. 
The critical period may be as short as twelve months 
Current literature has not explored the possible duration of the window 
of opportunity and what is less clear is the precise onset and duration of this 
window, to which there should be a general consensus to aid in study desi gn, 
and this can be largely influenced by the methods adopted by researchers to 
define peri- and post-menopausal groups. 
The current study suggests that the critical period is as short as twelve 
months from last menstrual bleed. If this be the case, many s tudies that have 
relied on age of the participant as the determinant of peri - or post- grouping 
may be overlooking this short, twelve month period. For example, it has also 
been demonstrated that late initiation of HRT can increase the risk for dementia 
and may impair memory performance due to a decrease in hippocampal volume 
and reduced cholinergic activity (Lam & Leranth, 2003; Voytko et al., 2009). For 
studies defining menopausal stage by age, it is likely that the participant has in 
fact experienced amenorrhoea 12 months or more. This is because most post -
menopausal women recruited in some (but not all) such studies are a decade 
beyond the average age of the menopause (for example, the WHIMS). By 
defining a group by age, this does not account for individual differences in the 
climacteric and experienced symptoms, where the average age of the 
menopause has average upper and lower boundaries of plus or minus seven 
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years. To account for individual variance, it is far more accurate to record the 
participant’s  last menstrual bleed, and deduce stage in the climacteric from this. 
At points the literature can appear mixed and there is some evidence that 
discrepancies are due to differences in timing of HRT initiation relative to stage 
in the climacteric. This is something the current study was able to directly test.   
For example the WHIMS which recruited menopausal women with a mean 
age of 72 years and were shocked at the detrimental effects of the therapy, 
resulting in early termination of the study. Another exam ple of studies which 
may add confusion to the literature is the study by Ditkoff and colleagues (1991), 
who look at the effect of HRT on episodic memory and QoL and found no 
differences between HRT users and those receiving a placebo. Participants were 
aged from 32 to 60 years, and it is possible that HRT had no benefits to the older 
adults who would have typically been years from their last menstrual bleed. 
Such studies add confusion to the literature as have not separated participants 
for peri- and post- menopausal phase. 
Part of the confusion is because peri-menopausal groups contain 
participants who are post-menopausal, again something that the present study 
was able to address. 
The study is one of the first direct tests of the critical period hypothesis 
in relation to WM, showing not only that early initiation of HRT is protective of 
WM, but also that late initiation of the therapy is detrimental to WM. The study 
supports the critical period hypothesis whereby HRT maintains and/or improves 
WM when initiated prior to and during the onset of the menopause (Grigorova, 
& Sherwin 2006; Lacreuse, & Herndon 2003). The study confirms literature that 
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suggests that, if this window of opportunity is overlooked and HRT is initiated in 
the later stages of the climacteric, there will be detrimental effects on WM. The 
results of the RSpan and OSpan are consistent with the critical period hypothesis, 
and agree with studies by Rapp and colleagues (2003), Farquhar, Marjoribanks, 
Lethaby, Suckling and Lamberts (2009) and Zandi and colleagues (2002) who 
found HRT use in post-menopausal women to cause detrimental effects on 
cognition. The one year follow up further adds validity to the critical period 
hypothesis and demonstrates the longer lasting effects of HRT initiation relative 
to stage in the climacteric, something previous studies have not addressed.  
Early and late HRT initiation can affect different types of working memory  
Several studies have demonstrated an effect of HRT use on different 
types of WM. For example, Smith and colleagues demonstrated an effect of 
oestrogen use on spatial WM. Grigorova, Sherwin and Tulandi (2006) 
demonstrated that oestrogen deficiency results in deficits in verbal and  non-
verbal WM using modified versions on the N-Back test. Combined with the 
present study, such studies suggest that different types of WM are oestrogen 
responsive. 
The completion of both non-verbal and spatial WM tasks and the 
increased activation in the frontal lobes shown by previous studies (Cutter et al., 
2003; Shaywitz et al., 1999) suggest that the findings are specific to WM and not 
simply a reflection of changes in verbal memory function. For example, Joffe and 
colleagues (2006) demonstrated increased activation in the PFC in oestrogen 
users on completion of verbal and spatial WM tasks. In addition, participants 
receiving the HRT performed better on these tasks. Although HRT may protect 
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episodic memory, it has also demonstrated using the present st udy and studies 
described above that HRT use can protect different types of WM, and not just 
those with a verbal constraint. To coincide with this, the present study 
demonstrated changes in verbal WM, mathematical WM and spatial WM.  
In the current study, age was included as a covariate in analysis, and HRT 
did not have effect on verbal and mathematical WM when considered alone. It 
was the interaction of HRT use and time of initiation which accounted for 
differences in WM performance. 
An observational study design allowed exploration of the long lasting effects of 
time of HRT initiation on WM 
 
Natural brain aging results in a decrease in brain volume and neuron size 
and a 46% reduction in dendrite spine numbers in humans over the age of 50 
(Esiri, 2007). Changes appear to occur most profusely in the prefrontal cortex 
which sub serves the specific cognitive functions that decline with age including 
WM (Esiri, 2007). HRT initiated during the peri -menopausal stage can reduce 
these declines, by maintaining brain function in the prefrontal cortex (Keenan et 
al., 2001). Specifically, the synthesis of new neurons continues throughout life 
and old age, suggesting that it is the decline of synapses between neurons, 
neurotransmitter concentration, dendrite spine density and a change in neuronal 
networks dependant on oestrogen concentration that may be the cause of 
cognitive decline (Brinton, 2001). These effects might not be apparent straight 
away, and it might take some time for differences between cognitive 
performance of early HRT initiators and late HRT initiators to transpire. The 
present study, being observational, allowed the exploration of later effects of 
HRT.  
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In addition to this, several studies have indicated a link between late HRT 
use and a reduction in neuronal performance in the prefrontal cortex, but this 
has not always transpired in task performance itself (Shaywitz et al., 1999; 
Cutter et al., 2003). It has been suggested that oestrogen change first and 
foremost affects brain structure and mechanisms, and changes in cognitive 
performance follow (Jones & Gallo, 2001). If this be the case, the n the 
observational design allowed for exploration of this.  
In the present study, it is important to consider that on average, those 
who initiated the therapy during their peri -menopausal stage took the therapy 
for 5.01 years, terminating the treatment 3.42 years ago. This suggests two 
things. Firstly there has been enough time for the therapy to have effect, and 
the beneficial effect of HRT on WM to be apparent at the time of testing. The 
present study design allowed exploration of this. Secondly, even tho ugh the 
average last dose of therapy was taken 3.42 years prior to data collection, those 
in the peri-menopausal HRT initiated stage have still scored the highest for all 
WM tasks, despite having an average age of 54.91 years (4.67 years older than 
peri-menopausal women with no history of HRT use). For late users, the 
detrimental effects were also apparent, where participants had terminated the 
therapy (on average) 4.81 years ago. The present study’s observational design 
meant that these longer lasting effects could be explored, something that all 
past studies have overlooked. The longer lasting effect of HRT initiation on WM 
further demonstrates the importance of initiating HRT during the peri -
menopausal stage, determined by last menstrual bleed.  
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Critique of the present study and area’s to be improved  
The study incorporated an observational design where participants were 
recruited and then allocated to one of four groups. This was a naturalistic study, 
where the participants received different concentrations of HRT for different 
durations. They may have ceased treatment due to recommendation from the GP; 
or perhaps they felt their symptoms had ceased or that the treatment was 
yielding adverse effects. Despite being an observational study and not being able 
to control for certain factors, the results of the present study are still clear. A 
RCT controlling for therapy type and duration would have simply been too costly 
and would possibly have reduced the number of women volunteering for the 
study, however we may expect the marginal improvements in RSpan 
performance of peri-HRT users (as compared to controls) to be significant had 
this been the case, as suggested in the implications of the present study. The 
study had a four year preparation and execution plan and as such, the 
researchers felt it an excellent opportunity for a longitudinal observational study 
design. Both RCTs and observational studies have proved successful in 
demonstrating the critical period hypothesis (Joffe et al., 2006; MacLennan et al., 
2006), with the present study adding to this. RCTs usually cover a limited 
amount of time (e.g. one to three months; Dumas et al., 2008; LeBla nc et al., 
2007) and few go on to explore later outcome after a prolonged period. By using 
an observational study design it was possible to pinpoint the effects of HRT on 
WM several months and years after the therapy had been initiated, something 
that other studies have not yet done.  
Sherwin (2007b) outlines (in her meta-analysis) that RCTs demonstrate an 
improvement in WM in younger HRT users, whereas observational studies show 
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improvements on a broader range of cognitions. There seems to be a slight lack  
of precision in observational studies and often researchers include larger test 
batteries (to which the build-up of tasks can cause cognitive exhaustion for the 
latter tasks) including more global cognitive tasks such as the mini mental state 
examination (MacLennan et al., 2006). The present study was much more 
specific, choosing only three WM tasks and one SA task to prevent cognitive 
exhaustion, and avoid type one error. The selected tasks have high validity, were 
challenging to a degree (to which there would have been subjective variation), 
and proved to be sensitive to HRT initiation.  
Participant inclusion criteria and group definition were important in the 
study design. First it was determined whether the participant had a history of 
HRT use or not (with a minimum of three months consecutive use). For those 
with a history of HRT use, participants were established as peri - or post-
menopausal depending on when their therapy had been initiated relative to 
their last menstrual bleed (with in, or in excess of 12 months). Participants with 
no history of HRT use were established as peri- or post-menopausal depending 
on when their last menstrual bleed was (again with in, or in excess of 12 months). 
This caused some problems, as those deemed as peri -menopausal users could 
have gone years without treatment, and years without menstrual bleeds. 
However the present study was designed to detect the long term effects of the 
therapy after peri-menopausal initiation and as such it was acceptable to invite 
participants who had initiated the therapy during the peri -menopause but were 
no longer receiving the therapy and no longer peri -menopausal.  
As the study relied on opportunity sampling it was important that groups 
were balanced for age (Philips & Sherwin, 1992), education (Jones & Gallo, 2001; 
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Phillips & Sherwin, 1992; Rasgon et al., 2005) and health (Joffe et al., 2006; 
Philips & Sherwin, 1992). Measurement of these variables also worked towards 
establishing potential covariates needed in analysis. Confidence in observat ional 
findings of HRT use on cognition are limited by concerns involving the ‘healthy 
user bias’, the tendency for women choosing to receive HRT to be better 
educated, healthier perhaps due to being more health conscious (Matthews et 
al., 1996) and younger (Maki, 2006). This further heightens the need for studies 
to balance their groups for age, education and health; there was no evidence 
that this was a problem for our sample.  
The present study found no relationship between HRT use and MQoL score, 
or phase of the climacteric and MQoL score (consistent with a study by Polo-
Kantola et al., 1998). P. Jacobs and colleagues (2000) suggest that a decline in 
QoL during the menopause is often later followed by an improvement in QoL, 
and that the end of the climacteric often coincides with QoL evaluation reported 
as high. If this is the case, it would be expected that those in the later stage of 
completion of the menopause would rate their QoL and MQoL as slightly higher 
than those in the middle. Equally, it could be expected that those in the earlier 
stage would rate their score as slightly higher than the middle. The present 
study included a peri-menopausal group (peri to middle) and a post-menopausal 
group (middle to post) which would account for the similar MQoL mean scores 
across groups and could be the reason no relationship was found between MQoL 
score and menopausal phase and between MQoL score and HRT use. It may have 
been possible to further break down the groups in quintiles across the 
climacteric based on last menstrual bleed to see if MQoL did correlate with 
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either HRT use, or precise stage in the climacteric, but this was not a core focus 
of the study. 
Several items from the MQoL scale were chosen to establish QoL and 
symptoms impact. On hind sight, it may have been more appropriate to use all 
48 items, however the test battery was lengthy and challenging, and it was 
thought that 14 items from relevant domains rather than the full 48 items would 
suffice whilst preventing cognitive strain. On discussion with the lead creator of 
the scale, 14 items were chosen to demonstrate MQoL. The MQoL scores varied 
across group and correlated with RSpan and OSpan. As such, the scores were 
used as a covariate. Other studies that have used a menopausal QoL score or 
symptoms impact as covariates include Joffe and colleagues (2006). As the 
present study wanted to consider the interaction of time on initiation of HRT, it 
was important to use symptoms impact as a covariate to ensure that these 
symptoms (such as hot flushes; Maki et al., 2008) were not impacting on 
cognitive performance. Because MQoL score and CSpan score did not correlate, 
it is possible that the CSpan is a less sensitive measure for the menopausal 
population. 
Clinical research has demonstrated that WMC negatively correlates with 
depression (Nazarboland & Farzaneh, 2009). GHQ-12 scores showed no evidence 
of an association between mood and WMC in this sample, and therefore were 
not used as a covariate. The GHQ-12 asks participants to rate how they have 
been feeling for a specific item over the past two weeks. For example; Have you 
recently: felt worried to which the participant would respond Much more than 
usual, A bit more than usual, Same as usual, Much less tha n usual. The majority 
of participants scored 22-24 points, selecting same as usual for each item. It is 
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possible that the chosen mood scale was not a good measure of mood in this 
group; unable to pick up on small differences between mood amongst the 
participants. 
Mean GHQ-12 and MQoL scores for each of the four menopausal groups 
became even more similar after the one year follow up suggesting that as 
women move through the climacteric, symptoms perhaps alleviate. Several 
studies assessing the link between the critical period and cognitive performance 
have chosen not to use mood as a covariate. Lord and colleagues (2008) used a 
mood scale to exclude those who exceeded a particular score but did not use 
mood as a covariate, and Grigorova and colleagues (2006) measured mood using 
the Profile of Mood States Bi Polar form and the Beck Depression Inventory but 
did not use them as a covariate. There can be huge differences in subjective 
estimation of mood and symptoms, and although subjective belief can impact on 
performance this is often difficult to ascertain due to the diverse differences in 
estimation. 
Participants invited to take part in the study were asked to be of normal 
mental and physical health. To coincide with previous research (Espeland et al., 
2004; Kampen & Sherwin, 1994; Henderson et al., 1996; Schmidt et al., 1996; 
Steffens et al., 1999; Verghese et al., 2000), participants were excluded if they 
had a history of stroke, heart disease, alcohol or drug abuse, if they had 
probable dementia or if they had a hysterectomy. This would exclude any person 
with memory deficits or degenerative disease from taking part in the study. 
Participants who took part in the study had varied experience of chronic illness. 
Despite a large proportion of participants reported having a current chronic 
condition differences in WM function were still present between groups. 
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Because the researchers did not have access to medical records, it was difficult 
to measure the extent of experience of illness.  
In addition, although participants were asked details on medications taken 
at point of testing, the absences of access medical records in the present study 
did cause limitations to the study design. For example, certain medications may 
affect oestrogen level, such as thyroid medicat ion. And migraine-related 
medication may also effect the endocrine system, and in turn, cognition. With 
better resources and funding, it may have been possible to take saliva samples in 
order to determine oestrogen levels to eradicate possible effect of me dications. 
As it stands, groups were balanced for experience of chronic condition, 
medication use and number of GP visits, and the conditions described by the 
participants were typical of a menopausal population. Despite poorer health 
experienced in some of the participants, differences in WM performance were 
still found in peri-HRT initiators and post-initiators as compared to non-HRT 
using controls. 
With an upper age limit of 65 years, this also excluded anyone with age 
related cognitive decline of a certain degree. Average number of GP visits per 
year did not differ across groups, and were similar with UK averages (4.5 GP 
contacts per year; Hippisley-Cox, 2009). Previous studies have not always 
controlled for age and health and both can affect WM performance. The selected 
covariates were both appropriate and necessary, adding strength to the study 
design. 
The presence of metabolic deterioration in the absence of cognitive 
change may be explained by high educational accomplishment, which is known 
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to compensate for mild impairment (Jones & Gallo, 2001). Specifically, those 
who are highly educated may use alternative systems to access cognitive 
functioning when the current systems are interrupted. Those who are less 
educated find metabolic deterioration more problematic and back-up systems 
become less accessible. Participants were asked their highest level of education 
(as did studies by Grigorova et al., 2006; deGroot et al., 2003; Lord et al., 2008; 
and MacLennan et al., 2006). This did not differ between groups or correlate 
with WM performance. 
Maki (2006) has proposed that the beneficial effects of HRT on cognition 
only occur in women whose cognitive function is already slightly impaired due to 
menopausal symptoms or slightly impaired due to age-related declines in brain 
function. Indeed, effects may be detrimental once impairment has started. 
However Viscoli and colleagues (2005) suggests that  HRT benefits are only 
evident in women who are cognitively intact. The current cognitive state of 
participants in the present study was not explicitly assessed. Generally, 
participants described themselves as of normal health. The present study 
demonstrated an improvement in WM in healthy, peri-menopausal women, and 
a detrimental effect in healthy, post-menopausal women. The results are 
applicable to a large proportion of the healthy population. Mulnard and 
colleagues (2000) identified that studies demonstrating improvements in 
memory by use of HRT in those with AD are based on a small group design over a 
short amount of time. The present study included a larger number of 
participants, allowing larger implications on the general population.  
The strength of the present study is that the researchers defined groups by 
stage in the climacteric, and not by age. In addition to this, the researchers were 
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able to confirm the longer lasting beneficial role of early HRT use and 
detrimental role of late HRT use. The inclusion of a group of past users provides 
additional information about the potential long-term protective effect of 
oestrogen on the brain after treatment cessation.  
Future research - The critical period 
 
The present study suggests that the window of opportunity is relatively 
small, with detrimental effects of HRT on WM when the therapy is initiated as 
little as 12 months after the participant’s last menstrual bleed. It would be 
worth conducting a large observational study considering the WM of several  
hundred women who have all initiated the therapy within and beyond 12 months 
after their last menstrual bleed in order to try and better define the window of 
opportunity. Specifically, when exactly does initiating HRT start to become 
detrimental to WM? How diverse is this window of opportunity across the 
population? The present study defines this window better than previous studies 
where groups were defined by age rather than personal symptoms.  
In the present study, the role of oestrogen initiation on WM p erformance 
has also been well explored, and the implications of HRT initiation on WM 
performance dependant on stage in the climacteric is more clear.  
The present study has been able to confirm that late HRT initiation is 
detrimental to WM. For other cognitions such as SA, the role of HRT initiation on 
this cognition’s maintenance or destruction is less clear. It is important to 
explore and define cognitions susceptible to oestrogen change as women 
become challenged in deciding whether HRT use is appropriate in aiding them 
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through completion of the climacteric. Understanding the precise occurrence of 
the critical period will also aid in this decision.  
Cyclical use of HRT 
Simpkins and Singh (2008) suggest that continuous exposure to HRT may 
result in a diminished effect of oestrogen benefit on cognition as duration of 
exposure increases. They go on to suggest that oestrogens should be 
administered cyclically rather than continuously so that exposure is followed by 
a small period of deprivation and recovery of oestrogen receptor number and 
function. This would mimic that of a natural fluctuation of oestrogen in the body 
and for these reasons, the suggestion of a more cyclic use rather than constant 
makes sense. To further support this, cyclic HRT distribution in  ovariectomised 
rats can improve spine density in the brain (Wooley, Gould, Frankfurt, & 
McEwen, 1990) whereas continuous exposure does not (Markowska & 
Savonenko, 2003). And finally, no improvement was seen in WM on 
ovariectomised rats score until the method of HRT management was changed 
from continuous to a cycle of changing oestrogen levels (Gresack & Frick, 2006). 
In human studies, continuous exposure of women to oestrogens caused a down -
regulation of ER-alpha in the brain and other tissues (Mohamed & Abdel-
Rahmann, 2000; Thakur & Sharma, 2007) and early beneficial effects of 
oestrogens on the brain can be expected to diminish over time of oestrogen 
exposure (Simpkins & Singh, 2008). In the present study, women who had 
initiated the therapy had continuous use until cessation, suggesting that for this 
population continuous use still resulted in benefits for peri -initiators, and 
detriments for post-initiators. In future RCTs, researchers may wish to consider a 
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combination of HRT initiation and duration, where perhaps a cyclic 
administration could be considered.  
Lower dose for short period may help cognition momentarily in post -menopausal 
women 
A more cyclical administration of HRT may be suitable for those still near 
the peri-menopausal stage, but for those in the post-menopausal stage it has 
been established that normal levels of HRT at continuous use could be 
detrimental to WM. Studies considering the impact of HRT when initiated during 
the post-menopausal stage have had mixed results. Most support the critical 
period hypothesis suggesting that late HRT initiation will have no effects or 
adverse effects however some demonstrate a promotion of cognition if a small 
dose of HRT is given over a short period of time. This includes improved verbal 
memory in over 65 year olds (Duka at al., 2000; Yaffe at al., 2000), increased 
dendrite growth in hippocampal tissue (Norbury et al., 2003) and symptoms of 
AD (Zandi et al., 2002).  
Although the present study was unable to ascertain the dose of therapy 
across participants; the duration of therapy was recorded. Specifically, those 
who initiated the therapy in the post-menopausal stage had an average therapy 
use of 3.77 years. This far exceeds Zandi’s recommended dose of two  months 
prescription for a cognitive ‘boost’ if initiated post -menopause. Krug and 
colleagues (2006) were able to demonstrate improved WM and hippocampal 
function in postmenopausal women after 100ucg HRT were administered for 
three days only. The implications of this are unexplored and it would be useful 
to consider the effects of this small dose of oestrogen. For example, supposing 
cognition can be boosted by as little as a one off dose of up  to two months HRT 
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use, it should be considered how long this cognitive boost will last in post -
menopausal women, where the present study demonstrates longer lasting 
detrimental effects of HRT use in post-menopausal women who had received the 
therapy in excess of (on average) three years. Are the benefits of short term use 
something that can be repeated in post-menopausal women or should it be 
limited? These are questions that lay unanswered as of yet and the current 
usefulness of a one off boost is yet to be determined. 
An extremely interesting study would be the initiation of HRT in women 
with early onset-dementia to see if HRT can combat dementia in women who are 
still menstruating. 
Progesterone addition 
Another question requiring clarification is that of  the addition of 
progesterone to the therapy, and how this might impact on cognitive 
performance. Progestagens are added to HRT in order to counteract increased 
risk of endometrium hyperplasia due to unopposed oestrogen. Animal studies 
have demonstrated that the addition of progestagens to the therapy can 
encourage projections from the cell body of the neuron (neurite outgrowth) 
which can lessen beneficial effects of oestrogens in the brain (Woolley & 
McEwen, 1993). Human studies have more mixed results but  the majority show a 
diminished effect of oestrogen on cognition if progestagens are included 
(Ohkura et al., 1995; Rice et al., 2000) and some demonstrate no effect 
(Hogervorst, Riedal, Boshuisen, & Jolles, 1999). Many studies consider oestrogen 
only (such as the WHIMS) and for the general population, most women will be 
prescribed a therapy containing progestins.  
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It is important to consider the error of drawing conclusions concerning the 
effect of one hormone on brain function (oestrogen) when in some case s two 
hormones are administered (oestrogen and progesterone; Sherwin, 2008). 
Wegesin and Stern (2007) demonstrated a difference in executive function 
during a source recall task between HRT users (oestrogen only) and HRT users 
(oestrogen and progesterone combined). Participants receiving oestrogen only 
outperformed non-users on the Wisconsin card sorting task but those taking the 
combination therapy performed no differently to non-users of HRT. The 
researchers concluded that the addition of progestins to HRT may reduce the 
benefits of oestrogen on executive function. Lee and McEwen (2001) suggest 
that, despite the effects of progestins on the brain being poorly described, they 
may have an opposite effect on cognition to oestrogen. Based on this, Sherwin 
(2008) is adamant that the effects of oestrogen and progesterone should be 
considered separately on cognitive function. In the present study, participants 
were asked if their therapy was oestrogen only or contained progesterone. The 
addition of progesterone did not have an effect on cognitive performance in this 
case, but the group sizes were too different to draw conclusions at this point.  
Brinton (2001) suggests that we now have enough information to develop a 
therapy designed for the unique requirements of the brain to help prevent 
degenerative disease. The addition of progesterone to a hormone replacement 
regimen can cause many women to have additional side effects of irritability and 
depression, causing detrimental effects on mood and general sense of wellb eing 
(Panay & Studd; 1997). Yet the side effects of progesterone and progestins have 
been shown to be dependent on dose and route of administration. If 
progesterone is administered orally it seems to produce the greatest side effects 
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(deLignieres, Dennerstein & Backstrom, 1995), can lead to a decrease in dendrite 
density (Wooley & McEwen, 1993) and this can lead to a decrease in cognitive 
performance scores when compared to an oestrogen only group (Rice et al., 
2000). Differences of physiologic effects on the brain can be seen between 
oestrogen only users and oestrogen plus progesterone users on completion of 
cognitive tasks using PET (Berman at al., 1997). Follow up studies should focus 
on the potential detrimental effects of HRT when initiated during the p ost-
menopausal stage considering the effects of oestrogen only therapy and 
oestrogen plus progesterone on WM capacity. Route of administration should 
also be considered. This may avoid cognitive decline in late HRT initiators.  
On-going studies 
The Kronos Early Estrogen Prevention (KEEPS) trial has been designed to 
asses a variety of potential differences in health between users of oral 
conjugated equine oestrogens, transdermal oestradiol and a placebo control. 
The primary goal is to increase knowledge rega rding HRT’s potential effect on 
heart disease. A small component of this study will look at cognitive differences 
between the groups. At present there are 720 women assigned randomly to one 
of the three conditions and the intervention will have a duration of at least five 
years which may help to give early indications of differences between the groups 
for cognitive decline. Similar to the present study, the researchers will initiate 
the therapy at the time of the biologically defined menopause. In theory, t his 
should mean that HRT is initiated at the critical point, and should show most 
beneficial effects to cognition. However the women participating in KEEPS are 
42-58 years old with their last menstrual cycle occurring within six months to 
three years. The present study demonstrated a detrimental effect of HRT on WM 
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when initiated as little as 12 months from the last menstrual bleed, meaning 
that a proportion of the women recruited in the KEEPS study will be missing the 
critical point of initiation. Researchers intend to evaluate the relationship 
between whole brain and ventricle volumes as well as the relationship between 
cognition and vascular risk factors. A further study will test the effect of HRT on 
STROOP task performance. It is not yet clear what other cognitive domains will 
be assessed, but tasks of WM would be useful, as these relate to every day 
memory. These are the types of cognitive issues that women complain about 
when they reach the menopause, and the present study was able to confirm this 
by demonstrating a difference in performance on outcome measures that assess 
every day memory. 
Further thoughts to consider and GP recommendations  
Current developments in large population-based studies put into question 
the safety of long-term use of oestrogen. Although it may protect against 
colorectal cancers and osteoporosis, it may also increase the risk of breast 
cancer and coronary heart disease (Rossouw et al., 2002). Sherwin (2007) 
suggests that HRT use is relatively safe if it is not used beyond four y ears, which 
encourages the question ‘when is the right time to take HRT for optimal 
protective effects?’ Memory complaints during the menopause are the largest 
reported problem (Norbury et al., 2003, Philips & Sherwin, 1992) and whether 
physical health or cognitive health should be prioritised in doctor 
recommendations for HRT use is yet to be considered.  
HRT has clear benefits on physical symptoms, the clarity of the benefits of 
HRT on cognitive symptoms is less well defined, and the present study helps 
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contribute to further clarification of the research field. For physical symptoms, 
HRT is initiated if those symptoms exceed a certain point (and not otherwise, 
due to increased risk of oestrogen-related cancers). It is important that the 
impact of HRT on cognition is well defined in order to ascertain whether the 
benefits on cognition are substantial enough to prescribe HRT knowing the risks. 
WM represents normal day to day memory, and problems in WM experienced 
during the menopause are subjective. Whether these issues warrant the use of 
HRT, or are just minor annoyances, will be up to the patient. But if the optimal 
use of HRT for WM is established, this will have large contributions to the 
decision making process. The present study helps to define the critic al period as 
within 12 months of last menstrual bleed, meaning that for those with problems 
in WM experienced during the menopause, HRT should not be recommended as 
alleviation for after this point. 
Summary 
The present study adds insight into the potential  long lasting effects of 
early HRT initiation, and supports a critical period for neuroprotection.  
There has been much speculation regarding the details of the critical period 
hypothesis, and in particular the possible outcome of HRT if taken at different 
stages in the climacteric. Generally, less is understood about what happens if 
HRT is taken post-menopause. Discrepancies in the literature led to the 
suggestion of the critical period hypotheses, which has been described and 
speculated upon in several studies, but not directly tested. The present study 
offers unique insight into the critical period, suggesting the window of 
opportunity for HRT initiation ends as little as 12 months after last menstrual 
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bleed. The study was able to achieve this by testing women grouped according 
to stage in the climacteric, and not simply based on age.  
Oestrogen enhances performances on tasks dependent on the pre -frontal 
cortex, although the effects are complex and can be affected by many factors, 
such as length of time elapsed since last menstrual bleed (Daniel & Hulst, 2006; 
Dohanich et al., 2009). As is currently understood, oestrogen receptor sites 
become less active in the brain during the menopause as oestrogen levels 
decline. This causes declines in WM. If HRT is taken during the early onset of the 
menopause, the oestrogen supply remains constant and the receptor sites active. 
Studies have shown WM to be maintained in peri-menopausal women receiving 
HRT. If HRT is not taken and oestrogen supply to these receptor sites c ontinues 
to decline, they reduce in activity and initiation of HRT at this point may be 
overwhelming and damaging. Studies have shown WM to be worsened by late 
HRT use. The present study adds to the literature, by confirming detrimental 
effects in WM by late HRT use as little as 12 months beyond the last menstrual 
bleed. This information has large implications, as a large proportion of women 
initiate HRT after this time period. Postmenopausal women are in an oestrogen -
deprived state and are at risk of stroke and other neurodegenerative disease 
(Simpkins & Singh, 2008). Therefore it is important to consider the wider 
implications for early oestrogen therapy use and longer lasting effects.  
Current GP recommendations state that the benefits of HRT use up to th e 
age of 60 outweigh the costs. The present study adds to this detrimental list, and 
guidelines need to consider that late use may have detrimental effects on 
cognition. However the failure of recent trials to show benefits of HRT in older 
women makes it more difficult to convince pharmaceutical companies to take on 
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the expense of new clinical trials. In RCTs different oestrogen preparations have 
been used in different doses and an abundance of psychometric measures have 
been used to measure a restricted number of cognitive domains. More robust 
trials are needed to draw stronger conclusions, where guidelines on suggested 
time frame for initiation can be reached. Other considerations may include 
method of administration and duration and style (cyclic or const ant). The 
present study can be used as a guide in future trials where by peri - and post-
menopausal groups can be defined by last menstrual bleed, as opposed to age.  
The long term effects of HRT are not yet known and it is unclear to whether 
the neuroprotective effects are longer lasting or short term once the therapy has 
been terminated. The present study contributes to the understanding by 
incorporating a longitudinal, observational design, suggesting that the beneficial 
and detrimental effects of HRT on WM dependent on time of initiation are 
longer lasting then first anticipated. RCTs don’t often incorporate a long follow 
up and longitudinal studies tend to review the longer term use of HRT rather 
than the period after treatment cessation. This study has reviewed the period 
after treatment cessation which adds a unique level to the research and further 
studies may also want to consider this in their study design.  
The present study clearly demonstrates a critical period for HRT initiation, 
and that this impacts on WM. The researchers’ controlled statistically for 
participant characteristics that are known to independently influence cognitive 
functioning in older people such as age, level of education and health. In the 
present study, mean differences between the four groups were greatest for the 
Rspan and Ospan tasks. These are challenging WM tasks with a verbal constraint. 
Collectively, the WM span tasks were a good measure of WM capacity for this 
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group and have confirmed both a beneficial time and a potentia lly damaging 
time of initiation of HRT on WM. Discrepancies between other research may, in 
part, be due to inappropriate tasks chosen. Future studies should consider both 
the difficulty and nature of the tasks they choose, making sure they demonstrate 
executive functions that are mediated by either the pre-frontal cortex or 
hippocampus. Groups should be defined by last menstrual bleed, and not age, 
where age can be used as a covariate. Observational studies can contribute to 
our understanding of the longer lasting effects of HRT initiation on cognition, 
research that has greater need for expansion.  
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Phytoestrogens as an alternative to HRT 
 
4.1 A history of Hormone Replacement Therapy 
 
HRT can be received as a continuation of the menstrual cycle thus 
allowing the prolongation of fertility, however most women primarily 
incorporate HRT into their endocrine system in order to prevent and reduce 
menopausal symptoms such as hot flushes, a decreased sex drive, sleeping 
problems, mood swings and cognitive decline (Cassidy et al., 2006; Sherwin, 
2008). This is not the sole reason for taking the therapy and evidence suggests 
that HRT also reduces the risk of osteoporosis and heart disease (Wuttke,  Jarry, 
Westphalne, Christoffel, & Seidlova-Wuttke, 2003). Opting to take HRT in order 
to improve quality of life during the menopause is not taken lightly by 
practitioners and many patients are reminded of the potential detrimental 
effects of the treatment to health during their decision making process. These 
unfavourable health effects have slowly been brought to light in the past four 
decades and it is these potential damaging effects that challenge the 
dispensation of HRT causing women to seek alternative routes. 
HRT was made available in the 1930’s to treat hot flushes and other 
physical changes that women reported as experiencing during the menopause. 
The first brand of HRT coined Premarin originated from America and contained 
conjugated equine oestrogens only. It was not until the 1950’s that concern 
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began to stir for those receiving the therapy when an increased rate of uterine 
cancer was identified in those using the treatment (Grey, 1951). To combat bad 
press, by the early 1960’s a new list of reasons why women should initiate the 
treatment began to accumulate, and several books such as Feminine Forever 
(Wilson, 1966) were available claiming that with HRT, ‘the menopause is 
completely preventable’.  The researcher explained that when hormone l evels 
plummet during the menopause, women lose their femininity, making them no 
longer completely female.  Yet HRT would replace the hormones lost, allowing 
women to keep their femininity and be less boring. Sponsored by the drug 
companies responsible for the sales of HRT, Wilson travelled the country in 
order to deliver this information during several national lectures. Alas, in the 
mid 1970’s a link between oestrogen consumption and endometrial cancer was 
established (Mack et al., 1976; Smith, Prentice, Thompson, & Herrman, 1975; 
Ziel, & Finkle, 1975). This started a decline in women choosing to take HRT. 
Current non users were compared to HRT users to reveal that those who had 
used oestrogen therapy for five years or less were five times more at risk than 
non-users of endometrial cancer, whereas those who exceeded the five years of 
use were 14 times more at risk (Voigt et al., 1991). From 1975-1976, oestrogen 
use declined by 18% and then another 10% from 1976-1977. By 1980, the 
number of annual oestrogen prescriptions had fallen by 50% in the US (Col, 
Fairfield, Ewan-Whyte, & Miller, 2009). 
Manufacturers carried out extensive research and soon recognised that 
with the simple addition of synthetic progesterone the risk of endometrial 
cancer could be reduced (but not eradicated). A new product Prempro was 
manufactured, combining oestrogen with synthetic progesterone. Doctors were 
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free to prescribe the combined treatment to women with a uterus and at 
potential risk to endometrial cancer, whilst those who had undergone a 
hysterectomy received the oestrogen only treatment as usual. Recent research 
has established that, although the combined treatment may be better for lower 
risk of endometrial cancer, oestrogen alone can help to prevent coronary heart 
disease (Mendelsohn, & Karas, 1999). However HRT should not be used for the 
prevention of heart attack or stroke (Hully et al., 1998; Rossouw, 1996). 
Following the association between HRT initiation and endometrial cancer 
(Smith et al., 1975), by 1975 an association was also made between HRT 
initiation and breast cancer (Lippman, Bolan, & Huff, 1975).  
By the late 1970’s and early 80’s HRT was promoted as a treatment for 
aging, specifically as a cure for wrinkles, aches and pains, as well as menopausal 
specific symptoms such as hot flushes, insomnia and weight gain. It was also 
promoted as an aid for disease prevention in AD, depression and heart attack 
where several observational studies suggested that HRT might protect women 
against heart disease (Stampfer, Willett , & Colditz, 1985).  By the 1980s, several 
studies showed that oestrogen was effective in slowing the diminishment of 
bone density thus helping to prevent osteoporosis (Lindsey, Hart, Forrest , & 
Baird, 1980). In 1986, the food and drug administration reviewed the current 
evidence and suggested that HRT might indeed be an effective treatment for 
osteoporosis, but the studies completed on the prevention of heart disease were 
not adequate to support the use of HRT for this purpose. By the 1990’s, women 
began to wonder if HRT really was essential, and question why all women were 
given the same dose, despite menopausal symptoms being different in degree 
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and occurrence between individuals (Daly, Gray, Barlow, McPherson, & Roche, 
1993).  
In 1998 Hully and colleagues published a study (the HERS study) looking 
at the effects of HRT on heart disease. The researchers invited women with 
heart disease to take part in an intervention and found that those receiving the 
therapy had an increased risk in heart attack. The study was dismissed by HRT 
proponents who stated that the study did not apply to healthy women. In 2002,  
the women’s health initiative  completed a large study investigating the potential 
protective effect of HRT on heart disease, and released evidence  to suggest that 
HRT had no protective effect on heart disease and stroke and that perhaps it 
could even be responsible for an increased risk in these health issues. The first 
publication to arise from the study suggested that women who took the 
combined version of the treatment were at risk of breast cancer, stoke, heart 
attack and blood clots. Being such a large-scaled study, results had a huge 
impact worldwide and prescription rates faced a significant drop. Some women 
later returned to the treatment once their menopausal symptoms returned and 
were of unbearable degree, however research showed that over half the women 
who ceased to take the treatment felt little discomfort as a result ( Ockene et al., 
2005).  
Since serious health issues associated with the in itiation of HRT have 
been brought to the attention of health professionals, doctor s have been much 
more cautious in the prescription of HRT, only prescribing the treatment as a last 
resort for a limited time period only (approximately two months to begin with 
and no longer than five years). Since the completion of the WHI study, several 
studies have contested the propositions made suggesting HRT may in fact be 
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beneficial for the protection against specific disease as well as detrimental to 
others. Researchers have been tweaking the data from the WHI study to see if 
there is a subset of women who may benefit from HRT as well as identifying 
subsets who should avoid it (writing group for the women’s health initiative 
investigators, 2002). Primarily, those with a history of hormone specific cancers, 
blood clotting, heart disease and stroke should not be offered HRT unless there 
is no other alternative and their quality of life has vastly lessened.  
An alternative treatment is the use of biomedical hormones. These  are 
biochemical structures identical to female hormones of oestrogen, progesterone 
and testosterone that are normally manufactured by the endocrine system in the 
ovaries. They are crafted to be identical to that of the individual. In a recent 
large study completed in France by Fournier, Berrino and Clavel-Chapelon (2008), 
eighty thousand women with the combined average age of 52.4 years were 
observed over a twelve year period. Analysis revealed levels of breast cancer to 
be significantly lower in those receiving oestrogen combined with bioidentical 
progesterone when compared to those receiving oestrogen o nly or those 
combined with the normal form of progesterone, both of which had a marked 
increased risk in breast cancer.  
Although biomedical hormones may decrease the risk of breast cancer 
when compared to synthetic hormones, the risk is still increased when 
comparing biomedical hormones to no alternative sought. The development of  
identical biomedical hormones means the therapy can function  within the 
patient’s own biomedical structure to try work naturally with the body, however 
the detrimental effects are only slightly less to those of HRT and as such, little is 
resolved by choosing this route. 
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 The decision to initiate HRT is individual and the benefits,  side effects 
and risks will differ depending on the individual. It is up to the practitioner to 
best advice the patient to whether HRT is a reasonable option to consider in the 
reduction of menopausal symptoms or not. At present, there are a range of 
alternatives that can also be offered, such as the biomedical hormones or, in 
more recent years, natural alternatives and phytotherapy.  
 
4.2 Natural Solutions 
 
 
In the past three decades, the prospect of more natural supplements to 
help reduce menopausal symptoms has received much deliberation, with 
particular attention to the idea that natural supplements may avoid the 
detrimental problems associated with HRT. The concept of diet and its role in 
menopausal symptoms emanated from literature speculating the diff erences 
between Western women and Asian women, who have a diet rich in soy and 
report fewer menopausal symptoms (Vincent & Fitzpartick, 2000). Among 
menopausal women in Asian countries, 14-18% reported experiencing hot 
flushes as compared to 70-80% of European women (Barlow, Brockie, & Rees, 
1991). Umland and colleagues (2000) suggest that the differences in experienced 
menopausal symptoms are largely due to differences in diet, where Asian 
women consume high levels of soy. Also deriving from exploration of  the Asian 
diet on menopausal symptoms, epidemiological studies have revealed lower 
incidences of breast and ovarian cancer and coronary artery disease in those 
with soy-enriched diets (Adlercreutz & Mazur, 1997). In response to these 
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findings, a natural alternative was sought which will ‘mimic’ HRT’s more 
beneficial effects whilst avoiding its disadvantages.  
Following a line of investigation over the past three decades, specific 
alternative supplements to HRT have been identified, deemed to target and hel p 
reduce a range of menopausal symptoms in both healthy women, and women 
with breast and cervical cancer (Messina & Loprinzi, 2001). Some of these 
alternatives include the following: 
Agnus Castus stimulates and normalises the function of the pituitary 
gland which controls hormonal balance in the body. It has been shown to 
reduce hot flushes and menopausal symptoms in 45 – 60 year olds 
(Abbaspoor, Hajikhani, & Afshari, 2011). 
 
Black Cohosh is often used to relieve menopausal symptoms such as hot 
flushes and vaginal dryness, however research suggests it may not be 
effective in doing so (Leach & Moore, 2012). 
 
Red Clover is effective in alleviating hot flushes (Booth et al., 2006).  
However, due to its coumarin content (which can prove toxic to the liver 
and kidneys if accumulated over time), it should be used with caution on 
those suffering from coagulation disorders.  
 
Other supplements that have been claimed to help with menopausal symptoms, 
but with little or no empirical evidence include Evening primrose oil, Femal, 
Maca, Ginkgo Biloba and Sage. 
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Concern over potential adverse effects of HRT (Nelson, Humphrey, 
Nygren, Teutsch, & Allan, 2002) and recognition of menopausal symptoms being 
reported as less frequent in Asian women has led to increased interest in the use 
of phytoestrogen supplements by women experiencing menopausal symptoms 
(Farquhar et al., 2009). Epidemiological studies demonstrate associations 
between diets high in phytoestrogens and a reduction in menopausal symptoms, 
as well as a reduction in breast cancers and coronary heart disease, making 
phytoestrogens a suitable substitute for HRT (Umland, Cauffield, Kirk, & 
Thomason, 2000). 
 
4.3 Metabolism, hormonal action and brain plasticity of  
phytoestrogens 
 
Phytoestrogens are dietary components found in some plants and are 
comprised of isoflavones, ligens, coumestans and prenyl flavonoids (Cassidy, 
2004). Humans are exposed to phytoestrogens on a regular basis due to their 
widespread use in a variety of products (Lephart, Setchell, Handa & Lund, 2004). 
The most accessible phytoestrogen is the isoflavone, which has been extensively 
studies (for example, Whitten & Patissaul, 2001). Isoflavones are organic 
compounds belonging to the legume family  and act as phytoestrogens in the 
body. Isoflavones can be found in a range of food sources, such as soya. Because 
of the isoflavone’s accessibility with in soya, most studies have focused on soya 
as a source of phytoestrogen. 
 The interest in isoflavones, specifically to human health, has increased 
over the past 15 years, with particular interest in their structural similarity to 
oestrogens, resulting in biological activity related to oestrogen receptor 
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mediated mechanisms (Messina, 2007), and their potent ial to be an alternative 
to HRT (Atmaca et al., 2008). 
In animal diets, isoflavones remain inactive until they reach the 
gastrointestinal tract, where they become active. The active forms can then be 
metabolized to equol, similar to 17-beta oestradiol (Lephart et al., 2004). 
Phytoestrogens are structurally and functionally similar to oestradiol, and this 
enables them to bind to oestrogen receptors (Knight & Eden, 1995) and act in 
vivo like weak oestrogens (Fletcher, 2003). The organic structure of 17 -B- 
oestradiol and isoflavones can be seen in figure three for comparison. 
 
 
 
 
Figure 3:  Isoflavone and 17-B-oestradiol organic structure, cited 
from Rice & Whitehead (2006) 
 
 
Humans do however produce low levels of equol in comparison to 
rodents, at approximately 30% (Setchell, Brown, & Desai, 2002). In addition, 
phytoestrogens act like weak oestrogens as their affinity for binding is only 
between one-500th and one-1000th of that of oestrodiol, resulting in weak 
bindings to oestrogen receptors (Verdeal, Brown, Richardson, & Ryan, 1980). 
Nevertheless, phytoestrogens reach concentrations sufficient to elicit response 
(Knight & Eden, 1995) and by acting in the same way as oestrogen (Miniello et al., 
2003), the phytoestrogen is able to partially mimic its activity and this induces 
Image has been removed 
due to Copyright restrictions 
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similar responses though, some less mild within the body (Karch, 1999). The 
compounds may affect oestrogen action (Hwang et al., 2006), acting as 
oestrogen agonists and antagonists depending on the context (Hooper et al., 
2009) or by affecting the enzymes involved in steroid metabolism altering 
oestrogen circulation (Lacey et al., 2005). 
When phytoestrogens are metabolized, they bind onto the same receptor 
sites as do oestrogens, however if a phytoestrogen binds to a receptor this 
prevents oestrogen from exerting its effects. In menopausal women, oestrogen 
levels are low, and phytoestrogens may add to total increase of systemic 
oestrogen effect. But this will always be at a reduced level as compared to 
normally menstruating women, where phytoestrogens have about two 
percentage the ‘strength’ of oestrogens (Werbach & Murray, 1994).  This puts 
into question the likelihood of substituting HRT with isoflavone use.  
A broad range of oestrogens and oestrogenic molecules, such as 
isoflavones and phytoestrogens can promote the chemical antioxidant effects of 
oestrogens due to their chemical activity in the brain (Brinton, 2008). A smaller 
subset can activate biochemical cascades required for neuroprotection and an 
even smaller subset can activate the genomic mechanisms of oestrogen -induced 
neuroprotection (Behl, Moosmann, Manthey, & Heck, 2000; Brinton et al., 2000; 
Nilsen & Brinton, 2000). This is because phytoestrogens are able to enter the 
brain and act centrally as well as peripherally and evidence from human and 
animal studies suggests that phytoestrogens could affect cognition directly as 
well as by modulating the hormonal milieu (Hill & Dye, 2003). In their meta -
analysis, Hill and Dye suggest that phytoestrogens have the potential to 
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influence cognition through neural impact and oestrogenic activity and that this 
may be most beneficial in females entering the menopause.  
Pan, Anthony and Clarkson (1999) demonstrated that phytoestrogens 
regulate nerve growth and brain-derived neurotropic factor in the PFC and 
hippocampus of female rats. Luine, Attalla, Mohan, Costa and Frankfurt (2006) 
also showed that a diet rich in isoflavones can result in an increase in spine 
density of pyramid cells in the PFC of female rats, the same area abundant with 
oestrogen receptors (Tang, 2004), where WM and SA are mediated. Duffy and 
colleagues suggest that isoflavones target ER-beta, found in the PFC and 
hippocampus, and this can result in improved cognitions mediated  by these 
brain areas. 
Lephart and colleagues (2002) have demonstrated brain changes in rats 
receiving isoflavones and evidence from their study shows the female rat to be 
able to metabolise isoflavones well. However there is less evidence regarding 
metabolism of isoflavones in humans, and to what extent this affects the 
structure of the human brain.  Although rat studies have demonstrated a change 
in dendrite density and increased nerve growth in parts of the brain after 
exposure to isoflavones, other research suggests that isoflavones are not easily 
metabolized by humans. In their study, Setchell and colleagues (2002) 
investigated the bioavailability of isoflavones and mechanisms of intestinal 
absorption of an isoflavone supplement or soymilk containing isoflavones in 
humans at different points following exposure. The concentration of isoflavones 
was directly measured in timed blood samples one, two and eight hours after 
ingestion, and no traces of isoflavone were found.  
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Kreijkamp-Kaspers and colleagues (2004) investigated plasma levels of 
isoflavones in the blood after exposure of either 100 mg of isoflavone or a placebo in 
post-menopausal women. After 12 months of exposure, no difference was found 
between the two groups, suggesting poor absorption of the supplement. In contrast, 
isoflavone content is detected in blood plasma of Asian women who have diets 
high in isoflavone, suggesting again that it may be western women who fail to 
metabolise isoflavones (Adlercreutz et al., 2000).  
 Isoflavones have been extensively studied and found to improve insulin 
regulation and bone health (Scheiber, Michael, Rebar, & Robert 1999; Wagner et 
al., 2008) and to decrease frequency and severity of menopausal discomforts 
such as vaginal dryness, hot flushes and night sweats (Sacks, Lichtenstein, & 
VanHorn, 2006). Isoflavones have also been shown to have a ‘rejuvenating effect’ 
on the brain to significantly improve category fluency after a soy intervention, 
with trends in improved verbal memory, however unlike other phytoestro gens, 
isoflavones have been shown to prevent the growth of breast cancer cells (Kritz -
Silverstien, Von Muhlen, Barret-Connor, & Bressel, 2003). As such, there is a 
potential for isoflavones to improve cognition whilst offering minimal 
detrimental effects on general health.  
4.4 The effect of Isoflavones on menopausal symptoms 
 
Regular consumption of Isoflavones is thought to confer health benefits 
as research has shown they may play a role in lowering risk for a range of 
diseases. For example, soy isoflavones appear to reduce cardiovascular disease 
risk by inhibiting the growth of cells that form atherosclerotic plaques (Anthony, 
Clarkson, Hughes, Morgan, & Burke, 1996) and population-based studies show a 
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strong association between consumption of isoflavones and a reduced risk of 
breast and endometrial cancer (Messina, 2007).  
In question is the applicability of substituting HRT with isoflavones in the 
hopes of reducing menopausal symptoms to some significant degree. Isoflavones 
have been shown to help reduce menopausal symptoms and are often 
recommended by manufacturers as a natural alternative. Specifically, 
Isoflavones have been shown to reduce hot flushes. In their study, Chedraui, 
Miguel and Schwager (2011) evaluated the effect of soy derived isoflavones on 
hot flushes and mood in a high risk population. Fifty women aged 40 -59 with a 
BMI over 25 (suggesting obese) received 100mg of isoflavones daily over a three 
month period. Of these, 45 women completed the study. Menopausal symptoms 
(using the Menopause Rating Scale), frequency and intensity of hot flushes and 
mood (using the Hamilton Depressive Rating Scale) were assessed at both 
baseline and at 90 days. After three months of supplement treatment, 
menopausal symptom score significantly decreased to suggest less suffering as 
did the frequency and severity of hot flushes. Depressive rating scores 
significantly decreased to suggest improved mood. There was no effect on blood 
pressure levels or BMI values after treatment. The study did not use a placebo 
group as a control, so it is difficult to state whether the improvements were 
expectancy effects. Also, the population were obese and not reflective of a 
normal population with normal health. 
As well as mood and hot flushes, soy isoflavones may help in the 
preservation of bone substance and to prevent or reduce risk of osteoporosis.  
Unlike oestrogen, which helps prevent the destruction of bone, evidence 
suggests that isoflavones may also assist in creating new bone, which helps 
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prevent the development of osteoporosis. In their study, Atmaca and colleagues 
(2008) demonstrated that soy isoflavones have beneficial effects on bone 
mineral density, bone turnover markers and bone mechanical strength in 
postmenopausal women.  
Much like the HRT literature, the effect of isoflavones on menopausal 
symptoms is mixed and unclear. Although some studies suggest that isoflavones 
may alleviate menopausal symptoms (Ma, Qin, Wang, & Katoh, 2008; Marini et 
al., 2007) others have found no such effect (Nelson et al., 2006; Sacks et al., 
2006). St Germain, Peterson, Robertson and Alekel (2001) randomised 69  
menopausal women to either a placebo or isoflavone treatment (80mg/day) over 
24 weeks of treatment. A menopausal index was used at baseline and following 
the intervention to compare hot flushes and sleeping patterns. Both groups 
reported a reduction in hot flushes, yet analysis revealed no difference in hot 
flush severity before and after treatment. Hot flushes are the primary reason 
that women seek medical intervention (Tice et al., 2003). The effects of soy 
isoflavone intake on the frequency of hot flushes have been examined in a 
number of RCTs (Howes, Howes, & Knight, 2006; Huntley & Ernst, 2004; 
Kronenberg & Fugh-Berman, 2002) and results have been mixed. In their reviews; 
Krebs, Ensrud, MacDonald and Wilt (2004) and Hunt ley and Ernst (2004)  found 
that only one out of eight RCTs of soy foods reported a significant reduction in 
the frequency of hot flushes. Three out of five trials using soy isoflavone 
supplements reported a significant reduction. Only four out of ten studies using 
soy preparations found improvement in hot flushes. Improvements were 
described in both reviews as small.  
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Generally, the impact of isoflavones on menopausal symptoms such as 
hot flushes have been mixed and whilst evidence suggests isoflavones may 
alleviate such symptoms (Vincent & Fitzpatric, 2000) other studies have 
demonstrated no or little effect as compared to HRT (Lephart et al., 2002).  
Results of isoflavones on menopausal symptoms indicate that the effects 
of isoflavones on cognitive change during the menopause may also be  mixed. 
Similar in design to study one of the thesis, the present study will be considering 
isoflavones as a suitable substitute for HRT to prevent cognitive decline.  
 
4.5 The effect of Isoflavones on cognition 
 
With isoflavones and soy having mixed results on bone health, hot 
flushes and cholesterol, it must be considered that the results for cognition may 
also be mixed. Similar to the HRT literature, research has demonstrated a 
positive effect of soya consumption on certain cognitive tasks associate d with 
frontal lobe functioning such as SA and planning ability. In their study; Duffy and 
colleagues (2003) asked participants to consume either 30mg of phytoestrogen 
supplement twice a day over a 12 week period, or a placebo of 0.5mg of 
phytoestrogens per day. Participants were asked to complete a test battery 
including the revised Wechsler short story to measure episodic memory, the 
Delayed Matching to Sample test to measure short term non-verbal memory, a 
delayed picture recall task, the Paced Auditory Serial Addition Test (PASAT; 
Gronwall, 1977) to assess SA and a test of rule reversal and planning ability. On 
analysis it was revealed that the soya group performed significantly better on 
each of the tasks. The study was repeated by File, Hartley, Elsaba gh, Duffy and 
Wiseman in 2005 to see if similar results could be found with a briefer period of 
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soy consumption. Here, 50 postmenopausal women were given one capsule 
containing 60mg of phytoestrogen isoflavones daily over a six week period, or a 
placebo capsule containing no soya extract. Participants were tested on story 
recall, short term non-verbal memory, picture recall and SA. Despite being at the 
post-menopausal stage, soya consumers performed significantly better in the 
short term non-verbal memory and the SA task. 
The positive effects of isoflavones on cognition have also been 
demonstrated using an intervention of high soy food products, rather than a 
capsule. In their study, File and colleagues (2001) looked at the effects of high 
(100 mg isoflavones/day) versus low (0.5 mg isoflavones/day) soya diets on 
attention, memory and frontal lobe function in young (students) males and 
females. The diet was maintained for 10 weeks and participants were tested 
before and after the intervention. The test battery included the NART and 
Hospital Anxiety and Depression Scale (HADS) to indicate intelligence and mood. 
To test attention, participants were asked to complete the digit -symbol 
substitution (DSS) as well as the digit cancellation (DC) task. The paced audito ry 
serial addition test (PASAT) was used to measure SA. To measure episodic 
memory, participants were asked to complete a short story recall from the 
Wechsler scale, as well as test of rule reversal and shifting. For longer recall, 
participants were asked to recall pictures after a 20 minute delay. To assess 
semantic memory, participants were asked to complete a category generation 
task and were given 20 seconds to recall items from (for example) a shopping list. 
They were later asked to recall as many words beginning with the letter ‘S’ to 
demonstrate verbal fluency. Improvements were found in both males and 
females for long term and short term memory, and in females only for verbal 
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related tasks. The soya intervention had no effects on the PASAT, DSS and D C. 
There were no differences between high soya and low soya diet on story recall, 
however there was an improvement from baseline of the high soya group in both 
rule reversal and picture recall. In the letter fluency task, there were 
improvements in the high soya group for females only, where the dietary 
intervention seemed to hinder the males’ performance. The researchers 
concluded that even weak exposure to phytoestrogens can have a positive effect 
on episodic and frontal lobe functioning such as verbal me mory and SA, and 
positive effects of isoflavone on cognition were more evident in females. The 
study was unable to show the positive effects of isoflavones on SA (using the 
PASAT), as demonstrated by Duffy and colleagues (2003).  
Kritz-Silverstein and colleagues (2003) asked 27 healthy women to take 
110mg isoflavones per day over a six month period, and compared them to 26 
women taking a placebo. The study also measured cognitive functions but in 
addition to the study by File and colleagues (2001) the interv ention took place 
over a longer six month period. Women were aged 55-74 years of age and had 
never received any form of HRT. Before and after treatment, participants were 
asked to complete a category fluency task and a paragraph recall task assessing 
immediate and delayed verbal memory. Results showed improvement in the 
category fluency task for women consuming the soy isoflavones. However, unlike 
studies by Duffy and colleagues (2003) and File and colleagues (2001), there 
were no improvements in verbal memory. The researchers concluded that 
isoflavone consumption could be potentially beneficial to the groups’ cognitive 
performance, and in particular verbal memory despite not reaching significant 
differences. 
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In a similar study, Ho and colleagues (2007) used a slightly lower dose of 
80mg daily isoflavone consumption, consumed by 80 women again during a six 
month intervention in a double-blind, randomised, placebo-controlled trial, as 
compared to 88 women on a placebo control. Women were aged between 55 
and 75 years and were of normal health, having never received any form of HRT. 
Women were assessed before and after intervention on tasks of memory, 
executive function, attention, motor control, language and visual perception. 
Overall, and in agreement with Kritz-Silverstein and colleagues, there were no 
significant differences across any cognitive measure between the isoflavone and 
placebo groups. It could be perhaps that the dose was too low in the Ho study, 
or that the 6 month period was too long and beneficia l effects were missed.  
Similar to studies by Duffy and colleagues (2003), and File and colleagues 
(2005); Hartley, Elsabagh and File (2004) assessed the beneficial role of soya and 
Gincosan (a natural combination of extracts from ginkgo, a herbal remedy f or 
cognitive problems experienced during the menopause) on frontal lobe 
functioning. Participants were asked to complete a test of rule reversal and 
shifting (as in File et al., 2001) and planning ability using the Stockings of 
Cambridge test (SoC). Overall, no significant differences were found between 
soya and gincosan users and placebo controls on completion of the rule reversal 
and shifting, and no significant differences were demonstrated by participants in 
learning new rules.  However, when participants were asked to reverse these 
rules, the soya groups performed significantly better at completing this more 
difficult component of the task than placebo controls. On completion of the SoC, 
those consuming soya in their diet after 12 weeks were able to pla n a task better 
than the placebo controls, also for the most difficult level of the task. The 
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information combined suggests that soya can help to improve frontal lobe 
mediated tasks, but this may be dependent on difficulty of the task, and also 
type of task. 
It should be considered that studies with small sample sizes have 
demonstrated an effect of isoflavone use on cognition (Chedraui, n = 45; Duffy 
and colleagues, n = 33; File and colleagues, n = 50) whereas studies which have 
included larger populations (Ho et al., 2007, n = 80; Kreijkamp-Kaspers et al., 
2004, n = 202; Fournier et al., 2007, n = 79) have found no effects of isoflavone 
use on cognition. Sample sizes can be seen in table 2.1.  
 
4.6 Isoflavones and the critical period hypothesis 
 
 
The effect of Isoflavones on cognition in menopausal women is less 
developed than the HRT literature, and the collective results do not point to any 
obvious theories. Core components of the literature have been summarised in 
table 2.1; and the content will be discussed over the next section. 
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Table 2.1:  A breakdown of the isoflavone literature including age of 
participant, duration of intervention, supplement potency, sample 
size and study outcome. 
Authors (and 
Date) 
Sample size 
(total count) 
Included 
age 
Study outcome 
Bryant et al. 
(2005) 
23 18-35 Improved verbal memory 
Chedraui 
(2011) 
45 40-59 Reduced menopausal symptoms 
Duffy et al. 
(2003) 
33 50-65 Benefits to memory and attention 
File et al. 
(2005) 
50 51-66 Benefits to non-verbal memory and SA 
File et al. 
(2001) 
 18-35 Benefits to verbal memory 
Ho et al. 
(2007) 
80 55-75 No differences on a large cognitive battery  
Hartley et al. 
(2004) 
57 51-66 Mixed results 
Kritz-
Silverstein et 
al. (2003) 
53 55-74 Mixed results 
Kreijkamp-
Kaspers et al. 
(2004) 
202 60-75 No effect on a large cognitive battery 
Fournier et al. 
(2007) 
79 48-65 No effects on WM or SA 
Authors (and 
Date) 
Duration of 
intervention 
Potency 
(daily) 
Tasks showing benefit of 
intervention 
Tasks which were 
unaffected 
Bryant et al. 
(2005) 
Two months 68mg  Verbal memory  
Duffy et al. 
(2003) 
12weeks 60mg  Wechsler short 
story 
 Delayed 
Matching to 
Sample test 
 Delayed picture 
recall 
 PASAT 
 Rule reversal 
 Planning ability 
 
File et al. 
(2005) 
Six weeks 60mg  Short term non-
verbal memory 
 Sustained 
attention task 
 Story recall 
 Picture recall 
File et al. 
(2001) 
Ten weeks 100mg  Rule reversal 
 Delayed picture 
recall 
 Letter fluency 
 Verbal fluency 
 Digit-Symbol 
Substitution 
 Digit 
Cancellation  
 PASAT 
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  Wechsler scale 
 category 
generation 
 
Fournier et al. 
(2007) 
Four months 70mg   STROOP 
 Pattern 
recognition 
 Benton Visual 
Retention Task 
 Visual-spatial 
WM 
 Verbal WM 
Hartley et al. 
(2004) 
Six weeks 
and Twelve 
weeks 
120mg  Task planning 
ability 
 Rule reversal 
and shifting 
 Planning ability 
Ho et al. 
(2007) 
Six months 80mg   Wechsler 
Memory Scale 
 Verbal fluency 
(EF) 
 Trail Making 
Test (EF) 
 Digit Span (A) 
 Digit vigilance 
(SA) 
 Motor control 
 Picture recall 
 Language 
 Visual 
perception 
 Global 
cognitive 
function 
Kritz-
Silverstein et 
al. (2003) 
Six months 110mg  Category fluency 
 
 Paragraph 
recall 
Kreijkamp-
Kaspers et al. 
(2004) 
12 months 99mg   MMSE 
 Rey Auditory 
Verbal 
Learning Test 
 Immediate 
recall 
 Delayed recall 
 Digit Span 
forward and 
reversed 
 Complex 
attention tasks 
 DSS 
 Trail making 
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Phytoestrogens have a relative likeness to the biological properties of the 
oestrogen receptor-beta subtype, and some RCTs have shown benefits to frontal 
lobe cognitions and verbal memory. However groups have been poorly defined, 
for example in the study by Duffy and colleagues (2003), where the researchers 
refer to participants as peri-menopausal, when they are between the ages of 50 
and 65 years suggesting the majority to in fact be post -menopausal.  
The effect of soy isoflavones on the cognitive performance of young peri-
menopausal women has been investigated in four studies, two of which report 
improved verbal memory (Bryant at al., 2005; File et al., 2001). File and 
colleagues (2001) 10-week study reported that 100 mg soy per day was 
associated with improved verbal and non-verbal episodic memory, mental 
flexibility, verbal fluency and planning ability in young women. Bryant and 
colleagues (2005) double-blind, randomised, placebo-controlled trial of 68 mg 
soy isoflavones per day administered in prepared soy food across two 
consecutive menstrual cycles found improvements on verbal memory only, and 
not for other cognitive functions. And finally, a study by Chedraui et al. (2011) 
demonstrated reduced menopausal symptoms in women aged between 40 and 
59 years of age. These studies confirm a beneficial role of isoflavone use in 
cognitive function for younger and peri -menopausal women in a handful of the 
large number of selected cognitive tasks.  
Studies using post-menopausal women demonstrate little difference in 
cognitive performance despite isoflavone use. Kreijkamp-Kaspers and colleagues 
(2004) found no effect of isoflavone use on cognition in 202 postmenopausal 
women aged 60 to 75 years. The researchers used a wide range of cognitive 
assessment material. Participants completed the MMSE as a global test for AD, the Rey 
 
 
201 
 
Auditory Verbal Learning Test as a measure of verbal episodic Memory (Schmidt, 1996), 
the Doors as a measure of visual memory (Davis, Bradshaw & Szabadi, 1999), the Digit 
Span test as a measure of attention and WM, list generation as a measure of verbal 
fluency, the Boston naming task for verbal competence and semantic retrieval, the digit 
symbol substitution test as a measure of perceptual speed (Wechsler, 1945) and the Trail 
making test as a complex attention and mental flexibility task. Data collection took one 
morning, which is quite a long period of examination, leading to cognitive exhaustion. It is 
not clear whether the tasks were counterbalanced in order to control for this. It is 
possible that the tasks selected were not suitable, however the cognitive test 
battery did include difficult, frontal lobe mediated tasks (such as the Trail making 
test). Tasks were also chosen due to being sensitive to oestrogen use in HRT studies. It is 
more likely that isoflavone use did not benefit cognitive performance in post -
menopausal women.  
Contrary to this, a handful of trials which have been conducted in 
postmenopausal women (although some used women as young as 45 years of 
age) ranging in duration from six weeks to one year, with doses of soy 
isoflavones between 60 to 100 mg/day have generally shown cognitive effects of 
soy isoflavones in terms of improvements in memory and frontal lobe function 
(Casini et al., 2006; File, Duffy, & Wiseman, 2002). Other st udies have suggested 
that the beneficial effects of isoflavones on cognition are confined to women 
within 10 years of the menopause suggesting that there may be a critical point 
for isoflavone activation (Kreijkamp-Kaspers et al., 2004; Kritz-Silverstien et al., 
2003). And to add final confusion; two recent studies both failed to find positive 
effects of 70-80 mg/d isoflavones on a range of cognitive functions in younger 
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and older postmenopausal women (Fournier et al., 2007; Ho et al., 2007). The 
studies have been summarised for age in table 2.1.  
Overall, research has been mixed in approach, using differing amounts of 
isoflavone per day, sometimes in one dose and sometimes in two daily, over 
different durations of time. Selected cognitive tasks have also dif fered in domain, 
and some studies have used two or three tasks, whereas others have used very 
large cognitive test batteries. These characteristics of relevant studies have been 
added to table 2.1 for clarity. 
 
4.7 Summary and study design 
 
 
Despite the disparity of results within the literature, there are still a 
handful of traits that can be taken from the successful studies to assist with 
study design. 
Duration of intervention 
The extent that phytoestrogens mimic oestrogen within the body is still 
unclear, and this may be dependent on the dose consumed. In most cases 
natural treatments have a less potent effect than pharmaceuticals and therefore 
may take more time to have an effect. They may not show effect as quickly as 
pharmaceuticals. Studies that have demonstrated a positive effect of isoflavones 
on cognitive function have ranged from six weeks to six months. Of these studies, 
two have shown isoflavones to have a significant improvement on episodic 
memory after 12 weeks (Duffy et al., 2003) and six weeks (File et al., 2005) of 
isoflavone consumption. Two have shown improvements in SA after 12 weeks 
(Duffy et al., 2003) and six weeks (File et al., 2005) of isoflavone consumption. 
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And three studies have demonstrated improved executive function after ten  
(Kritz-Silverstein et al., 2003) and six or 12 weeks (Hartley et al., 2004) of 
isoflavone consumption. Studies that have used longer than three months 
duration (Fournier et al., 2007; Ho et al., 2007; Kreijkamp-Kaspers et al., 2004) 
have demonstrated no effect of isoflavone intervention on executive function 
including SA. For this reason, greater than 12 week’s isoflavone use is seen as 
inappropriate. Duffy and colleagues (2003) have included the SART in their study, 
and another SA attention task, demonstrating positive effects of 12 weeks 
isoflavone use on SA. Twelve weeks of isoflavone consumption is manageable, 
appropriate and thus cost effective. 
Daily dose of isoflavone  
Llaneza and colleagues (2010) recommend that at least 40 mg of soy 
isoflavones should be prescribed in each routine clinical practice for treatment 
of menopausal symptoms. However clinical trials have suggested that around 
100mg daily is more appropriate. Chedraui and colleagues (2011) identified a 
positive effect of soy isoflavones on hot flushes and mood when participants 
were asked to consume 100mg of isoflavones (one tablet) daily over a three 
month period. Ho and colleagues (2007) used a slightly lower dose of 80mg daily 
of isoflavone consumption and found no differences in executiv e function 
including SA between users and a placebo control. Fourier and colleagues (2007) 
also found no effect on executive function including SA, WM and verbal WM 
when initiating 70mg daily. It could be perhaps that these doses were too low to 
benefit executive function. Providing participants with three months 
100mg/daily isoflavone is not only more cost effective (and reduces risk of drop -
out rate) but also appropriate based on previous literature.  
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Isoflavone product 
It is not clear whether soy food products or an isoflavone supplement 
tablet are better for menopausal symptoms. File and colleagues (2001) used 
food products in their study, and found no benefits on SA using the PASAT, 
unlike Duffy and colleagues (2003), who used a supplement tablet and did find 
improvements in SA. Some have suggested that natural forms of isoflavone such 
as those found in soya milk are more beneficial in reducing menopausal 
symptoms than the supplement (Cassidy, 2004). Phytoestrogens can be found in 
smaller quantities in certain fruits, cereals and flaxseed (Rowland et al., 2003) 
and it should be considered that there is much variability in concentration of 
phytoestrogen in soya products. Generally, there is four mg of isoflavone per 
gram of protein, making a glass of soya milk (300ml) contain on average 40 – 50 
mg isoflavone, so participants would need to drink 600ml of soya milk to achieve 
the 100mg daily dose that the literature suggests is effective. For this reason, 
the isoflavone supplement might be an easier to handle source of soy than soy 
containing foods in intervention studies. In addition to this, for the present 
study design it is far more cost effective and convenient to use isoflavone tablets 
which can be given to the participant at the start of the intervent ion for them to 
administer once daily. It is also easy to substitute an isoflavone tablet with a 
placebo tablet. The content of each isoflavone tablet will ensure that the 
participant receives the target amount in one dose (100mg of isoflavone per day) 
rather than expecting them to consume large amounts of food or drink to gain 
the approximate amount. 
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Age of participant/stage in the menopause 
To specifically test the effect of age on susceptibility to isoflavone; Ho 
and colleagues (2007) looked at the effect of isoflavone compared to a placebo 
in women aged 55 - 65 years, and 65 - 75 years of age and found no differences 
in cognitive performance after six months daily consumption of 80mg of 
isoflavone verses a placebo. It can be argued that both age groups being 
investigated were post-menopausal and therefore too similar in cognitive 
performance other than slight aging effects. None-the-less, a lack of effect in the 
post-menopausal groups could still support the critical period hypothesis in 
these cases, and it would be better to compare performance to a younger, peri -
menopausal age group based on last menstrual bleed. This will also allow for 
‘stage’ to be defined by symptoms, and not age.  
Task selection 
Previous isoflavone research has focused on episodic m emory. To test 
episodic memory; several studies as mentioned above have used Wechsler ’s 
short story recall task. Of these, two have shown a significant improvement after 
twelve weeks (Duffy et al., 2003) and six weeks (File et al., 2005) of soya 
consumption. In the same studies, significant improvements in performance of 
the Delayed Matching To Sample test (DMTS) has tested short term; non -verbal 
memory, as well as following twelve weeks of Gincosan treatment (Hartley et al., 
2004). Participants demonstrated increased picture recall ability after 12 weeks 
(Duffy et al., 2003) and six weeks (File et al., 2005) of soya consumption; and 12 
weeks and six weeks (Hartley et al., 2004) of Gincosan treatment. The Wechsler 
short story recall has also been used in the past to demonstrate problems in 
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verbal WM associated with oestrogen change during the menstrual cycle and the 
menopause (Sherwin, 1994) but is actually designed to measure short term 
memory. Study one also demonstrated that Engle’s WM tasks are sensitive to 
oestrogen and can be used to test specific effects of oestrogen change (or 
isoflavone use) on WM function. 
SA tasks have given equally mixed results in isoflavone literature. Studies 
by Duffy and colleagues (2003), File and colleagues (2005) and Hartley  and 
colleagues (2004) failed to show significant differences between soya and 
Gincosan users in two tasks of frontal lobe functioning; a test of rule reversal 
and shifting (IDED) and planning ability using the SoC. However when a more 
complex rule was added to the IDED the soya groups performed significantly 
better at completing this component of the task. This suggests that, like WM 
tasks, the selected SA task will need to incorporate a certain level of difficulty in 
order to be sensitive enough to measure cognitive change between isoflavone 
users and placebo controls. The SART achieves this and has been developed to 
detect subtle impairments of attention.  
Studies that have demonstrated a difference in SA between isoflavone 
users and placebo controls also seem to be dependent on duration of the 
intervention. Specifically, SA appears to be positively affected by soya 
consumption over a 12 week period but not a six week period. Studies 
demonstrating an effect of isoflavone use on SA such as those by Duffy and 
colleagues (2003) and File and colleagues (2005) have used the PASAT. The 
PASAT is frequently used by neuropsychologists to measure attentional 
processing (Gordon & Zillmer, 1997), and this includes assessment of TBI 
patients with damage to the PFC (Tombaugh, 2006).  The PASAT has been used 
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as a measure of SA (Spreen & Strauss, 1998) and WM in the form of divided 
attention (Audoin et al., 2003; Cicerone & Azulay, 2002; Webb & Ochs, 2003). 
The task involves adding together successive pairs of digits read from a list of 61 
numbers presented at different speeds. Due to the increase in speed of 
presentation of the digits across trials, the task becomes very chal lenging and 
this is demonstrated by low percent of correct responses (Tombaugh, 2006). 
Difficulty level in cognitive tasks has been demonstrated to be sensitive to 
oestrogen change and because the PASAT has different levels of difficulty it can 
be manipulated for the present study. 
It was decided to continue with the use of the SART as a measure of SA 
and to also include the PASAT to replicate previous isoflavone studies. Both 
tasks are easy to administrate and quick to complete.  
Oldenhave, Jaszmann, Haspels and Everaerd (1993) and Ledesert, Ringa 
and Breart (1995) show a relationship between menopausal status and QoL in 
both peri-menopausal and post-menopausal women, where those with poor QoL 
experience worsened menopausal symptoms. For this reason it is im portant to 
consider factors that may contribute to better QoL. The role of women’s 
employment status can have effect on QoL, both mentally and physically. P. 
Jacobs and colleagues (2000) suggest that working outside of the home can have 
a positive effect on MQoL. They point out that those reaching retirement age are 
also likely to be at the end of the climacteric change. Their data suggests that 
some of the decline in QoL at the end of the menopause may be reflecting other 
social changes in women’s lives associated with ageing rather than hormonal 
changes, making it reasonable to request employment status. It also further 
determined the necessity to include age. P.Jacobs, Hyland and Lay concluded 
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that there is a relationship between self-rated menopausal status and QoL, and 
between lifestyle and QoL. They also include the importance of medical history. 
For these reasons, the full MQoL scale was included as well as details of 
participants’ current medication, how often in the past few months they had 
visited a GP and whether they were suffering from any current chronic 
conditions. By using the full MQoL scale and additional health questions, balance 
between groups for menopausal symptoms can be checked, as well as potential 
impacting factors such as other supplements used. The physical symptoms of hot 
flushes, sleep disturbance and lowered mood, for example, are associated with 
changes in cognition (Joffe, Soares, & Cohen, 2003). By using all items of the 
MQoL scale, a large proportion of impacting symptoms will  be taken into 
consideration.  
Expected outcomes 
Generally the isoflavone literature complements earlier findings of HRT 
studies whereby intervention can result in improvements to menopausal 
symptoms (mainly hot flushes, some cover on bone density and cogn ition, verbal 
memory). Isoflavone literature has demonstrated improvements in attention and 
cognition in isoflavones users as compared to placebo controls, but not in all 
cases. Whether improvements to menopausal symptoms are dependent on time 
of administration of isoflavones relative to onset of the menopause is yet to be 
clarified. Due to the undefined and confused nature of the literature, expected 
outcome is difficult to define in this case. Finally, whether outcome depends on 
time of administration relative to the menopause will be tested. 
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4.8 Method 
 
Study Two, Stage One (Baseline) 
Participants   A total of 55 peri-menopausal women (last menstrual 
bleed within 12 months) and 57 post-menopausal women (last menstrual bleed 
in excess of 12 months; total number = 112) between 45 and 65 years of age 
with normal health were recruited within the Plymouth and London areas 
through use of internet advertisement, word of mouth and advertisement 
throughout Plymouth University. Women were randomly assigned into either 
placebo (53) or intervention (59) groups. The lead researcher asked co -workers 
to arrange and number the supplements and placebo before they were 
dispatched to participants; numbers were later matched to the supplement or 
placebo for data entry. Groups were divided based on peri -menopausal and 
post-menopausal stage (as per baseline). Participants fitted one of the four 
levels of study status accordingly; Isoflavone users peri-menopause (n = 29), 
isoflavone users post-menopause (n = 30), placebo users peri-menopause (n = 26) 
and placebo users post-menopause (n = 27). 
Participants were asked to consume one tablet daily (100mg of isoflavone 
or a flour pill) over a three month period. All participants were given the same 
instructions for partaking in the intervention, that one pill should be taken daily 
with breakfast, and that if a pill was missed during two consecutive days or more 
than five times on separate occasions across the three months that they should 
contact the researcher straight away. Participants were healthy with normal 
ovarian functioning leading to the menopause (those with one or two ovaries 
removed, the uterus part or fully removed, or a combination were excluded from 
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the study). Participants were excluded if they suffered from any cognitive 
degenerative disease, had a history of (or directly related to a descendant with) 
cancerous cells, having a history of HRT use, suffered from learning difficulties 
(such as dyslexia, which may interfere with the memory tasks) and were asked to 
be fluent in English.   
 
Measures  Participants provided informed consent. To measure SA, 
the SART was selected for its easy use and low cognitive load/strain. For a 
concise account of SART please refer to the measures section of study one, stage 
one (page 87). As an additional measure of SA, participants were asked to 
complete the PASAT. The PASAT requires participants to add consecutive 
numbers as they are presented on an auditory tape and respond orally with the 
accurate sum. As each digit is presented, the participant must sum that number 
with the digit that was presented prior to it (rather than with the previous 
response). An example is shown below. 
 The participant hears the starting number ‘three’ followed by ‘five’.  
 The participant must add the five to the three and say ‘eight’ out loud to 
earn one point. 
 The participant hears the following number; the number ‘ two’. 
 The participant must add the two to the previous number heard (five) 
whilst ignoring their previous response (eight). The participant would be 
expected to respond ‘seven’ to earn one point.  
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A sequence and the correct response are as follows: 
 
3…   5…   2…      9… etc 
 
 
Additional forms of the PASAT, which vary in length of the inter-stimulus 
interval and the number of trials, have been developed for use in research and 
clinical practice (Sherman et al., 1997; Potter & Barrett, 1999). The standard 
form consists of sixty-one single digits presented in four trials. The trial begins 
with inter-stimulus intervals of 2.4 seconds and this time decreases by 0.4 
seconds on each of the subsequent trials (Gronwall, 1977). Experimenters can 
gauge PASAT performance on the average amount of time needed to produce an 
accurate response by trial. In this version the researchers used three stages to 
the PASAT identical to the design used in studies by File (2005) and Duffy (2003). 
The first trial has been set intervals of 2.7 seconds between the stimuli. The 
second trial has set intervals of 2.0 seconds. A final  trial, with intervals of 1.6 
seconds between stimuli. The task was selected to measure SA. In the Duffy 
paper, one more optional trial was used with intervals of 1.2 seconds between 
stimuli, but it was agreed that this speed was too quick, unrealistic, and put 
participants under too much strain to use in this trial. Thus, three trials with 
accelerating speed were used. 
The 5 gets 
added to 
the 3 
The 9 gets 
added to 
the 2 
The 2 gets 
added to 
the 5 
Participant 
says “8” 
Participant 
says “11” 
Participant 
says “7” 
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To measure WM, two of Engles’ WM tasks were selected including RSpan 
and OSpan as a sensitive and thorough measure of WMC (as demonstrated in 
study one). For a concise account of these WM tasks, please refer to the 
measures section of study one, stage one (pages 83-86).  
To measure mood, participants were asked to complete the GHQ-12 (see 
study one, stage one on page 88). The 12 items were scored and added to a total. 
Participants were asked to complete all 42 items of the MQoL scale, rather than 
the shortened version used in study one. As before, they were asked to respond 
to the range of menopausal symptoms by rating that symptom on a six point 
scale to how strongly they had been feeling it over the past few months. For 
example; participants would be asked “I can concentrate easily” to which they 
would response from “I am never like this” to “I am always like this” over a si x 
point scale. Items were scored and added to a total.  A full version of the MQoL 
scale can be found in appendix A; page 290. 
Individuals were asked for their age, level of education. Details of the 
menopause were requested to determine whether the participant was peri or 
post-menopausal according to the approximate date of their last menstrual 
bleed. The questionnaire enquired into possible sources of natural oestrogens in 
the body, such as soya supplements. Details regarding general physical health 
including medication taken, visits to the local GP within three months and any 
chronic conditions were recorded. Participants were asked to highlight food 
groups which dominated their diet, how many times a month they exercised 
(minimum of 30 minutes for each session) and if they were smokers or non-
smokers. To conclude, participants were asked about their general thoughts on 
cognition and the menopause, and whether one can affect the other. These 
 
 
213 
 
where categorised and scored. The included questions can be found in appendix 
A, page 287. 
Procedure  Participants completed the study on University campus or 
in their own homes. Participants were asked to complete the SART on a lap top 
using the space bar to respond. They were then asked to complete the PASAT by 
listening to the audio recording as the researcher wrote down their verbal 
responses. This was then followed by the RSpan and the OSpan on the lap top, to 
which the researcher recorded responses. As counter -balancing the tasks had no 
effect on the results of study one, tasks were not counterbalanced this time. 
Participants were then presented with the GHQ-12, the MQoL scale and 
biographical questionnaire on paper, and asked to respond to each item where 
possible.  
 
Study Two, Stage Two (first follow up) 
Participants  A total of 104 women returned to complete the study. This 
included 25 (of 29) peri-menopausal isoflavone users, 24 (of 26) peri -
menopausal placebo users, 29 (of 30) post-menopausal isoflavone users and 26 
(of 27) post-menopausal placebo users. 
Measures  Participants were asked to complete the same test battery 
three months later to assess potential effects of the intervention against 
baseline. A short questionnaire recorded any changes since the last meeting. 
Specifically, participants were asked if they had experienced any changes to the 
menopause, including if peri-menopausal, whether they had initiated HRT, if 
there were any changes to their supplement intake, details regarding general 
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physical health including medication taken, v isits to the local GP within three 
months and any newly developed health conditions were recorded.  
Procedure  Participants were contacted every four weeks by email 
and/or telephone to check how they were fairing with the supplements. Two and 
a half months after the initial assessment, participants were contacted via email 
and/or telephone to arrange a follow up appointment to coincide within the 
week of their last supplement intake. Participants completed the study on 
University campus or in their own homes as previous.  
Participants were asked to complete the SART, the PASAT, the RSpan, the OSpan, 
the GHQ-12, the MQoL scale and the biographical questionnaire as per baseline.  
 
 
Study Two, Phase Three (final follow up) 
 
Participants   A total of 97 women returned to complete the study. This 
included 23 peri-menopausal women in the intervention group, 27 post -
menopausal in the intervention group, 23 peri-menopausal women in the control 
group and the remaining 24 being post-menopausal placebo controls. 
 
Measures  Participants were asked to complete the same test battery 
to assess intervention against baseline. A short questionnaire recorded any 
changes since the last meeting. In addition to the previous two meetings, at the 
end of the trial participants were provided with information regarding the study 
and a Marks and Spencer voucher (to the value of £20) as a thank you for their 
time. 
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Procedure  Two and a half months after the first follow up assessment; 
participants were contacted via email and/or telephone to arrange a final 
appointment to assess the potential lasting effects of the supplement after a 
three month break from the treatment. Participants completed the study on 
University campus or in their own homes as previous. 
Participants were asked to complete the SART, the PASAT, the RSpan, the 
OSpan, the GHQ-12, the MQoL scale and the biographical questionnaire as per 
baseline.  
4.9 Results 
 
 A total of 97 women aged between 45 and 64 years of age com pleted all 
three stages of the study. Of these, 46 women were peri -menopausal and 51 
women were post-menopausal. A total of 50 women were given a three month 
isoflavone intervention and these women were compared to 47 women who 
unknowingly received three months of a placebo. Over all; 23 women in the 
intervention group were in their peri-menopausal stage, with the remaining 27 
being post-menopausal. And 23 women in the control group were in their peri -
menopausal stage with the remaining 24 being post-menopausal. 
Table 2.2 shows mean age, months since last menstrual bleed, GHQ-12 
and MQoL scores, GP visits and count of chronic conditions, those using 
medication and those using other supplements across the four study groups.  
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Table 2.2: Mean (and standard deviation) age (years), months since last 
menstrual bleed (months), GHQ-12 score, MQoL score, GP visits in 
past three months, count of chronic conditions, medication use 
and supplement use for the four groups 
 Peri-
menopausal 
controls 
Peri-
menopausal 
intervention 
Post-
menopausal 
controls 
Post-
menopausal 
intervention 
 
Age (years) 
 
48.96 (3.88) 
 
50.38 (3.87) 
 
54.37 (7.72) 
 
55.10 (4.20) 
 
 
Last menstrual 
bleed (months) 
 
4.00 (7.50) 
 
4.07 (4.80) 
 
56.48 (46.99) 
 
64.73 (44.01) 
 
GHQ-12 
 
 
23.66 (4.24) 
 
23.65 (5.63) 
 
25.70 (6.70) 
 
24.78 (5.36) 
 
MQoL 
 
186.15 (31.62) 
 
195.19 (45.60) 
 
196.20 (37.56) 
 
181.46 (36.30) 
 
 
Mean GP visits 
 
0.76 (0.95) 
 
0.85 (1.08) 
 
1.27 (1.28) 
 
1.19 (1.12) 
 
Count of 
chronic 
conditions 
 
18 
 
17 
 
21 
 
15 
Count of 
medication use 
 
19 
 
17 
 
21 
 
17 
 
Count of other 
supplements 
 
19 
 
15 
 
19 
 
17 
 
 
The average age of participants was 52.28 years (SD = 4.87) with an upper 
age of 64 years and a lower age of 45 years. The two peri -menopausal groups are 
matched for age, as are the two post-menopausal groups. The two peri-
menopausal groups are also matched for time since last menstrual bleed, as are 
the two post-menopausal groups. 
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The GHQ-12 was scored conventionally (as in study one). Individual 
scores of the GHQ-12 were explored to see if the dynamics in the studies 
population were normally distributed. Table 3.1 shows the average score of the 
GHQ-12 across each group (lower scores representing worse mood). The 
sample’s mood scores were normally distributed across groups, and groups did  
not differ between mean mood score dependant on phase (F(1,108) = 2.27, p 
= .14, d = .021) supplement use (F(1, 108) =0 .19, p = .66, d = .002) or the 
interaction between the two (F(1, 108) = 0.19, p = .66, d = .002). 
The MQoL was scored conventionally (as in study one). Participants rated 
48 items and could score between 48 and 288. Differing from the GHQ -12, a 
higher score represents greater QoL. Average MQoL scores per group can be 
seen in table 3.1.  The sample’s mood scores were normally distributed a cross 
groups, and groups did not differ between mean MQoL score dependant on 
phase (F(1, 108) = 0.04, p = .84, d = .001) supplement use (F(1, 108) = 0.10, p 
= .75, d = .001) or the interaction between the two (F(1, 108) = 1.78, p = .19, d 
= .023). 
To check the health status of participants, women were asked how many 
times they had visited their GP in the past three months, whether they suffered 
from any chronic conditions, whether they were smokers, whether they were 
receiving medication and whether they were receiving other supplements. 
Details can be seen in table 3.1. 
Of the total population, 66.1% (n = 74) stated that they were taking 
medication at time of completion of the study. Medication use did not differ 
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between peri- and post- users; X2(1, n = 112) = .02, p = .89, or between 
supplement and placebo users; X2(1, n = 112) = .17, p = .68. 
Participants were also asked if they suffered from a chronic condition, to 
which 63.4% of the population (n = 71) indicated that they suffered from a 
chronic condition. Most frequent conditions included underactive thyroid, 
asthma and general aches and pains. The total count of reported conditions can 
be seen in table 2.3. Count of chronic condition did not differ between peri - and 
post- users; X2(1, n = 112) = .00, p = .96, or between supplement and placebo 
users; X2(1, n = 112) = .39, p = .53. 
 
Table 2.3: Count of reported chronic conditions across the total group  
Condition Count 
Allergies 3 
Asthma 20 
Chromes disease 2 
Diabetic 2 
HBP 7 
High cholesterol 2 
Insomnia 1 
IBS 3 
Low mood 7 
Migraine 4 
Osteoporosis/Arthritis/ 
Back/bone pain 18 
Underactive thyroid 11 
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Participants were asked if they were taking any other supplements. This 
was of interest, as it was expected that most women taking part in the study 
would already be consuming supplements as a part of their daily diet. A high 
proportion of participants (62.5%, n = 70) were already taking other 
supplements/vitamins. Supplement use did not differ between peri- and post- 
users; X2(1, n = 112) = .02, p = .88, or those with and without a history of HRT 
use; X2(1, n = 112) = .19, p = .66. Most frequent supplement use included 
Vitamin B, calcium, cod liver oil and multi-vitamins. Because of the high 
frequency of those taking supplements, it  was assumed that these women would 
be used to the daily regime of supplement use. Those already including soy in 
their daily diet indicated that they were not consuming a large enough quantity 
to reflect the 100mg dose in the current study (for example, s oya milk). For this 
reason they did not need to be excluded from the study. Descriptions and 
frequencies of these supplements can be seen in table 2.4.  
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Table 2.4: Count of reported supplements/vitamins 
Supplement Count 
Anti-oxidant 2 
Calcium 17 
Cod liver/fish oils/ essential fatty 
oils 17 
Garlic 2 
Glucosamine 7 
Multi Vit 17 
Primrose 9 
Selenium  3 
Soya 6 
Vit B/iron/folic acid 19 
Vit C 9 
Vit D 4 
 
Participants were asked for their highest level of education. Total count 
of highest level of education across intervention groups are seen in table 2.5. 
 
Table 2.5: Count of education level across intervention groups  
 Peri-
menopausal 
intervention 
Peri-
menopausal 
placebo 
Post-
menopausal 
intervention 
Post-
menopausal 
placebo 
Alevel 8 7 3 3 
GCSE 5 4 4  
Postgrad 8 2 10 10 
Professional    2 
Undergraduate 8 13 13 12 
 
Level of education did not differ between peri - and post- users; X2(1, n = 
112) = 11.43, p = .22, or supplement and placebo users; X2(1, n = 112) = 5.21, p 
= .27. 
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The groups were similar in terms of mental and physical health, 
education and employment. The peri-HRT and peri-control groups matched each 
other for age. The post-HRT and post-control groups also matched each other for 
age and were older than the peri-groups. 
RSpan had a strong positive correlation with OSpan (r = .756, p < .001) 
suggesting that as performance of one WM task increased, so does the other 
establishing that the combinations of these tasks will are a strong measure of 
WM. The RSpan correlated with PASAT-1 score (r = .397, p < .001), as did OSpan 
(r = .483, p < .001) suggesting that as WM score increases, so does SA score. The 
RSpan also correlated with the more difficult PASAT-2 score (r = .312, p = .001), 
as did OSpan (r = .341, p < .001), further suggesting that as WM score increases, 
so does SA score. OSpan and RSpan, and PASAT-1 and PASAT-2 did not correlate 
with age. 
The PASAT-1 correlated with MQoL score (r = .339, p = .002), as did the 
PASAT-2 (r = .302, p = .008) that QoL is associated with better SA. For this reason 
it is necessary to use MQoL score as a covariate for the PASAT. OSpan correlated 
with GHQ-12 score in the final phase of data collection only (r = .249, p = .011) 
and for this reason it was not seen as appropriate to use as a cov ariate. 
A repeated measures design was used to test the effects time of 
intervention on cognitive performance. Analysis embraced a nested design, to 
test main effects of HRT use (or non-use) and stages in the menopause (peri or 
post depending on time of last menstrual bleed) and the predicted interaction 
between the two. Age was used as a covariate despite not correlating with task 
performance in this sample for reasons described in study one. For the PASAT, 
 
 
222 
 
MQoL was also used as a covariate due to its correlation with performance. 
Reaction time was used as a covariate for the SART. No other appropriate 
correlations for covariates were found.  
 
WM: RSpan 
Table 2.6 shows the mean WM score for each stage of the RSpan across group.  
 
Table 2.6:  Mean RSpan score (and standard deviation) for baseline, three month 
and six month follow up 
 
  Intervention Mean score SD 
  Baseline  
Peri-menopausal Placebo 32.74 6.59 
 Isoflavone 30.67 5.21 
Post-menopausal Placebo 29.28 5.93 
 Isoflavone 30.14 5.48 
Total  30.65 5.83 
  Three months  
Peri-menopausal Placebo 33.70 6.81 
 Isoflavone 31.93 5.88 
Post-menopausal Placebo 29.72 6.02 
 Isoflavone 31.54 6.27 
Total  31.67 6.08 
  Six months  
Peri-menopausal Placebo 33.44 6.96 
 Isoflavone 33.58 5.14 
Post-menopausal Placebo 30.18 5.72 
 Isoflavone 30.92 5.18 
Total  30.53 5.85 
 
The data were normally distributed and Levene’s test of equality of error 
variances was non-significant (p = .39). Sphericity was assumed (Mauchley’s test: p = .07). 
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A 3 (Time of measurement: baseline, three months and six months) x 2 (Menopause 
phase: peri- and post) x2 (Intervention: placebo and isoflavone) mixed ANCOVA was 
conducted with menopause phase and intervention as between factors, and time of 
measurement as within factor. 
There was a significant difference between peri- and post-menopausal users 
overall (p = .017) showing better performance in the peri-menopausal group. A t-test 
showed a difference in mean score between peri-menopausal (mean = 33.24, SD = 6.02) 
and post-menopausal women (mean = 30.42, SD = 5.40) at stage three of the RSpan (p 
= .014). Overall, no main effect of intervention was found (p = .60), and intervention did 
not interact with menopausal phase (p = .24).  
Taking into account the within factor of time of measurement the results show 
that the scores on Rspan across the trials did not depend on the type of intervention that 
participants were given (placebo vs. isoflavone). That is, time of measurement did not 
interact with the intervention (F(2, 196) = 0.96; p = .01; partial ƞ2 = .01). Time of 
measurement did not interact with menopausal phase (F(2, 196) = 2.87; p = .58; partial ƞ2 
= .008).   And no significant three-way interaction was found between time of 
measurement, intervention, and menopausal phase (F(2, 196) = 1.71; p = .18; partial ƞ2 
= .017). No further analysis was needed. 
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OSpan 
Table 2.7 shows the mean WM score for each stage of the OSpan across group.  
 
Table 2.7:  Mean OSpan score (and standard deviation) for baseline, three 
month and six month follow up 
 Intervention Mean score SD 
  Baseline  
Peri-menopausal Placebo 35.65 6.67 
 Isoflavone 33.63 4.84 
Post-menopausal Placebo 30.88 5.47 
 Isoflavone 31.46 6.64 
Total  32.83 6.14 
  Three months  
Peri-menopausal Placebo 35.57 6.94 
 Isoflavone 34.59 5.00 
Post-menopausal Placebo 31.10 5.93 
 Isoflavone 32.57 6.62 
Total  33.42 6.28 
  Six months  
Peri-menopausal Placebo 36.26 6.39 
 Isoflavone 34.07 4.80 
Post-menopausal Placebo 30.32 5.43 
 Isoflavone 32.43 6.66 
Total  33.20 6.15 
 
The data were normally distributed and Levene’s test of equality of error 
variances was non-significant (p = .121). Sphericity was assumed (Mauchley’s test: p 
= .058). A 3 (Time of measurement: baseline, three months and six months) x 2 
(Menopause phase: peri- and post) x2 (Intervention: placebo and isoflavone) mixed 
ANCOVA was conducted with menopause phase and intervention as between factors, and 
time of measurement as within factor. 
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There was a significant difference between peri- and post-menopausal users 
overall (p < .001) showing better performance in the peri-menopausal group. The 
difference is prominent at all three stages. At stage one, a t-test showed a difference in 
mean score between peri-menopausal (mean = 33.93, SD = 6.02) and post-menopausal 
women (mean = 30.98, SD = 5.97, p = .011). At stage two, a t-test showed a difference in 
mean score between peri-menopausal (mean = 34.42, SD = 6.27) and post-menopausal 
women (mean = 31.53, SD = 6.30, p = .017). And at stage three, a t-test showed a 
difference in mean score between peri-menopausal (mean = 35.08, SD = 5.63) and 
post-menopausal women (mean = 31.43, SD = 6.14) at stage three of the OSpan (p 
= .002). Overall, no main effect of intervention was found (p = .60), and intervention did 
not interact with menopausal phase (p = .19). 
Taking into account the within factor of time of measurement the results show 
that the scores on Ospan across the trials did not depend on the type of intervention that 
participants were given (placebo vs. isoflavone) and time of measurement did not 
interact with the intervention (F(2,196) = 1.47; p = .233; partial ƞ2 = .015). Time of 
measurement did not interact with menopausal phase (F(2, 196) = 0.51; p = .58; partial ƞ2 
= .013).   And no significant three-way interaction was found between time of 
measurement, intervention, and menopausal phase (F(2,196) = 1.69; p = .188; partial 
ƞ2 = .017). No further analysis was needed. 
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SA - PASAT-1 
PASAT-1 scores were marked out of 60. Participants were asked to 
calculate 60 sums in two minutes 42 seconds, being the easier of the two PASAT 
tasks. Table 2.8 shows the average SA score for the PASAT across group at baseline, 
three months and six months following.  
 
Table 2.8:  Mean PASAT-1 score (and standard deviation) for baseline, three month 
and six month follow up 
 
 Intervention Mean score SD 
  Baseline 9.27 
Peri-menopausal Placebo 51.36 7.05 
 Isoflavone 50.41 8.26 
Post-menopausal Placebo 47.00 5.62 
 Isoflavone 46.78 7.37 
Total    
  Three months  
Peri-menopausal Placebo 51.57 8.90 
 Isoflavone 52.82 5.28 
Post-menopausal Placebo 48.45 8.41 
 Isoflavone 49.60 5.33 
Total  50.61 6.75 
  Six months  
Peri-menopausal Placebo 51.71 8.56 
 Isoflavone 53.71 5.12 
Post-menopausal Placebo 47.55 9.08 
 Isoflavone 50.04 7.01 
Total  50.88 7.44 
 
The data were normally distributed and Levene’s test of equality of error 
variances was non-significant (p = .328). Sphericity was not assumed (Mauchley’s test: p 
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= .002). A 3 (Time of measurement: baseline, three months and six months) x 2 
(Menopause phase: peri- and post) x2 (Intervention: placebo and isoflavone) mixed 
ANCOVA was conducted with menopause phase and intervention as between factors, and 
time of measurement as within factor. 
There was no difference between peri- and post-menopausal users overall (p 
< .69). Overall, no main effect of intervention was found (although this was marginal; p 
= .056), and intervention did not interact with menopause phase (p = .56). 
Taking into account the within factor of time of measurement the results show 
that the scores on PASAT-1 across the trials did not depend on the type of intervention 
that participants were given (placebo vs. isoflavone) and time of measurement did not 
interact with the intervention (F(2,122) = 2.90; p = .070; partial ƞ2 = .045). Time of 
measurement did not interact with menopausal phase (F(2, 196) = 0.04; p = .21; partial ƞ2 
= .058).   And no significant three-way interaction was found between time of 
measurement, intervention, and menopause phase (F(2,122) = .074; p = .896; partial 
ƞ2 = .001). 
 
 
 
 
 
 
 
 
 
228 
 
PASAT-2 
Participants were asked to calculate 60 sums in two minutes, becoming a 
more challenging task. Table 2.9 shows the average SA score for the PASAT 
across group at baseline, three months and six months following.  
 
Table 2.9:  Mean PASAT-2 score (and standard deviation) for baseline, three month 
and six month follow up 
 
 Intervention Mean score SD 
  Baseline  
Peri-menopausal Placebo 35.93 8.46 
 Isoflavone 37.06 9.90 
Post-menopausal Placebo 32.27 6.66 
 Isoflavone 33.19 7.63 
Total  34.55 8.31 
  Three months  
Peri-menopausal Placebo 36.79 9.33 
 Isoflavone 37.71 11.15 
Post-menopausal Placebo 31.10 7.48 
 Isoflavone 35.81 12.02 
Total  35.72 10.67 
  Six months  
Peri-menopausal Placebo 37.93 11.14 
 Isoflavone 39.53 10.02 
Post-menopausal Placebo 33.73 7.52 
 Isoflavone 37.00 10.30 
Total  37.29 9.97 
 
The data were normally distributed and Levene’s test of equality of error 
variances was non-significant (p = .175). Sphericity was assumed (Mauchley’s test: p = .56). 
A 3 (Time of measurement: baseline, three months and six months) x 2 (Menopause 
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phase: peri- and post) x2 (Intervention: placebo and isoflavone) mixed ANCOVA was 
conducted with menopause phase and intervention as between factors, and time of 
measurement as within factor. 
As can be seen in Table 3.13 mean scores between each group for the PASAT-2 
are slightly more diverse then PASAT-1, probably due to the increased difficulty of the 
task, SDs being larger. There was no difference between peri- and post-menopausal users 
overall (p = .72). Overall, no main effect of intervention was found (p = .45), and 
intervention did not interact with menopause phase (p = .48).  
Taking into account the within factor of time of measurement the results show 
that the scores on PASAT-2 across the trials did not depend on the type of intervention 
that participants were given (placebo vs. isoflavone) and time of measurement did not 
interact with the intervention (F(2,196) = 948; p = .390; partial ƞ2 = .015). Time of 
measurement did not interact with menopausal phase (F(2, 196) = 0.27; p = .77; partial ƞ2 
= .004).   And no significant three-way interaction was found between time of 
measurement, intervention, and menopause phase (F(2,196) = 471; p = .626; partial 
ƞ2 = .008). Nor further analysis was needed. 
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SART 
Table 2.10 shows the mean SART across group at baseline, three months 
and six months following. A lower score represents better SA attention.  
 
Table 2.10:  Mean SART score (and standard deviation) for baseline, three 
month and six month follow up 
 Intervention Mean score SD 
  Baseline  
Peri-menopausal Placebo 6.70 3.32 
 Isoflavone 6.37 2.90 
Post-menopausal Placebo 7.60 2.36 
 Isoflavone 7.50 4.12 
Total    
  Three months  
Peri-menopausal Placebo 5.87 3.47 
 Isoflavone 6.60 2.93 
Post-menopausal Placebo 7.84 3.84 
 Isoflavone 7.29 4.19 
Total    
  Six months  
Peri-menopausal Placebo 5.96 2.64 
 Isoflavone 6.78 2.94 
Post-menopausal Placebo 7.92 2.97 
 Isoflavone 7.28 3.35 
Total  7.00 3.04 
 
The data were normally distributed and Levene’s test of equality of error 
variances was non-significant (p = .60). Sphericity was assumed (Mauchley’s test: p = .11). 
A 3 (Time of measurement: baseline, three months and six months) x 2 (Menopause 
phase: peri- and post) x2 (Intervention: placebo and isoflavone) mixed ANCOVA was 
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conducted with menopause phase and intervention as between factors, and time of 
measurement as within factor. 
There was a significant difference between peri- and post-menopausal users 
overall (p = .047) showing better performance in the peri-menopausal group. The 
difference is especially prominent at Stage three, a t-test showed a difference in mean 
score between peri-menopausal (mean = 6.40, SD = 2.81) and post-menopausal women 
(mean = 7.58, SD = 3.16) at stage three of the SART (p = .048). Overall, no main effect 
of intervention was found (p = .95), and intervention did not interact with menopause 
phase (p = .49).   
Taking into account the within factor of time of measurement the results 
show that the scores on SART across the trials did not depend on the type of 
intervention that participants were given (placebo vs. isoflavone) and time of 
measurement did not interact with the intervention (F(2,196) = 359; p = .699; 
partial ƞ2 = .004). Time of measurement did not interact with menopausal phase (F(2, 
196) = 0.63; p = .53; partial ƞ2 = .009). And no significant three-way interaction was 
found between time of measurement, intervention, and menopause phase 
(F(2,196) = 1.75; p = .176; partial ƞ2 = .018). No further analysis was needed. 
 
4. 10 Discussion 
 
The present study found no differences between WM or SA performance 
of isoflavone users compared to placebo controls. Those in the peri -menopausal 
stage had significantly higher RSpan scores at stage three and OSpan scores at 
all three stages of the study. Those in the peri -menopausal stage made fewer 
mistakes during completion of the SART at stage three of the study than those in 
the post-menopausal phase. These differences were regardless of isoflavone use.  
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When the interaction of time and intervention was taken into 
consideration, at baseline, after three months of receiving the intervention and 
after a three month wash out period, supplement use did not have an effect on 
WM or SA score at any one of these three points. No other differences were 
found. 
Similar to the present study, Ho and colleagues (2010) found no 
differences in performance of memory and attention tasks between isoflavone 
users and placebo users. The present study also coincides with the study by File 
and colleagues (2001) who found no difference in memory performance or 
performance of the PASAT between isoflavone users and placebo users and also 
Fournier and colleagues (2007) who found no differences in SA or WM 
performance between isoflavone users and placebo users.  The present study 
also coincides with studies that have demonstrated no effect of isoflavone use 
on other types of cognition (Kreijkamp-Kasers et al., 2004). Several studies have 
also demonstrated mixed results (File et al., 2005; Hartley et al., 2004; Kritz -
Silverstein et al., 2003), showing both improvements and no eff ect of 
supplement use on different frontal lobe functions. The present study 
contradicts in part with these studies, as well as with studies that have 
demonstrated an effect of isoflavone use on WM, SA and cognition (Bryant et al., 
2005; Duffy et al., 2003). 
Integration into current literature 
On the whole, research has demonstrated a mixed effect of isoflavone 
consumption on cognition in menopausal women, and the total amount of 
evidence in either direction is sparse. The present study design was driven by 
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studies that have demonstrated an effect of isoflavone use on executive function. 
For example, several studies have demonstrated beneficial effects of isoflavone 
use on SA (Duffy et al., 2003; File et al., 2005). The relationship between WM 
and isoflavone use is less explored. The present study suggests no effect of 
isoflavone use on WM and also SA. 
The present study was similar in design to studies by Duffy and 
colleagues (2003) and File and colleagues (2005) but differed in results. The two 
studies found positive effects of isoflavone use on PASAT score and memory task 
performance. The present study failed to replicate these findings and no 
differences were found on PASAT score and WM performance between women 
receiving either isoflavones or a placebo control. This was, in part, unanticipated 
due to the PASAT being replicated in presentation with precise methodology.  
Despite the present study being similar in design to studies by Duffy and 
colleagues (2003) and File and colleagues (2005) in collective daily dose, type of 
isoflavone used, duration of the intervention and some of the selected tasks, 
there are some marked differences in preparation, methodology and execution 
that should be considered.  
Firstly, the two studies asked participants to consume a lower dose of the 
product, but twice daily. The present study used a single larger daily dose. A 
lower dose of cyclic bursts of the supplement may be easier for western women 
to metabolise as opposed to a single, larger quantity, but this is yet to be 
explored. Kritz-Silverstein and colleagues (2003) also considered the 
administration of isoflavones in two daily doses and found improvements in the 
category fluency task. Secondly, the present study had a wider age group 
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included in the study (45-65 year olds) whereas Duffy and colleagues, and File  
and colleagues considered participants who were from 50 years (to 65) and 51 
years (to 66) of age. Hartley and colleagues (2004) also demonstrated a positive 
effect of isoflavone use on planning ability in 51 year olds (to 66), but not rule 
reversal. 
In another study that demonstrated improved cognitive function in 
menstruating young women, File and colleagues (2001) found improvements in 
isoflavone users for tasks with verbal components. Of interest, the food 
products were consumed at different sittings during the day, similar to studies 
by Duffy and colleagues (2003) and File and colleagues (2005). Although 
differences were found for the verbal tasks, no differences in performance were 
found between the two groups during completion of the PASAT, DSS and D C, 
tasks used to measure SA. This is consistent with the present study. In many soy 
food products, an estimation of isoflavone content is given which may lead to 
small differences in serving content and amount ingested. The impact of 
quantity of isoflavone on cognition is not well established and therefore the 
impact of this difference cannot be fully appreciated. These differences in daily 
dose of isoflavone may account for small differences between study results. In 
the present study, some women were already exposed to small amounts of soy 
in their diet, which may have accounted for differences in metabolism where 
women with prolonged exposure to isoflavone consumption are able to 
metabolise it more easily (Adlercreutz et al., 2000).  
To coincide with the present study, a larger study by Ho and colleagues 
(2003) involving 168 women found no difference in cognitive performance with a 
once daily isoflavone intervention. Women were of a similar age to participants 
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in the study by Kritz-Silverstein and colleagues (55 - 75 years). It is likely that 
most of the included participants had completed the menopause and were 
experiencing low levels of menopausal symptoms (if any). The present study also 
showed no impact of isoflavone use on cognition in post-menopausal women 
aged 55-65 years. In addition to this, the present study included younger, peri -
menopausal women and also demonstrated no effect of soy isoflavone on 
women closer to the onset of the menopause.  
Generally studies have found no effect of isoflavone use  on a wide range 
of cognitions in postmenopausal women (Fournier et al., 2007; Ho et al., 2007; 
Kreijkamp-Kaspers et al., 2004). Most of these studies have included large age 
groups and did not consider smaller divisions of the climacteric, or use age as a  
covariate to eliminate aging effects. The present study considered stage in the 
climacteric with age as a covariate and no effect of isoflavone use was found in 
either peri- or post-menopausal women. 
Isoflavone potency, metabolism and action 
At present, there is no recommended daily dose or duration of 
intervention to maximise effects of isoflavones on menopausal symptoms. 
Because of this, studies have explored different potencies of daily supplement 
use as well as different durations of isoflavone intervention and found mixed 
results.  
Previous studies have demonstrated a positive effect of isoflavone use on 
episodic memory and executive function after six to 12 weeks of supplement use 
(Bryant et al., 2005; Duffy et al., 2003; File et al., 2005; Hartley et  al., 2004). 
Other studies have demonstrated no effects of isoflavone use on episodic 
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memory and executive function when supplement use exceeds this time 
(Fournier et al., 2007; Ho et al., 2007; Kreijkamp-Kaspers et al., 2004). The 
present study initiated the intervention for 12 weeks and still demonstrated no 
effect of isoflavone use on WM or SA.  
Typically, the potency of the supplement amongst studies has remained 
between 60mg and 120mg daily. There is no immediate pattern between 
potency level and effect of supplement use on cognition, but generally studies 
which have considered potencies less than 60 mg per day have demonstrated no 
effects of supplement use on menopausal symptoms. It is also unclear if studies 
have considered the role of previous exposure to isoflavones within the diet, 
where early and consistent exposure in Asian women has resulted in better 
metabolism of isoflavones (Adlercreutz et al., 2000). Existing exposure to 
isoflavones may create individual differences between participant metabo lism. 
The biological effects of soy isoflavones are strongly influenced by their 
metabolism (Rowland et al., 2003) where only about 33% of individuals from 
Western populations metabolize isoflavones appropriately to benefit from them 
(Jou et al., 2008; Setchell, Brown, & Desai, 2003). Because of this, it is possible 
that participants in the present study were unable to metabolise the isoflavone 
product. Isoflavones promote the chemical antioxidant effects of oestrogens, 
but it is a smaller subset of specific isoflavones that activate biochemical flows 
required for neuroprotection, and an even smaller subset that activate the 
genomic mechanisms of oestrogen-induced neuroprotection (Nilsen & Brinton, 
2000). This suggests that isoflavone metabolism (resulting in eventual 
neuroprotection) may be difficult as compared to HRT. Previous studies that 
have demonstrated a beneficial effect of isoflavone use have considered two 
 
 
237 
 
smaller daily doses (Duffy et al., 2003; File et al., 2005) and exposure through 
natural food products, rather than supplement (File et al., 2001).  
Generally, animals such as rats are more able to metabolise isoflavones 
than humans (Setchell et al., 2002). Rat studies have demonstrated increased 
nerve growth and brain-derived neurotropic factor in the PFC after being 
exposed to isoflavones (Pan et al., 1999) and isoflavone exposure can promote 
spine density growth of pyramid cells in the PFC of female rats (Luine et al., 
2006). The effect of isoflavones on the human brain and in particular the PFC is 
not well understood. 
The PFC mediates executive functions including WM and SA and Duffy et 
al. (2003) suggest that isoflavones target ER-beta receptors in these areas to 
promote related cognitions. Kreijkamp-Kaspers and colleagues (2004) demonstrated 
no effect of isoflavone use on a large cognitive test battery investigating PFC mediated 
tasks. At the same time, plasma levels of isoflavones in the blood were taken before and 
after 12 months daily treatment. No difference was found between plasma levels of the 
two groups, suggesting poor absorption of the supplement. Setchell and colleagues 
(2002) also found no traces of isoflavone in blood samples directly after and 
shortly following exposure in adult females. The two studies combined suggest that 
metabolism of isoflavones after continuous exposure is poor in humans and the likelihood 
of these isoflavones acting as oestrogen receptors in the PFC is weak. 
Studies do not demonstrate a beneficial effect of isoflavone use on cognition in 
larger populations  
Generally, studies with small sample sizes have demonstrated an effect of 
isoflavone use on cognition. One study has shown improved menopausal 
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symptoms with isoflavone use in menopausal women aged 40-59 years (Chedraui, 
2011). Two studies have shown improvements in memory and SA in 50 to 65 year 
olds (Duffy et al., 2003; File et al., 2005). The studies described have used small 
numbers of participants (Chedraui, n = 45; Duffy and colleagues, n = 33; File and 
colleagues, n = 50). Three studies that have used larger populations (Ho et al., 
2007, n = 80; Kreijkamp-Kaspers et al., 2004, n = 202; Fournier et al., 2007, n = 
79) have found no effects of isoflavone use on cognition. Each study included 
large cognitive test batteries covering exploration of executive f unction 
including episodic memory and SA. One of these studies only included post -
menopausal women defined by age (kreijkamp-Kaspers et al., 2004; 60-75 years) 
and it is possible they were no longer experiencing menopausal symptoms. One 
study considered women similar in age to the present study (Fournier et al, 2007; 
48-65 years of age). Participants were considered in one group and not split for 
stage of the climacteric. It is also not clear if age was used as a covariate.  
Studies including larger populations may be more generalised to the 
overall population as incorporate larger variation. These larger studies, including 
the present study, have demonstrated no effect of isoflavone use on cognition. 
In accordance with the healthy user bias effect, i t is likely that women who are 
interested in alleviating their menopausal symptoms will take part in a study 
considering ways to achieve this. It has also been suggested that women who 
report worse levels of menopausal symptoms, with more hot flushes repor ted 
daily, experience the greatest benefit from isoflavone therapy (Howes  et al., 
2006). It is possible that previous studies with smaller number of participants 
have attracted those who have higher experiences of menopausal symptoms. In 
accordance with Howes and colleagues, these women would benefit most from 
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isoflavone use. The present study included more participants, encouraging more 
variation between task score, self-ratings of mood and self-ratings of 
menopausal symptoms. Participants were recruited d irectly on approach in the 
street, and details of the study were kept minimal. This approach may have 
slightly reduced the healthy user bias effect and the larger group would 
encourage variation. It is perhaps because of the smaller number of participants 
recruited in previous studies resulting in less variation, that previous studies 
have demonstrated an effect of supplement use, where the present study has 
not.  
Isoflavones studies and the critical period 
HRT use has a protective effect on WM when initiated early in the 
climacteric. The present study tested the critical period using tasks that are 
susceptible to oestrogen change (RSpan and OSpan, as demonstrated in study 
one) and tasks that have been shown to be sensitive to isoflavone use (the 
PASAT). The study was the first direct measure of the interaction between the 
critical period and isoflavone use. Despite the careful selection of tasks, no 
difference was seen in performance of these tasks between early or late 
supplement users and placebo controls. 
Currently, there are no studies exploring the effect of the critical period 
and isoflavone use on cognition in menopausal women and most studies include 
women described as menopausal who are (typically) several years from last 
menstrual bleed. One study demonstrated a positive effect of isoflavone use on 
menopausal symptoms in young menopausal women (Chedraui, 2011, 40 -59 
years). It is likely that some of the women included would have been post -
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menopausal. Three studies have included women who are 50-65 years of age, 
two of which demonstrated a beneficial effect of isoflavone use on memory and 
SA (Duffy et al., 2003; File et al., 2005) and one of which had mixed results 
dependant on the type of cognition (Hartley at al., 2004). These studies had 
smaller sample sizes. Out of three studies including post-menopausal women, 
two of these studies found no effects on a variety of cognitive tasks (Ho et al., 
2007, 55-75 years; Kreijkamp-Kaspers et al., 2004, 60-75 years) and one found 
mixed results (Kritz-Silverstein et al., 2003, 55-74 year olds). These three studies 
included larger populations accounting for more variation between participants. 
And one study found no effects of WM and SA in women with a similar age to 
the present study (Fournier et al., 2007, 48-65 years). The mixed results do not 
indicate an effect of supplement use based on time of initiation of the 
supplement.  
Limitations of the present study design 
HRT use has a protective effect on WM. The present study tested the 
critical period using tasks that are susceptible to oestrogen change (RSpan and 
OSpan, as demonstrated in study one) and tasks that have been shown to be 
sensitive to isoflavone use (the PASAT). The study was the first direct measure of 
the interaction between the critical period and isoflavone use. Despite the 
careful selection of tasks, no difference was seen in performance of these tasks 
between early supplement users and placebo controls. Previous studies have 
shown improvements in episodic memory with isoflavone use and perhaps t asks 
representing this type of memory should have been selected.  
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One must never assume that natural supplement use will lead to the 
same outcome amongst individuals. The biological effects of soy isoflavones are 
strongly influenced by their metabolism (Rowland et al., 2003) where only about 
33% of individuals from Western populations metabolise isoflavones 
appropriately to benefit from them (Setchell, Brown, & Desai, 2003; Jou et al., 
2008). Taking blood samples of those using isoflavones may help to determ ine 
what proportion of the supplement has entered the blood system. Kreijkamp-
Kaspers and colleagues (2004) demonstrated poor absorption of 100 mg of isoflavone 
after 12 months of daily exposure. The present study also considered 100 mg of daily 
isoflavone use and it is possible that those in the present study did not metabolise the 
supplement. Due to financial constraints, the present study was not able to take saliva or 
blood samples to determine this. 
There is also evidence that those exposed to regular intake of isoflavones such as 
Asian women are more able to metabolise the isoflavone as compared to western women. 
A food diary kept by participants leading up to and throughout the study would have 
helped to determine any other exposure to isoflavones and likelihood of metabolism. 
Nuero-imaging studies looking at functional and structural differences 
between isoflavone and placebo users may also help to determine if isoflavones 
are targeting receptors and building concentrations large enough to elicit 
response. The current study was also unable to collect this data, due to financial 
constraints. 
Other cautions regarding supplement use include their minimised or 
adverse effects when taken with other drugs. Populations interested in 
supplement interventions are likely to be receiving other supplements or forms 
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of medication, which can change the rate at which a drug is absorbed into the 
system. On consultation with a healthcare practitioner, there were no perceived 
cautions needed to be taken with isoflavone use and other drug intake in this 
case. Participants were asked whether they were receiving any other 
supplements or medications, but access to medical records was not possible and 
this limited the availability of such data. 
Although participants were asked details on medications taken at point of 
testing, the absences of access to medical records in the present study did cause 
limitations to the study design. For example, certain medications may affect 
oestrogen level, such as thyroid medication. Again, blo od or saliva samples 
would have helped determine current oestrogen levels in the body. Groups were 
balanced for count of chronic condition, medication use and recent GP visits.  
The present study also excluded those above the age of 65 years to help 
combat aging effects on cognition and age was used as a covariate.  
Direction of literature 
The present study replicated the results of studies with larger 
populations that have considered isoflavone intervention in menopausal 
symptoms including cognition. The study included two of Engle’s WM tasks 
(based on implications from study one), the PASAT to measure SA (as suggested 
by previous isoflavone literature) and the SART as an additional measure of SA. 
In contrast to some of the previous studies, PASAT performance  did not differ 
between isoflavone users and placebo controls. In addition, WM and SART 
performance did not differ between isoflavone users and placebo controls.  
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Several studies demonstrate a positive effect of isoflavone use on verbal 
memory (Bryant et al., 2005; Duffy et al., 2003; File et al., 2001) and episodic 
memory (Duffy et al., 2003). The effect of isoflavone use on WM is poorly 
understood and few studies have demonstrated no effect of isoflavone use 
(Fournier et al., 2007). The present study included different types of WM (verbal 
and mathematical) and one study demonstrated no effect of isoflavone use on 
visual-spatial WM and verbal WM, suggesting that different types of WM are not 
affected by isoflavone use. It is possible that isoflavone use does  not affect WM 
capacity and it may have been more suitable to include an episodic memory task 
rather than WM.  
Despite studies with larger populations demonstrating no effect of 
isoflavone intervention on cognition in menopausal women, there are some 
avenues that still need exploring before an effect of isoflavones in larger 
populations can be ruled out.  
There is little consistency in study design across the literature as a whole. 
The inconsistencies have led to potential areas of investigation. Main differences 
between studies that have demonstrated an effect of isoflavone use on 
cognition and those which have not such as the present study are the 
administration of isoflavone, typically two 30-50mg supplements to be taken 
twice daily, as compared to the present studies 100mg daily dose. There are still 
no clear recommendations for the amount of isoflavone to be taken daily and 
whether this should be in one or several portions throughout the day.  
Generally studies have demonstrated no effect of isoflavone use on 
menopausal symptoms and cognition if less than 60mg or more then 120mg of 
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isoflavone are received daily, and studies have proved more successful when this 
amount has been administered in two doses, but different dosing regimens have 
not been compared in a single study. This is of particular importance when 
considering the success of isoflavone use on PASAT performance in studies that 
have split the supplement throughout the day, as compared to the present study 
that demonstrated no effect with one daily dose.  Therefore future research 
should consider different daily doses of isoflavone use (between 6 0 and 120mg 
daily) and single doses compared to two doses of half the potency per day.  
Generally, studies with a shorter duration (six to 12 weeks) have shown 
beneficial effects of isoflavone use on cognition. If the benefits are short lived, 
this has large implications for the use of isoflavones as an alternative to HRT. It 
may be that a cyclic treatment plan is needed for optimal effects. Research 
should take a focus on the potential duration of treatment to promote optimal 
effects and whether this treatment plan could be repeated after a wash out 
period to sustain effects. For example, three months on, three months off.  
A further issue that needs further investigating is the metabolism rates of 
isoflavones in western women. There is a need for better understanding of 
isoflavone metabolism for this group, whether high-isoflavone food products or 
a supplement pill will be better digested and metabolised, taking into 
consideration the convenience of a pill against more natural food products. 
Individual differences should be considered. This will contribute to better 
understanding of metabolism of isoflavones into equol, concentrations in the 
blood and concentrations in the brain.  
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As it has been suggested that rate of isoflavone metabolism can be based 
on the body’s natural need and that isoflavones benefit women experiencing 
stronger menopausal symptoms, the literature should perhaps focus on the 
degree of menopausal symptoms experienced and the relative effect of 
phytoestrogens on these symptoms. The present study included the MQoL scale 
to measure menopausal symptoms. Future studies could consider testing 
cognitive response to isoflavone use in women experiencing severe menopausal 
symptoms. In all other studies investigating the relationship between isoflavone  
use and cognition, a global menopausal symptom measure should be adopted 
and this will ascertain whether the positive effect of isoflavone use on cognitive 
impairments in menopausal women correlates with experience of symptoms. To 
build on this, studies that have considered the effect of isoflavone use on 
cognition in post-menopausal women have shown little or no effect. Future 
studies should recruit women who are in the peri -menopausal or early post-
menopausal phase experiencing strong menopausal symptoms, and compare 
these to women matched for age and degree of symptoms, as is important to 
establish the role of isoflavones in a group where there is potential for benefit 
initially. 
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General discussion 
 
Taken together the findings of the thesis clearly demonstrate that HRT 
plays a neuroprotective role in the maintenance of WM when taken at the 
appropriate time, before oestrogen receptors become too oestrogen deficient. 
Isoflavone intervention did not affect cognition, regardless of early or late use in 
relation to stage in the climacteric. It may be possible to relieve menopausal 
women of hot flushes with short-term isoflavone use, but the present study 
demonstrated that short-term isoflavone use does not benefit cognition. The 
present research has potentially important and practical implications. As 
isoflavones are not a good substitute for HRT, those with cognitive problems 
experienced during the menopause may not be able to use isoflavones as a 
substitute to HRT. It is possible to decelerate the onset of cognitive decline with 
initiation of HRT, but this is dependent on time of initiation, the sooner being 
the better. The thesis reports one of the first studies to define menopausal 
group by stage in the climacteric, as opposed to age. The implications of this are 
large, as the study was able to demonstrate that women as little as 12 months 
from last menstrual bleed were susceptible to the cognitive detriments of ‘late’ 
HRT use. Past studies are problematic because they have defined group by age, 
and as a result have often included post-menopausal women in their peri-
menopausal defined groups. This may account for discrepancies in the literature 
where several studies considering the effect of HRT use on cogn ition have 
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yielded non-significant effects in supposedly ‘peri-’ menopausal women. Of final, 
large importance the present study has confirmed a detrimental effect of HRT on 
cognition when initiated during the post-menopausal stage. This is of particular 
importance, as the literature on effects of HRT on post-menopausal cognition is 
rather confused, again partly due to poor definition of groups.  
 
HRT can have detrimental effects on WM when initiated post -menopause 
Study one can be integrated well into the current body of literature, 
supporting studies that confirm a critical period for protective effects of HRT on 
and confirming a detrimental effect when exceeding this. The study has helped 
to close the gap for this window of opportunity and this has helped define the 
critical period. It is very important to consider that for half the women in this 
study, HRT was initiated after 12 months of their last menstrual bleed. Most 
women initiate HRT between the age of 50 and 54 years (Sennik, 2009) and for 
many, the window of opportunity for nueroprotection will be exceeded at this 
point. Because of this, a large proportion of women (21% of the total population 
in 2009) are not benefitting cognitively from earlier use of the  therapy, and may 
be in fact putting their current cognitive capacity at risk of late initiation effects. 
This should be considered in GP recommendations.  
 
GP recommendations 
Doctors are advised that HRT should not be prescribed for reported 
problems in cognition. Two studies (Norbery et al, 2003; Philips & Sherwin, 1992) 
have reported memory to be the largest complaint by women experiencing the 
menopause, and disrupted cognition is a major symptom for some women. This 
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information is strongly supported by neuroimaging studies that show differences 
in white and grey matter, hippocampal volume and neural activation in the 
frontal lobes between younger, menstruating women and menopausal women, 
as well as HRT users and non-users. The present study has demonstrated that 
early HRT use maintains WM performance, and that late HRT acts as a detriment. 
For these reasons, GPs may have to re-consider their recommendations, and if a 
patient is experiencing disruptive cognition then HRT should be recommended as 
an alleviant if this falls within the critical period. Although there is a need for 
balance between increased risks in initiating HRT use (venous thromboembolism, 
stroke, endometrial cancer, breast cancer and ovarian cancer) and increased 
risks in not initiating HRT use, GPs are informed that the benefits of short term 
use outweigh the risks in the majority of women under the age of 60. Generally, 
GPs recommend women to take a minimum effective dose for the shortest 
possible duration. In the present study, women had an average HRT duration of 
4.46 years, and HRT use resulted in long lasting effects on memory.  Gaps in the 
research (such as duration of HRT use and the critical period, and a potential for 
short use in post-menopausal women) need to be addressed to better 
understanding of the critical period, but what is known so far is substantial 
enough to advertise the beneficial role of early HRT use on cognition and the  
critical period should be discussed more vividly in guidelines for HRT use.  
 
Isoflavones are not a sufficient substitute for HRT for the protection of WM 
Many women are exploring alternative therapies; however the 
substitution of isoflavones for HRT to aid cognition may be rather unwise. The 
isoflavone study used three tasks from study one, and an additional SA task. 
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Despite the two chosen WM tasks proving to be susceptible to HRT use in study 
one, performance on these tasks was not affected by isoflavone use in study two. 
The study was modelled on studies by Duffy and colleagues (2003) and File and 
colleagues (2005) and was similar for daily dose, type of i soflavone used, 
duration of the intervention and type of cognitive domains explored. The 
present study differed by asking participants to consume the supplement once 
daily, instead of two smaller doses daily. A lower dose of cyclic bursts of the 
supplement may be easier for western women to metabolise and this may 
explain why the PASAT failed to reproduce positive results in study two. It 
cannot be assumed that supplement use will lead to the same outcome amongst 
individuals, partly due to the large variation in uptake and metabolism. The 
biological effects of soy isoflavones are strongly influenced by their metabolism 
(Rowland et al., 2003) and only approximately 33% of individuals from Western 
populations metabolize isoflavones appropriately to benefit from them (Jou et 
al., 2003; Setchell et al., 2003). Although oestrogens and phytoestrogens share 
the same phenolic ring structure necessary for antioxidant effects in the brain, 
this is usually at lower potency for phytoestrogens (Chen, Oji, & Brinton, 1998)  
and phytoestrogens bind weakly to oestrogen receptors (Kuiper et al., 1998) . 
This means concentrations sufficient to elicit response may not be reached. 
Participants in study two had a higher average level of education than study one, 
which may account for small differences in WM performance across groups 
because those who have higher levels of education may have an advantage in 
completing WM tasks (Baddely et al.,1986).  However this will not account for 
differences in PASAT performance between the present study, and Duffy and 
Files’s studies. The present study had larger population sample then both Duffy 
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and File’s studies, and it is possible that it is a better representation of the 
general population. 
Typical patterns in isoflavone-cognition literature are not yet well 
established which may account for the range of results across  studies. The 
precise dose, pattern of administration and duration of the intervention has 
varied across studies, possibly contributing to the mixed results, and there is no 
clear recommended method of conduct. But one conclusion that can be 
determined is that isoflavones taken at this particular daily dose, which was 
typical of that used in the literature, are not a good substitute for HRT in the 
prevention of WM decline during the menopause.  
 
Prioritising research 
The critical period hypothesis has been supported in studies using 
oestrogen only, oestrogen and progesterone, from as little as a single dose to 
several years’ continuous use. The critical period hypothesis has helped to 
explain much of the discrepancies in the literature: HRT benefits cognitio n when 
taking during the peri-menopause but may have no effect or be detrimental 
when started post-menopause. The present study confirmed this general pattern 
of findings, by directly comparing women who initiated HRT peri - or post-
menopause, and finding benefits of peri-menopausal HRT relative to no HRT, and 
detrimental effects of post-menopausal HRT relative to post-menopausal non-
users. Women in this study used HRT for different lengths of time, and used 
different variations of HRT. It is not yet clear whether including progesterone in 
HRT affects cognition relative to oestrogen-only HRT. It is also not clear how the 
duration of HRT affects cognition or interacts with the timing of initiation of the 
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therapy. Future research should test the effects of different types of HRT and 
different durations of therapy on cognitive performance in women who are peri -
menopausal according to the definition used in this study, for example, 
experiencing symptoms of menopause but still within 12 months of their last 
menstrual bleed. 
This study defined peri- and post-menopause more clearly than most 
previous research, by referring to individuals’ symptoms rather than population 
averages. By doing so, it has contributed to the definition of the critical period 
by limiting it to as little as twelve months. Future research should aim to further 
define the critical period by looking at the twelve months between last 
menstrual bleed more closely, and considering variation between women.  
It is not yet clear whether natural forms of isoflavone or synthetic 
supplements are beneficial in reducing menopausal symptoms and whether 
either can be an effective substitute for HRT. It is possible that isoflavones and 
HRT can help different symptoms where a small body of evidence suggests that 
isoflavones help to reduce hot flushes in both peri - and post-menopausal women. 
Successful isoflavone studies often include a short intervention (6 -12 weeks) in 
peri-menopausal women, and it is possible that the beneficial effects of 
isoflavones on cognition is very short lived, perhaps due to the potency of 
oestrogen action in isoflavones being smaller than that for HRT.  
 
To conclude 
To conclude, initial HRT and cognitive research has been very confused 
and the implications poorly understood. Recent psychological and 
neurobiological studies have helped to resolve some of the bewilderment in the 
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literature in several ways. Firstly, the locations of oestrogen in the brain and its 
effects on mechanisms in those areas have been linked to cognitions that are 
mediated by the brain areas. This has allowed some consistency in cognitive 
domains tested, and the impact of the change of oestrogen (synthetic and 
organic) on these cognitions has since been explored. Secondly it is recognised 
that there is potential for different types of oestrogen therapy (oestrogen only 
or oestrogen and progesterone) in different doses work differently in the body 
and brain, and the duration of the therapy may also have different impacts on 
cognition. But most importantly, that oestrogen use has different effects on 
cognition when initiated at different points of the climacteric, regardless of 
duration and type. Vincent and Fitzpatrick (2000) reviewed isoflavone research 
to ascertain the effectiveness of isoflavones on menopausal symptoms. Through 
their meta-analysis they concluded that it would be premature to assume 
isoflavones could be an alternative to HRT and that little could be assumed 
about the long-term benefits with regards to menopausal symptoms including 
attenuation of memory loss. The present research found no evidence that 
isoflavones benefit WM or attention, even when administered during the critical 
period.  
The information from the current thesis should be considered in revised 
recommendations for established treatment plans in women suffering from 
menopausal symptoms, specifically dependent on whether they are peri or post -
menopausal. 
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Appendix  A  
 
Study One (Baseline and follow up) material  
1.1 Example answer sheet for the WM tasks (completed by the PI)  
 
OSpan 
a) _______    _______         
b) _______    _______ 
c) _______    _______ 
 
 
1.  _________        _________        _________        _________        _________         
2.  _________        _________        _________        _________        _________         
3.  _________        _________        _________        _________        _________         
4.  _________        _________        _________        _________        _________         
5.  _________        _________        _________        _________        _________         
6.  _________        _________        _________        _________        _________         
7.  _________        _________        _________        _________        _________         
8.  _________        _________        _________        _________        _________         
9.  _________        _________        _________        _________        _________         
10. _________        _________        _________        _________        _________         
11. _________        _________        _________        _________        _________         
12. _________        _________        _________        _________        _________         
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1.2 Selected items form the OSpan task 
 
 
 
1.3 Selected items form the RSpan task 
 
 
 
1.4 Selected items from the CSpan task 
 
 
 
 
1.5 Selected items from the SART task   
 
 
 
1.6 GHQ-12 scale (completed by the participant) 
 
 
 
 
1.7 Selected items chosen from the MQoL scale  
 
 
Scale has been removed due to Copyright restrictions  
Scale has been removed due to Copyright restrictions  
Scale has been removed due to Copyright restrictions  
Scale has been removed due to Copyright restrictions  
Scale has been removed due to Copyright restrictions  
Scale has been removed due to Copyright restrictions  
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1.8 Biographical questionnaire (completed by the researcher on behalf 
of the participant) 
 
Demographic questionnaire 
Age:…….   
 
Have you begun the menopause?  YES   NO  
Details .................................................................... 
 
When was your last menstrual bleed?................. 
 
Have you ever taken any form of HRT:  YES   NO  
Details: (type)……………(duration)………………………………………………………… 
Last therapy dose…………………… 
Pill  Patches Implant Nasal spray Other 
 
Highest Level of Education:…………………………………………………. 
 
Any prescribed drugs?    YES   NO  
Details .................................................................... 
 
GP visits past three months:………. 
 
Any Chronic conditions?  YES   NO  
Details .................................................................... 
 
 
298 
 
Do you believe the menopause effects: 
Memory?   
Decrease a lot  Decrease a little Stays the same 
Increase a little  Increase a lot  
Details ……………………….…… 
 
Your own memory? 
Decrease a lot  Decrease a little Stays the same 
Increase a little  Increase a lot  
Details ……………………….…… 
 
Cognition? 
Decrease a lot  Decrease a little Stays the same 
Increase a little  Increase a lot  
Details ……………………….…… 
 
Your own cognition?   
Decrease a lot  Decrease a little Stays the same 
Increase a little  Increase a lot  
Details ……………………….…… 
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Appendix  B  
 
Study Two (Baseline, three month follow up and six month follow 
up) material 
 
The example WM completion form, images from RSpan, OSpan, CSpan 
and SART and the GHQ-12 as in appendix A. 
 
2.1 Demographic questionnaire 
Pre-screening questions (completed by the researcher) 
Age:…….   
Have you ever taken any form of HRT:  YES   NO  
Details: (type)……………(duration)………………………………………………………… 
 
History of cancer?     YES   NO  
Details .................................................................... 
 
 
Demographic questionnaire 
Highest Level of Education:…………………………………………………. 
Work status:    PT   FT  NONE    
 
Any prescribed drugs?         YES    NO  
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Details .................................................................... 
 
GP visits past three months:………. 
 
Any Chronic conditions?  YES   NO  
Details .................................................................... 
 
 
Have you begun the menopause?  YES   NO  
Details .................................................................... 
 
Do you believe the menopause effects: 
 
Memory  YES   NO  Details ……………………….…… 
Bone health YES   NO  Details ……………………….…… 
Mood  YES   NO  Details ……………………….…… 
Confidence YES   NO  Details ……………………….…… 
Activity YES   NO  Details ……………………….…… 
Anything else? YES   NO  Details ……………………….…… 
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Do you feel your diet is high in any of the following: 
 
Saturated fats     
Unsaturated fats   
Salt     
Carbohydrates    
Sugars     
Calcium    
Soya     
Fruit     
Vegetables    
Alcohol     
Meat and Fish    
 
Please list any supplements you are taking at the 
moment: …………………………………………………………. 
 
Are you a smoker?   Yes    No   
 
Do you exercise: 
Daily   Weekly   Monthly   Not at all  
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2.2 MQoL scale (full version completed by participant) 
 
 
 
 
Scale has been removed due to Copyright restrictions  
